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The Japanese Association for Infectious Diseases (JAID) and
Japanese Society of Chemotherapy (JSC) announced the “Guide for
the Use of Antimicrobial Drugs” in 2001 and the “Guidelines for the* Corresponding author. Center for Infectious Diseases, Nara Medical University,
840 Shijo Town, Kashihara City, Nara 634-8522, Japan. Tel.: þ81 744 22 3051;
fax: þ81 744 24 9212.
E-mail address: info@kansensho.or.jp (K. Mikasa).
http://dx.doi.org/10.1016/j.jiac.2015.12.019
1341-321X/© 2016 The Authors. Published by Elsevier Ltd onbehalf of Japanese Society of Chem
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Use of Antimicrobial Drugs” in 2005. Subsequently, the “The JAID/
JSC guide to clinical management of infectious diseases 2011” was
published. With its revision, guidelines were newly prepared.
Concerning respiratory infectious diseases, in Japan, the Japanese
Respiratory Society published guidelines for the management of
community-acquired pneumonia, hospital-acquired pneumonia,
respiratory tract infection, and -/nursing and healthcare-associated
pneumonia. Furthermore, the Japanese Society of Pediatric Pulmo-
nology and Japanese Society for Pediatric Infectious Diseases
announced the “Guidelines for the Management of Respiratory In-
fectious Diseases in Children in Japan”. Internationally, many
guidelines, including those established by the American Thoracic
Society and Infectious Diseases Society of America, have been pub-
lished from various countries. Thereafter, clinical research on res-
piratory infectious diseases has advanced, leading to the
accumulation of many outcomes regarding epidemiology, clinical
diagnosis, and treatment. However, the types of microorganisms
that cause respiratory infectious diseases have increased with theotherapyand The Japanese Association for Infectious Diseases. This is anopen access article
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with causative microorganisms through the recent compromised
host's severe status. The place of treatment varies: from the outpa-
tient clinic to the ICU. Physicians responsible for treatment also vary:
practitioners, hospital doctors, pulmonologists, emergency physi-
cians, board certiﬁed member of JAID, Japanese antimicrobial
chemotherapy physician. There are a large number of options of
antimicrobial drugs that are available, including new drugs; thera-
peutic strategies are confused.On theotherhand, recently, the entity
of PK-PD has been commonly recognized, and the importance of
scientiﬁcally using antimicrobial drugs has been emphasized. In
addition, the JapaneseSocietyofChemotherapyestablisheda system
for antimicrobial chemotherapy-certiﬁed physicians, and promoted
thewidespread, adequateuseof antimicrobial drugs. Basedon these,
the two societies prepared the JAID/JSCGuidelines for the Treatment
of Respiratory Infectious Diseases. If speciﬁc treatment guidelines
can be presented, this may contribute to an improvement in the
treatment responses of respiratory infectiousdiseases, a reduction in
health expenditure, and the prevention of resistant bacteria.
The guidelines were prepared based on the EBM so that they
reﬂected the management of respiratory infectious diseases in
Japan and covered all such diseases in adults and children. To
prepare the guidelines, a committee was established in 2012, and a
draft was published on homepage based on an approval from the
boards of directors at the two societies through a review-based
consensus. Opinions were collected from the two societies' mem-
bers. In Japan, there have been no such guidelines covering respi-
ratory infectious diseases. In the future, with further advances in
research, the contents of the guidelines must be revised. However,
we successfully provided treatment guidelines that are the most
advanced at present.
The guidelines were prepared for all clinicians to understand the
Treatment of Respiratory Infectious Diseases and manage them
with antimicrobial drugs adequately. They do not limit treatment
by individual physicians or affect their rights to select it. The
guidelines may be commonly applied for respiratory infectious
disease management/research/education in Japan, improving the
quality of respiratory infectious disease management, preventing
an increase in the number of resistant bacteria, and contributing to
national health. We hope that the guidelines will be utilized by a
large number of clinicians in respiratory infectious disease man-
agement. Lastly, we thank the committee members and secretariat
staff for their cooperation.
1. Descriptions on the recommendation grade and evidence level
2. Deﬁnition of ﬁrst- and second-choice drugs
3. Precautions
- In this article, with respect to the administration method
(especially doses) of antimicrobial drugs, they are recom-
mended based on sufﬁcient doses. Considering the products
adopted at each medical institution, antibiograms, severity,
underlying disease, age, and presence or absence of organ dis-
order, the dose should be increased or decreased if necessary.Recommendation grade Evidence level
A Strongly recommended, I Randomized comparative study
B General recommendation II Non-randomized comparative study
C Comprehensive evaluation
by the attending physician
III Case report
IV Specialist's opinion
First-choice drugs Drugs to be recommended for initial treatment
Second-choice drugs Alternative drugs when ﬁrst-choice drugs cannot
be used due to allergy, organ disorder, or local factors- The spectra of third-generation cephems for intravenous in-
jection, CTX and CTRX, are similar, but CTX, which is excreted
in the kidney, should be primarily usedwhen liver dysfunction
is present, and CTRX, which is excreted in bile, should be
primarily used when renal dysfunction is present.
- As quinolones exhibit antitubercular actions, patients with
pulmonary tuberculosis should be excluded for use.
4. A list of antimicrobial drug abbreviations and doses for neonates
are presented at the end of this volume.2. Pneumonia (Adults)
2.1. Community-acquired pneumonia
2.1.1. Empiric therapy
- - - Executive summary- - -
 Patient with bacterial pneumonia should be treated primarily
with high-dose penicillin (AII). In elderly patients and those
with underlying lung diseases, the use of respiratory quinolones
may be considered positively (BII).
 In case of atypical pneumonia, a macrolide or tetracycline is the
ﬁrst choice. Respiratory quinolones should be reserved as
alternative drugs (BII), but may be used depending on local
circumstances about drug resistance (CIII).
 In case of whether pneumonia or atypical pneumonia dose not
diagnose, comobination with high-dose penicillin and a mac-
rolide or tetracycline should be attempted ﬁrst (BII). Respiratory
quinolones should be reserved as alternative drugs (BII).
 In severer cases requiring treatment in the ICU, a macrolide or
new quinolone should be used aggressively in combinationwith
a broad spectrum b-lactam such as high-dose penicillin from the
beginning of treatment (AII).- - - Explanation- - -
Community-acquired pneumonia refers to hospital-acquired
pneumonia that develops 48 h or more after admission or pneu-
monia that develops in healthy adults on social activities other than
medical practice-/nursing-associated pneumonia [1e3]. As signs
and symptoms, cough, sputum, thoracic pain, and dyspnea appear,
and this disease acutely occurs with systemic symptoms such as
fever and general malaise [1e3]. However, these symptoms are not
marked in some elderly patients. Furthermore, atypical pneumonia
including Mycoplasma is characterized by a small amount of
sputum, and can be differentiated (Tables 1 and 2) [4,5].
Concerning examination, Gram staining and culture of sputum
are used to identify causative microorganisms and select subse-
quent treatment strategies [6,7] (AII). Kits for rapid diagnosis with
urine or nasal swab are also used for auxiliary diagnosis [8,9] (AII).
A blood test shows inﬂammatory ﬁndings such as leukocytosis and
an increase in the CRP level, facilitating a certain assessment of the
disease [5,10]. On thoracic imaging, consolidation or a ground glass-
like shadow is observed [1e5] (II).
When patients are in an immunosuppressive state related to an
underlying disease, a causative microorganism test should be per-
formed, considering the possibility of opportunistic infection
[1e3,11,12] (A). In elderly patients, aspiration pneumonia is
frequently observed, and the management of this disorder is
necessary (Refer to the section “2.4 Aspiration pneumonia” on
Page. 19). In the presence of renal dysfunction, the type and dose of
an antimicrobial drug must be carefully selected [11,12] (AII).
Table 1
Items used to differentiate between bacterial and atypical pneumonia [3].
1. Under 60 years of age
2. No or minor underlying diseases
3. Stubborn cough
4. Poor chest auscultatory ﬁndings
5. No sputum, or no identiﬁed aetiological agent by rapid diagnosis
6. A peripheral white blood cell count below 10,000/mL
Table 2
Criteria for differentiation [3].
In cases using the 6 items in Table 1:
In cases where at least 4 of 6
items are satisﬁed
Atypical pneumonia suspected
In cases where 3 or less of 6
items are satisﬁed
Bacterial pneumonia suspected
The sensitivity and speciﬁcity for detecting atypical pneumonia is
77.9% and 93.0%, respectively.
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pneumonia in accordance with “The JRS Guidelines for the Man-
agement of Community-acquired pneumonia in Adults in 2007”
(edited by the Committee to Prepare Guidelines regarding Respi-
ratory Infectious Diseases, Japanese Respiratory Society) (Tables 1
and 2) [3]. Although Legionella pneumonia is routinely classiﬁed
as atypical pneumonia, various types of atypical pneumonia do not
include Legionella pneumonia in this differentiation method.
a. Bacterial pneumonia
(1) Outpatient treatment
Bacterial pneumonia is primarily caused by Sterptococcus
pneumoniae, Haemophilus inﬂuenzae, and Moraxella catar-
rhalis [1e5,13,14] (II). Basically, these types of pneumonia
should be treated by orally administering high-dose peni-
cillin [1e4] (AII). In Japan, macrolide-resistant S. pneumoniae
is detected in most cases; therefore, macrolides are not
recommended as the ﬁrst choice, differing form those in
Europe and the United States [4,5,10,13,14] (AII).
For outpatient treatment, b-lactamase inhibitor-
containing penicillin is commonly used. Therapy with
CVA/AMPC or SBTPC (2 tablets/3e4 times a day) is recom-
mended with respect to the efﬁcacy and suppression of
resistant bacteria [1,4,11] (AII). However, such high-dose
prescriptions are not always accepted by health insurance
system in Japan, and the following prescriptions (examples)
should also be considered.
In elderly patients or those with underlying lung diseases
such as COPD/old pulmonary tuberculosis, the use of res-
piratory quinolones should be considered positively from
the perspective of the effects on penicillin-resistant Pneu-
mococcus and tissue transfer [11,14,15] (BII). However, many
new quinolones also have antimicrobial activities against
Mycobacterium tuberculosis; therefore, the presence or
absence of active tuberculosis must be strictly checked
before administration [16] (AII).
(2) Hospital treatment
For hospital treatment, injection is primarily used. How-
ever, basic concepts for drug selection are similar to those at
the outpatient clinic. Considering S. pneumoniae,
H. inﬂuenzae, and M. catarrhalis, high-dose penicillin or
cephems, which are effective for these microorganisms,
should be selected [1e4] (AII). If more potent treatment is
required, respiratory quinolone injection should be used
[15,17] (BII).- - - Drugs to be recommended- - -
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times a
day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
* Concerning CVA/AMPC and SBTPC, up to 1000 mg of
AMPC or up to 750 mg of ABPC are approved dosage in
Japan.
Combination therapy with AMPC (oral preparation)
should also be considered.
[Example] CVA/AMPC, oral (125/250 mg), 1 tablet/3
times a day þ AMPC, oral (250 mg), 1 tablet/3 times a
day<> Second choices
- LVFX, oral, 500 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- MFLX, oral, 400 mg/once a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a
day
<> Second choice
- LVFX, intravenous drip, 500 mg/once a dayb. Atypical pneumonia
(1) Outpatient treatment
Atypical pneumonia is primarily caused by Myco-
plasma pneumoniae, Chlamydophila pneumoniae, and
Legionella pneumophila [1e5,10,11,13,14] (II). The oral
administration of a macrolide or tetracycline is the ﬁrst
choice [1,4,5,7] (AII). To suppress resistant bacteria, res-
piratory quinolones should be reserved as alternative
drugs [1,4,11,12,18] (BII).
However, recently, the appearance of macrolide-
resistant M. pneumoniae in adults has raised an issue in
Japan. Respiratory quinolones must be used as the ﬁrst
choice depending on local circumstances about drug
resistance [18] (CIII).
(2) Hospital treatment
For hospital treatment, injection is primarily used.
However, basic concepts for drug selection are similar to
those at the outpatient clinic. If more potent treatment is
required, new quinolone injection should be used
[1e4,11,15,17] (BII).- - - Drugs to be recommended- - -
(1) Outpatient treatment
A First choices
- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
- MINO, oral, 100 mg twice a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- MFLX, oral, 400 mg/once a day
K. Mikasa et al. / J Infect Chemother 22 (2016) S1eS65S4- TFLX, oral, 300 mg/twice a day
(2) Hospital treatment- AZM, intravenous drip, 500 mg/once a day
- MINO, intravenous drip, 100 mg/twice a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day.
- PZFX, intravenous drip, 500 to 1000 mg/twice a dayc. Cases in which whether the disease is bacterial pneumonia
or atypical pneumonia is unclear
(1) Outpatient treatment
In this case, combination therapy with high-dose
penicillin and a macrolide or tetracycline should be
selected as the ﬁrst choice to cover both bacterial and
atypical pneumonia [1e4,11,13,14,17,18] (BII).
As respiratory quinolones cover both bacterial and
atypical pneumonia, they are convenient, but should be
reserved as alternative drugs from the perspective of
suppression of resistant bacteria [1e4,11,15,17,18] (BII).
However, in elderly patients or those with underlying
lung diseases such as COPD/old pulmonary tuberculosis,
the use of respiratory quinolones should be considered
positively from the perspective of the effects on
penicillin-resistant Pneumococcus and tissue transfer
[11,14,15] (BII). Recently, the appearance of macrolide-
resistant M. pneumoniae in adults has raised an issue.
Respiratory quinolones may be used as the ﬁrst choice
depending on local circumstances about drug resistance
[18] (CIII).
(2) Hospital treatment
For hospital treatment, injection is primarily used.
However, basic concepts for drug selection are similar to
those at the outpatient clinic. If more potent treatment is
required, new quinolone injection should be used
[1e4,11,15] (BII).
(3) Severer cases requiring treatment in the ICU
In severer cases requiring treatment in the ICU,
S. pneumoniae should be initially considered, and a
macrolide or new quinolone should be used aggressively
in combination with a broad spectrum b-lactam such as
high-dose penicillin from the beginning of treatment
primarily to cover latent atypical bacteria (in particular,
when L. pneumophila is not covered, the condition may
become fatal) [1e4,11,17,18] (AII). In particular, combi-
nation therapy with a macrolide is recommended from
immunological aspects to suppress excessive inﬂamma-
tion related to cytokines [19] (CII).
As the possibility that causative microorganisms may
be enteric bacteria including ESBL-producing bacteria
cannot be ruled out, carbapenem injection should be
used as a ﬁrst-choice drug in patients with a background
factor for which ESBL-producing bacteria are frequently
detected [11,20] (BII).
The sensitivity of a urinary antigen kit to S. pneumoniae
and Legionella spp. is approximately 60%. Therefore, even
when the patient is negative for these bacteria in the
initial phase, the possibility of pneumonia related to
these bacteria should not be ruled out [1e4,8,9] (II).- - - Drugs to be recommended- - -
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
* Concerning CVA/AMPC and SBTPC, up to 1000 mg of
AMPC or up to 750 mg of ABPC are approved dosage in
Japan. Combination therapy with AMPC (oral prepara-
tion) should also be considered.
[Example] CVA/AMPC, oral (125/250 mg), 1 tablet/3
timesadayþAMPC, oral (250mg),1 tablet/3 timesaday
þ one of the followings:
- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
- MINO, oral, 100 mg/twice a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- MFLX, oral, 400 mg/once a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a
day
þ one of the followings:
- AZM, intravenous drip, 500 mg/once a day
- MINO, intravenous drip, 100 mg/twice a day
- CAM, oral, 200 mg/twice a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day(3) Severer cases requiring treatment in the ICU
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
þ one of the followings:
- AZM, intravenous drip, 500 mg/once a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day
- MINO, intravenous drip, 100 mg/twice a day2.1.2. Deﬁnitive therapy
- - - Executive summary- - -
- When causative microorganisms are identiﬁed based on the
results of microbial examination of good-quality sputum, blood
culture, and urinary antigen (S. pneumoniae, L. pneumophila)
tests and drug susceptibility testing of the causative agents,
deﬁnitive therapy should be performed if possible [2,3] (BIII).
- The place of treatment and drugs should be selected in accor-
dance with the severity of the disease [2,3] (AII).
- Antimicrobial drugs should be selected in reference to the sus-
ceptibility of isolated bacteria to antimicrobial drugs or a drug-
susceptibility tendency in the area [2,3,13,22] when these data
are available (AII).
- The administration period of an antimicrobial drug is deter-
mined in accordance with the improvement of symptoms and
laboratory data, with a target of 5e7 days [2,21] (BIII).
- When the patient is infected with L. pneumophila or
C. pneumoniae, the optimal administration period is about 14
days [21] (BIV).
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a. Streptococcus pneumoniae
- The Clinical and Laboratory Standards Institute (CLSI) has
established higher criteria for breakpoints for penicillin sus-
ceptibility on the administration of parenteral antimicrobial
drugs for S. pneumoniae infections other than meningitis [23],
based on the following ﬁndings: patients with severe pneu-
monia due to S. pneumoniae with a low PCG susceptibility
(MIC: 0.12e4 mg/mL) showed no difference in responses to
PCG and outcome [24,25] (II). For the treatment of pneumo-
coccal pneumonia, the dose of penicillin should be increased
[23,26] (A).
- In Japan, most S. pneumoniae isolates are macrolide resistant
[13,22].
- Respiratory quinolones have potent anti-pneumococcal ac-
tivities (III). The clinical effects of such quinolones are similar
to those of high-dose AMPC [27] (II).
- In Japan, quinolone-resistant S. pneumoniae is detected in
2e3% of the isolates [13]. As quinolone resistance may be
readily induced by point mutations of DNA gyrase or topo-
isomerase genes [28], quinolones must be used adequately
(AIII).
b. Haemophilus inﬂuenzae
- The ABPC-resistant mechanism of H. inﬂuenzae involves b-
lactamase production and/or PBP mutation. Previously, b-
lactamase production was primarily involved, but, recently,
PBP mutation-mediated b-lactamase-negative ABPC-resistant
(BLNAR) strains have been increasingly detected. ABPC-
resistant strains with both b-lactamase production and PBP
mutation are classiﬁed as b-lactamase-positive CVA/ABPC-
resistant (BLPACR) strains.
- According to a national survey in Japan, 49 (39.8%) and 7
(5.7%) of 123 H. inﬂuenzae strains were BLNAR and b-lacta-
mase-producing strains, respectively [13].
- BLNAR strains are also resistant to ﬁrst- and second-
generation cephems.
- PIPC exhibits an antimicrobial activity against BLNAR strains.
However, it is ineffective for BLPACR strains.
c. Klebsiella spp., Escherichia coli, Proteus spp.
- The proportion of extended spectrum b-lactamase (ESBL)-
producing bacteria has slightly increased among isolates from
respiratory samples.
- According to a national survey in Japan, ESBL-producing bac-
teria account for 1.8e3.4% of respiratory sample-derived
Klebsiella spp. strains [13,29].
- Most ESBL-producing strains are simultaneously resistant to
quinolones [30]. Antimicrobials should be selected according
to the drug susceptibility of isolated bacteria.
- In Japan, carbapenemase-producing strains are extremely
rare.
d. Mycoplasma pneumoniae
- In the ﬁeld of pediatrics, the detection rate of macrolide-
resistant M. pneumoniae has markedly increased. In adults,
that of macrolide-resistant M. pneumoniae also increase
[31,32].
- Tetracyclines exhibit potent clinical effects on macrolide-
resistant M. pneumoniae [33].
- Respiratory quinolones have good activities against
M. pneumoniae [34,35].e. Legionella spp.
- It should be noted that pneumonia related to Legionella spp.
other than L. pneumophila SG1 cannot be diagnosed using
Legionella urinary antigen testing.
- As neither b-lactams nor aminoglycosides have antimicrobial
activities against Legionella spp., which proliferates within
host cells, they are clinically ineffective.
- Quinolones, macrolides, and tetracyclines have been
conﬁrmed to exhibit clinical effects on Legionella spp. Previ-
ously, EM was the ﬁrst choice for this infection, but many
recent studies have showed the clinical efﬁcacies of LVFX and
AZM [36,37].
- RFP is effective when combined with EM. The combination of
EM and RFP is useful. A study suggested the effects of com-
bination therapy with LVFX and a macrolide [38] (CIII).
- Although there are no marked differences in antimicrobial
drug susceptibility among Legionella spp., clinical reviews to
verify this are limited [39].
f. Chlamydophila pneumoniae
- Only a few studies have supported the clinical effects of
antimicrobial drugs against C. pneumoniae pulmonary
infections.
- Tetracyclines, macrolides, and quinolones may be effective.
These drugs are recommended primarily based on the results
of basic studies [34,40].
g. Staphylococcus aureus
- With respect to Staphylococcus aureus in Japan, there has been
an increase in the number of methicillin-resistant strains even
in patients with community-acquired pneumonia. In partic-
ular, recently, municipal-onset-type MRSA (CA-MRSA) with
Panton-Valentine-Leucocidine (PVL) has been detected in
Japan, raising an issue [41].
- In cases of MSSA infection (bacteremia), the clinical effects of
CEZ are superior to those of VCM [42].
- As the susceptibility of MRSA to oral antimicrobial drugs dif-
fers among isolates, drugs should be selected according to its
drug susceptibility Results.
h. Streptococcus spp.
- Among various types of Streptococcus, the Streptococcus angi-
nosus group is frequently detected, and characterized by
strong abscess-forming features [43]. Streptococcus pyogenes
and Streptococcus agalactiae may also cause pneumonia. The
former may lead to serious pulmonary infection [44] (V).
- There is no penicillin resistance, but macrolide resistance is
observed at a low frequency [45].
- The anti-Streptococcus activities of quinolones vary. Among
quinolones, GRNX, MFLX, and STFX have relatively potent
antimicrobial activities [13,46].
i. Moraxella catarrhalis
- The number of b-lactamase- producing strains has increased
since the 1990's. Currently, most strains produce b-lactamase
[13,47].
- b-lactamase produced byM. catarrhalis decomposes penicillin.
- In Japan, macrolide- or quinolone- resistance have not been
reported [13].
j. Anaerobes
- Most anaerobes that cause pneumonia exist in the oral cavity.
Peptostreptococcus spp., Prevotella spp., and Fusobacterium spp.
are involved. Mixed infection with microaerophilic Strepto-
cocci is often observed.
- In many cases, infection with anaerobes may be associated
with aspiration.
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Porphyromonas spp.) are susceptible to combination drugs
consisting of penicillin and a b-lactamase inhibitor, CLDM and
MNZ [48].
k. Pseudomonas aeruginosa
- In patients with chronic respiratory tract infection, Pseudo-
monas aeruginosa colonizes in the airway, and may cause
community-acquired pneumonia [49].
- As the susceptibility of P. aeruginosa to antimicrobial drugs
differs among clinical isolates, drugs should be selected ac-
cording to its drug susceptibility results.
- - - Drugs to be recommended- - -
- The drug susceptibility of each clinical isolate should be
classiﬁed in accordance with the CLSI criteria [23].
- Establishment of prescriptions recommended in this article
* Antimicrobials have been approved for speciﬁc diseases and
speciﬁc causative agents by JapaneseMinistry of Health and
Welfare. The approvals are based on the results of clinical
studies with Good Clinical Practice. As a general rule, the
recommendations in this section refer to this (AII). However,
recent trends in drug susceptibility are also considered.
* The recent drug susceptibility results of the nationwide
studies in Japan were referred [13,22].
* The recommendations without the approvals by Japanese
Ministry are graded by evidence levels.[1] S. pneumoniae (PC-susceptible)
(1) Outpatient treatment
A First choice
- AMPC, oral (250 mg), 2 tablets/3e4 times a day
<> Second choices
- GRNX, oral, 400 mg/once a day
- MFLX, oral, 400 mg/once a day
- LVFX, oral, 500 mg/once a day
- TFLX, oral, 300 mg/twice a day
- STFX, oral, 100 mg/1e2 times a day(2) Hospital treatment
A First choices
- PCG, intravenous drip, 2,000,000 to 3,000,000
units/4 times a day
- ABPC, intravenous drip, 1e2 g/3e4 times a day
<> Second choices
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
- LVFX, intravenous drip, 500 mg/once a day[2] S. pneumoniae (PC-resistant)
(1) Outpatient treatment
A First choices
- GRNX, oral, 400 mg/once a day
- MFLX, oral, 400 mg/once a day
- LVFX, oral, 500 mg/once a day
- TFLX, oral, 300 mg/twice a day
- STFX, oral, 100 mg/1e2 times a day(2) Hospital treatment
A First choices
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- PAPM/BP, intravenous drip, 0.5e1 g/2e4 times a day[3] H. inﬂuenzae (ABPC-susceptible)
(1) Outpatient treatment
A First choice
- AMPC, oral (250 mg), 2 tablets/3e4 times a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- ABPC, intravenous drip, 1e2 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000mg/twice a day[4] H. inﬂuenzae (b-lactamase-producing)
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000mg/twice a day[5] H. inﬂuenzae [b-lactamase-negative ampicillin-resistant
(BLNAR)]
(1) Outpatient treatment- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
- PIPC, intravenous drip, 2 g/3e4 times a day
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- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day[6] H. inﬂuenzae [b-lactamase-positive amoxicillin clavulanate-
resistant (BLPACR)]
(1) Outpatient treatment- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000mg/twice a day[7] Klebsiella spp. [non-extended-spectrum b-lactamase (ESBL)-
producing bacteria]
The results of drug susceptibility testing must be
conﬁrmed.
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- CTM, intravenous drip, 1e2 g/2e3 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000mg/twice a day[8] Klebsiella spp. (ESBL-producing bacteria)
The results of drug susceptibility testing must be
conﬁrmed.
(1) Outpatient treatment- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- PAPM/BP, intravenous drip, 0.5e1 g/2e4 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day- DRPM, intravenous drip, 0.5e1 g/3 times a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day[9] M. pneumoniae
(1) Outpatient treatment
A First choices
- CAM, oral, 200 mg/twice a day
- AZM sustained-release preparation, oral, 2 g/single
dose
- MINO, oral, 100 mg/twice a day
<> Second choices
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day
- LVFX, oral, 500 mg/once a day(2) Hospital treatment
A First choices
- MINO, intravenous drip, 100 mg/twice a day
- AZM, intravenous drip, 500 mg/once a day
<> Second choice
- LVFX, intravenous drip, 500 mg/once a day[10] Legionella spp.
As a rule, hospital treatment should be performed.
A First choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/2e3 times a day
- PZFX, intravenous drip, 500 to 1,000 mg/twice a day
- AZM, intravenous drip, 500 mg/once a day
<> Second choice
- EM, intravenous drip, 500 mg/3 times a day þ RFP, oral,
450e600 mg/once a day.[11] C. pneumoniae
(1) Outpatient treatment
A First choices
- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
- MINO, oral, 100 mg/twice a day
<> Second choices
- GRNX, oral, 400 mg/once a day
- MFLX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day(2) Hospital treatment
A First choice
- MINO, intravenous drip, 100 mg/twice a day
<> Second choice
- AZM, intravenous drip, 500 mg/once a day[12] MSSA
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
<> Second choices
(The results of drug susceptibility testing must be
conﬁrmed.)
- AZM sustained-release preparation, oral, 2 g/single
dose
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- MINO, oral, 100 mg/twice a day
- CLDM, oral, 300 mg/3e4 times a day(2) Hospital treatment
A First choices
- CEZ, intravenous drip, 1e2 g/2e3 times a day
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
<> Second choices
- MINO, intravenous drip, 100 mg/twice a day
- CLDM, intravenous drip, 600 mg/2e4 times a day[13] MRSA
(1) Outpatient treatmentThe results of drug susceptibility testing must be
conﬁrmed.
- ST combination drug (SMX at 400 mg/TMP at 80 mg),
oral, 2 tablets/twice a day
- LZD, oral, 600 mg/twice a day
* CA-MRSA: When MRSA is susceptible to macrolides,
quinolones, tetracyclines, and CLDM, these drugs can
be used.(2) Hospital treatment
Refer to the section “2.2 Hospital-acquired pneu-
monia- - - 2.2.3 Deﬁnitive therapy- - - (1) MRSA” (p.13).[14] M. catarrhalis
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
<> Second choices
- LVFX, oral, 500 mg/once a day
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice
a day
<> Second choices
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000mg/twice a day[15] Streptococcus spp.
(1) Outpatient treatment
A First choice
- AMPC, oral (250 mg), 2 tablets/3e4 times a day
<> Second choices
- AZM sustained-release preparation, oral, 2 g/single
dose
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
A First choices
- PCG, intravenous drip, 1,000,000 to 2,000,000
units/3e4 times a day
- ABPC, intravenous drip, 2 g/3e4 times a day
<> Second choices
- AZM, intravenous drip, 500 mg/once a day
- VCM, intravenous drip, 1 g/twice a day[16] Anaerobes
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
- CLDM, oral, 300 mg/3e4 times a day
- MNZ, oral, 500 mg/3e4 times a day
<> Second choices
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day(2) Hospital treatment
A First choices
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/3e4 times a day
<> Second choices
- IPM/CS, intravenous drip, 0.5e1 g/3e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- PAPM/BP, intravenous drip, 0.5e1 g/3e4 times a
day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day[17] P. aeruginosa
The results of drug susceptibility testingmustbe conﬁrmed.(1) Outpatient treatment
- CPFX, oral, 200 mg/3 times a day
- LVFX, oral, 500 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- TFLX, oral, 300 mg/twice a day(2) Hospital treatment
Refer to the section “2.2 Hospital-acquired pneu-
monia- - - 2.2.3 Deﬁnitive therapy- - - (4) P. aeruginosa”
(p. 14).2.2. Hospital-acquired pneumonia
2.2.1. Empiric therapy: cases in which gram staining is not available
- - - Executive Summary- - -
- As a rule, an appropriate antimicrobial drug should be admin-
istered in the early stage. If hospital-acquired pneumonia is
suspected, the administration of an antimicrobial drug at a
sufﬁcient dose should be promptly started [50e54] (AII).
- Before the administrationof an antimicrobial drug, a good-quality
airway sample should be collected. However, the start of treat-
ment should not be delayed for this purpose [50e53] (BII).
- When selecting an antimicrobial drug, the presence or absence of
risk factors for resistantbacteria shouldbeevaluated[50e53] (AII).
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is clariﬁed, or after the treatment responsiveness is evaluated,
whether or not de-escalation is possible should be reviewed
[50e53] (AII).- - - Explanation- - -
Deﬁnition: Hospital-acquired pneumonia is deﬁned as “pneu-
monia that newly develops 48 h or more after admission”. In many
cases, treatment is difﬁcult due to unfavorable patient conditions
such as the presence of an underlying disease, immune capacity,
and general condition [50e52].
Laboratory ﬁndings: Patients meeting 2 of 3 items, fever, an
abnormal leukocyte count, and purulent secretes, in addition to the
appearance of an abnormal shadow of the chest should be diag-
nosed with hospital-acquired pneumonia [50e52].
1) Ventilator-associated pneumonia (VAP): VAP refers to pneu-
monia that newly develops 48 h or more after endotracheal
intubation/ventilator initiation. Its onset within 4e5 days after
endotracheal intubation is classiﬁed as early-type, and its sub-
sequent onset as late-type [50,51,54,55].
2) Hospital-acquired pneumonia other than VAP: Several types of
hospital-acquired pneumonia other than VAP include (1) im-
munodeﬁciency (for example, neutropenia during anticancer
therapy, cell-mediated immunodeﬁciency related to the
administration of steroids or immunosuppressive drugs) and (2)
aspiration pneumonia including latent aspiration (Refer to the
section “2.4 Aspiration pneumonia” on Page 19). Appropriate
management and selection of antimicrobial drugs in accordance
with individual conditions are necessary [50].
With respect to microorganisms that are expected, refer to the
section “2.2 Hospital-acquired pneumonia- - - 2.2.2 Empiric ther-
apy: Cases in which Gram staining is available” (p. 10).
- - - Drugs to be recommended- - -
a. Cases in which there is no risk of resistant bacteria
Antimicrobial drugs should be selected, targeting Strepto-
coccus pneumoniae, H. inﬂuenzae, and Klebsiella spp. as causa-
tive microorganisms [50e52] (BIII). Although it is difﬁcult to
estimate/identify causative microorganisms using sputum
samples, bacteria that are not isolated/cultured from good-
quality sputum may not be causative microorganisms. If
resistant bacteria such as MRSA and P. aeruginosa are not
detected on sputum culture and there is no deterioration of
clinical symptoms, an initial drug should be continued [50]
(BIII). In patients in whom aspiration episodes are clear,
those in whom oral hygiene is not maintained, or those with
consciousness disorder, drugs with anti-anaerobe activities
should be selected, considering the involvement of anaerobes
[50] (BIII). If an adequate antimicrobial drug is administered,
the treatment period may be 7e10 days, excluding MRSA and
P. aeruginosa [50,53] (BII).
A First choices- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTX, intravenous drip, 1e2 g/3 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a day
* If the involvement of anaerobes is suspected, SBT/ABPC
should be selected.
<> Second choice
- LVFX, intravenous drip, 500 mg/once a day (As its antimi-
crobial activity against anaerobes is weak, monotherapywith this drug should be avoided in patients with aspira-
tion pneumonia.).b. Cases in which there is a risk of multi-drug-resistant bacteria
(Table 3) [51]
To cover multi-drug-resistant bacteria including
P. aeruginosa, broad-spectrum antimicrobial drugs with anti-
P. aeruginosa activities should be selected [50e52] (AIII).
Considering the frequency of ESBL in each institution, carba-
penems should be considered even when enteric bacteria,
including Klebsiella spp. and Escherichia coli, are suspected
(BIV). If P. aeruginosa is not isolated on good-quality sputum
culture, a treatment option should be de-escalated to drugs for
cases in which there is no risk of resistant bacteria [50e52]
(AII). If aspiration is suspected, or if the involvement of gram-
positive bacteria is suggested, combination therapy with
CLDM must be considered (BIV). If there is a risk of MRSA
carrier (Table 4), combination therapy with anti-MRSA drugs
should also be considered.
The mean administration period of antimicrobial drugs with
respect to causative bacteria in patients with an improvement
was approximately 10 days. However, that for resistant bac-
teria such as P. aeruginosa and MRSA was approximately 12
days [53] (BII). If appropriate antimicrobial drugs can be
administered after clarifying causative bacteria, a treatment
period of approximately 10 days is recommended [53,56,57]
(BII).
A First choices- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5 g/4 times a day or 1 g/3 times
a day
- MEPM, intravenous drip, 1 g/3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
<> Second choices
- CFPM, intravenous drip, 1e2 g/2e4 times a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a dayIf the involvement of anaerobes is suspected, one of the
following options should be combined with one of the
above regimens:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- SBT/ABPC, intravenous drip, 3 g/3e4 times a dayc. Severe cases
One of the following options must be combined with one of
the regimens for cases in which there is a risk of multi-drug-
resistant bacteria. When comparing the results between pa-
tients undergoing appropriate and inappropriate treatments,
the prognosis of the latter was signiﬁcantly poorer [58,59]
(BII). However, a study reported that the prognosis in a group
with compliance with recommended drug selection was
signiﬁcantly poorer than in a non-compliance group in pa-
tients in whom infection with drug-resistant bacteria in the
ICU was suspected even among those in whom the etiology
was bacteriologically investigated [60] (BII). Therefore, it must
be considered that, even when resistant bacteria are etiologi-
cally involved, the administration of an appropriate antimi-
crobial drug that covers them does not always improve the
prognosis.
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5 g/4 times a day or 1 g/3 times a
day
Table 3
Risk factors for multi-drug-resistant bacteria.
1. Previous use of antimicrobial drugs within 90 days
2. Interval of 5 days or more from admission
3. Admission from an area/hospital in which resistant bacteria are frequent
4. Immunosuppressive state or treatment
Table 4
Risk factors for carrying MRSA [50].
Conditions under which anti-MRSA drug therapy should be considered
(including gram stain)
1. Long-term antibiotic therapy
2. History of long-term hospitalization
3. History of MRSA infection and colonization
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- DRPM, intravenous drip, 0.5e1 g/3 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
One of the following options should be combined with one
of the above regimens:
A First choices- CPFX, intravenous drip, 300 mg/twice a day
- LVFX, intravenous drip, 500 mg/once a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day
<> Second choices
- AMK, intravenous drip, 15 mg/kg/once a day
- GM, intravenous drip, 5 mg/kg/once a day
- TOB, intravenous drip, 5 mg/kg/once a day- - - Precautions- - -
- In cases of HCAP/VAP, several types of bacteria are often isolated
on sputum culture, but whether or not detected bacteria are
causative microorganisms is unclear. Caution is needed when
selecting an antimicrobial drug.
- Drugs should be selected, considering bacteria that are
problematic in each institution and their susceptibility
pattern.
- It is necessary to examine whether or not de-escalation is
possible when causative microorganisms are identiﬁed and
their susceptibility is clariﬁed.2.2.2. Empiric therapy: cases in which gram staining is available
a. Usefulness of Gram staining and interpretation of staining
ﬁndings
- - - Executive summary- - -
- Based on ﬁndings on Gram staining performed using accurate
procedures, appropriate initial treatment with antimicrobial
drugs can be started [51,61e65] (AII).
- Gram staining improves the accuracy of hospital-acquired
pneumonia diagnosis [51,61e63].
- If bacterial cells cannot be conﬁrmed on Gram staining,
follow-up may be continued without affecting the patient's
prognosis and administering/switching an antimicrobial drug
[51,63,64] (BII).
- Microorganisms that cause hospital-acquired pneumonia
should be estimated based on the results of the clinicalmicrobiological culture (CMC: Gram staining and culture) of a
lower airway sample immediately before the start of treat-
ment, and not based on bacteria isolated on active surveillance
culture (ASC), which was conducted as a strategy to prevent/
control infection prior to onset [66].
- Microorganisms that cause pneumonia or (colonization of) the lower
airway should be estimated based on the presence or absence of
neutrophils or phagocytosis (excluding those patients with neu-
tropenia or functional impairment of neutrophil) [50] (BII).
- - - Explanation- - -
[Gram staining]
Diagnostic accuracy of hospital-acquired pneumonia is
improved by conﬁrming neutrophils and bacterial cells using
Gram staining of airway samples. This observation has also been
conﬁrmed through an increase in the likelihood ratio of
hospital-acquired pneumonia in patients with a clinical pul-
monary infection score (CPIS) of 6 points or higher [61]. As
bacteria isolated from the lower airways of inpatients are
common colonizers in many cases, Gram staining is also useful
for discerning colonization from infection by evaluating the
presence or absence of neutrophil and phagocytosis. Therefore,
it is desirable to combine bacterial culture with Gram staining
[51,61e65].
Antimicrobial-drug selection based on Gram staining ﬁndings
leads to appropriate empiric therapy in two-thirds of patients with
hospital-acquired pneumonia, and it can be continued as deﬁnitive
therapy in many cases [62].
If there are no bacterial cells on Gram staining of lower airway
sample in whom an antimicrobial regimenwas not changed within
the past 72 h, it is unlikely that the focus of infection/inﬂammation
is within the lungs (lower airway) [51]. In this case, the possibility
of pneumonia mimic, such as pleural effusion, atelectasis, and
pulmonary edema, is suggested if the lung ﬁeld opacity still re-
mains in chest X-ray. If there is no other infectious focus, the
discontinuation of an antimicrobial drug may be warranted
[50,66,67].
A study has reported that the culture results of ASC performed
as a strategy of routine infection control measure prior to the
development of nosocomial pneumonia accurately predicted the
causative pathogen in only 35% of cases [66]. Therefore, it is
necessary to submit airway samples for clinical microbiological
culture (CMC) immediately before the start of presumptive
treatment.
[Causative microorganisms and their origin]
Microorganisms that cause hospital-acquired pneumonia are
derived from the oropharynx, airway (including the nasal cavity
and nasal sinus), digestive tract, and environment. Gastrointes-
tinal tract-derived causative microorganisms are enteric bacteria
(primarily, Klebsiella spp., E. coli and others such as Proteus spp.,
Enterobacter spp., Serratia spp., Morganella spp., and Citrobacter
spp.). Those derived from the upper airway include
S. pneumoniae, H. inﬂuenzae, Moraxella catarrhalis, S. aureus
(namely methicillin sensitive strain), and oral anaerobes. Those
derived from the environment include methicillin-sensitive
S. aureus, Pseudomonas spp., Acinetobacter spp., and Steno-
trophomonas spp. [50,51,65,68].
As the above bacteria derived from the airway and gastroin-
testinal tract basically exert strong virulence to the airway, they can
be considered a core pathogen group of hospital-acquired pneu-
monia. Their potential for developing airway inﬂammatory
response is generally believed stronger than those caused by
environmental pathogen [67,68].
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- - - Executive summary- - -
- As gram-positive bacteria, S. aureus and Streptococcus spp. are
frequently detected. It is relatively easy to differentiate the
two types of bacteria based on gram staining ﬁndings.
- Among various types of Streptococcus sp., S. pneumoniae,
Streptococcus anginosus group, and b-Streptococcus spp. are
supposed as causative microorganisms.
- If Streptococcus spp. is suspected as causative microorganisms,
empiric therapy with penicillin is encouraged.- - - Drugs to be recommended- - -
(1) Gram-positive coccus in cluster (grape cluster-like apperace)
A In cases of early onset hospital-acquired pneumonia
(development within the ﬁrst 48 h after hospitalization)
without previous administration of antimicrobial drugs,
or in the absence of conditions under which environ-
mental bacteria directly invade into the airway, such as
airway aspiration or tracheotomy, MSSA may be
supposed.
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CEZ, intravenous drip, 1e2 g/2e3 times a day
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MINO, intravenous drip, 100 mg/twice a day
<> In cases of late onset hospital-acquired pneumonia
(development of 48H to 72H after hospitalization), those
who have had previous antimicrobial treatment, or un-
der tracheotomy or ventilator management, an antimi-
crobial drug that covers MRSA should be administered
until proven, based on the susceptibility testing,
otherwise.
- Refer to the section “2.2.3 Deﬁnitive therapy- - - (1)
MRSA- - -” (p. 13).(2) Diplococcus consisting of a pair of two cocci (GPDC: Gram-
positive diplococci)
S. pneumoniae should initially be suspected. Enterococcus is also
a GPDC in microscopic appearance, but is basically considered a
non-pulmonary pathogen [67].<> Cases in which there have been no previous treatment
with antimicrobial drugs or risks of penicillin-resistant
Pneumococcus
- PCG, intravenous drip, 2,000,000 to 3,000,000 units/4e6
times a day
- ABPC, intravenous drip, 2 g/4e6 times a day
<> Cases in which previous treatment with antimicrobial drugs
or a risk of PRSP is present
- CTRX, intravenous drip, 1 g/twice a day or 2 g/once a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- LVFX, intravenous drip, 500 mg/once a day
- VCM, intravenous drip, 1 g/twice a day
(TDM should be conducted so that a trough is 15e20 mg/mL
[69].)
(3) Gram-positive coccus in either short or long chain (GPC in
chain)a- or b-hemolytic streptococci is indicated.
- PCG, intravenous drip, 2,000,000 to 3,000,000 units/
4e6 times a day
- ABPC, intravenous drip, 2 g/4e6 times a day(4) Gram-positive bacillus with a rod-like morphology (GPR:
Gram-positive rod)Corynebacterium spp. may be indicated.
- VCM, intravenous drip, 1 g/twice a day
(TDM should be conducted so that a trough is
15e20 mg/mL [69].)c. Gram-negative bacteria
- - - Executive summary- - -- When gram-negative bacteria are observed,
H. inﬂuenzae, M. catarrhalis, Enterobacteriaceae,
P. aeruginosa, Acinetobacter spp., and Stenotrophomonas
spp. may be indicated [50e52,65,68] (BII).
- It is difﬁcult to estimate the type of bacteria based on the
morphology on Gram staining in comparison with gram-
positive bacteria.
- Gram-negative bacteria frequently detected as causative
microorganisms include enteric bacteria and P. aeruginosa.
- It is encouraged important to recognize the basic anti-
microbial drug susceptibility pattern of each type (group)
of bacteria to make sure that the empiric antimicrobial
therapy is appropriate (Table 5).
- - - Drugs to be recommended- - -
(1) Cases of early-onset hospital-acquired pneumonia in
which there have been no previous administration of
antimicrobial drugs or risk of resistant bacteria
Aero-respiratory pathogen, such as H. inﬂuenzae and
M. catarrhalis, and enteric bacteria, such as Klebsiella spp.,
are indicated.
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTRX, intravenous drip, 1 g/twice a day or 2 g/once a
day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- LVFX, intravenous drip, 500 mg/once a day(2) Cases of late-onset hospital-acquired pneumonia or
ventilator-associated pneumonia in which the risk of
resistant bacteria is high
An antimicrobial drug with anti-pseudomonal activity
that targets non-glucose-fermentative gram-negative rod
should be administered [50,51,68] (BII).
- CAZ, intravenous drip, 1e2 g/4 times a day
- CFPM, intravenous drip, 1e2 g/4 times a day
- CZOP, intravenous drip, 1e2 g/2e4 times a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
(3) In critically ill patients, carbapenem may be the ﬁrst line
drug, considering the involvement of multi-drug-
resistant bacteria such as ESBL.
- MEPM, intravenous drip, 1 g/3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a dayd. Polymicrobial infection
- - - Executive summary- - -- If several bacterial cells differing one another in Gram
staining and/or morphology are observed (polymicrobial
infection), anaerobes may be involved.
- Polymicrobial infection commonly reﬂects microaspiration
of oropharyngeal secretions into the lower airway.
Table 5
Basic susceptibility of various pathogen groups to antimicrobial drugs.
GNRa GNRb ESBL-GNRc P. aeruginosa Acinetobacter Gram(þ)d
ABPC þe/ þ/
PIPC þþ þ þþ þ/ þ/
SBT/ABPC þþ þf þg þh þþ
TAZ/PIP þþ þf þg þþ þ/ þþ
CTX,CTRX þþ þi þþ
CPZ þþ þi þþ þ
CAZ þþ þi þþ þþ þ
CFPM þþ þþj þþ þþ þþ
Carbapenem þþ þþ þþ þþi þþ þþ
Monobactam þþ þ þ/ þ/
CPFX þþ þþi þþi þþ þþk
a E.coli, K. pneumoniae, P. mirabilis, H. inﬂuenzae, and M. catarrhalis.
b Enterobacter, Citrobacter, Serratia, P. vulgaris, and M. morganii.
c Extended-spectrum b-lactamase(þ)GNR.
d Excluding MRSA and enterococcus. It must be considered that there are many penicillinas-producing strains of MSSA.
e This is limited to Susceptible E. coli, Proteus, and H. inﬂuenzae.
f b-lactamase inhibitors do not inhibit cephalosporinase activity.
g Clinical experience is limited.
h SBT has a time-dependent antimicrobial activity against Acinetobacter (BL: BLI/ 2:1, A susceptibility test with liquid medium is recommended).
i Both intrinsic resistance and resistance induced by antimicrobial drugs are probable.
j The drug may also show an antimicrobial activity against cephalosporinase (AmpC)-producing strains.
k Excluding MRSA, enterococcus, and S. pneumoniae.
Reference 74 was quoted/modiﬁed.
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antimicrobial drug with an activity against obligate
anaerobe is not always necessary [67,70].
- In non-severe cases, the administration of antimicrobial
agents with anti-MRSA activity may be withheld in the
initial phase even when Staphylococcus-like bacterial cells
are observed [70].- - - Explanation- - -
When several types of bacteria differing in Gram staining and
morphology are observed, the condition is commonly interpreted
as aspiration pneumonia, suggesting the involvement of anaerobes.
However, the number of hospital-acquired pneumonia (including
VAP) caused by anaerobes have been reported relatively smaller
than generally anticipated. [71], Polymicrobial infection does not
always require the prompt antimicrobial therapy that covers an-
aerobes. Even though when aspiration pneumonia is suspected,
SBT/ABPC is frequently prescribed assuming anaerobic infection,
which actually works good on many occasions, it has to be
acknowledged that SBT/ABPC exert good antimicrobial activity not
solely against anaerobes, but also aero-enteric pathogen of pneu-
monia such as Streptococcus pneumonia, oral streptococci,
H. inﬂuenzae, M. catarrhalis, and Klebsiella pneumonia.
Inpatients are often exposed to gram-negative bacteria residing
in the hospital environment. Furthermore, there are many op-
portunities to undergo antimicrobial drug therapy that affects the
indigenous microﬂora. For such reasons, gram-negative bacillus
(enteric bacteria or P. aeruginosa) frequently colonize within the
oropharyngeal region of the elderly patients or long-term bed-
bound patients, many of whom need airway suctioning or have
tracheostomy that may serve as portal of entry of environmental
pathogen. Oropharyngeal microﬂora primarily consisting of these
gram-negative bacteria can be aspirated into the airway after
surgery requiring sedation or anesthesia, or during or after
endoscopic examination [57,72,73]. Brieﬂy, anaerobes may be an
occasional pathoen in polymicrobial infection as seen on Gram
staining of patients with suspected aspiration pneumonia, but
S. pneumoniae, H. inﬂuenzae, S. aureus, Klebsiella spp., P. aeruginosa,and Acinetobacter spp. are more commonly involved in many
cases, being similar to the microorganisms that are thought to be
the major pathogen of hospital-acquired pneumonia. This is in
contrast with the community-onset aspiration pneumonia, rep-
resented by lung abscess, in that anaerobes are primarily involved
[67,71].
Anaerobes involved in hospital-acquired pneumonia include
facultative anaerobic a-hemolytic streptococci in the oral cavity
and obligate anaerobes. Oral obligate anaerobes include gram-
positive coccus (Peptostreptococcus sp.), gram-negative coccus
(Veillonella sp.), and gram-negative bacillus “oral pigmented” Bac-
teroides (Bacteroides melaninogenicus), Prevotella sp., Porphyr-
omonas sp., and Fusobacterium sp.). Many of these types of bacteria
are susceptible to b-lactams that do not contain a b-lactamase in-
hibitor, new quinolones, macrolides, and tetracyclines.
Therefore, patients with hospital-acquired pneumonia may be
basically treated by standard empiric therapy for hospital-acquired
pneumonia even when aspiration pneumonia related to several
types of bacteria is suspected [67].
- - - Drugs to be recommended- - -
(1) Cases in which it is not necessary to consider the involve-
ment of multi-drug-resistant bacteria, or early hospital-
acquired pneumonia
The involvement of oral Streptococcus, oral anaerobes,
S. pneumoniae, H. inﬂuenzae, and enteric bacteria should be
considered.
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- LVFX, intravenous drip, 500 mg/once a day(2) Late-onset hospital-acquired pneumonia or cases in which
there is a risk of multi-drug-resistant bacteria
In addition to the above pathogens, the involvement of
non-glucose-fermentative gram negative bacteria or ESBL-
producing enteric bacteria must be considered.
- CFPM, intravenous drip, 1e2 g/2e4 times a day
- CZOP, intravenous drip, 1e2 g/2e4 times a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
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- DRPM, intravenous drip, 0.5e1 g/3 times a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day2.2.3. Deﬁnitive therapy
a. Rule of antimicrobial chemotherapy
- - - Executive summary- - -
- For antimicrobial drug treatment, empiric therapy should be
switched to deﬁnitive therapy [50,51,65,68] (AII).
- When causative microorganisms are not P. aeruginosa or
S. aureus and there is a prompt improvement in the patient's
condition, the duration of antimicrobial treatment could be as
long as 1 week [57,65,68] (BI).- - - Explanation- - -
If drug susceptibility test is not conducted for some reasons after
the identiﬁcation of causative microorganisms, an antimicrobial
drug should be selected with reference to the susceptibility pattern
(local sensitivity) of the identiﬁed bacteria at each institution. If the
local sensitivity is not obtained, a drug should be selected based on
the basic susceptibility of various pathogens to antimicrobial drugs
(Table 5) [74].
In the treatment of hospital-acquired pneumonia, the duration
of antimicrobial therapy generally tends to be longer than required
for the following reasons: opacity on chest X-ray often remains for
reasons other than pneumonia even after the start of antimicrobial
drug treatment; and there may be a large number of latent non-
pneumonia (or non-infectious-disease) factors that may cause in-
crease in body temperature or CRP level in inpatients [75]. How-
ever, if appropriate antimicrobial drug treatment is performed, it is
possible to complete treatment in 1 week [57]. In strains such as
Enterobacter spp., Serratia spp., Citrobacter spp., andMorganella spp.
(Table 5 GNRb), the expression of intrinsic antimicrobial-drug-
resistance genes encoded in chromosome genes is induced during
antimicrobial drug treatment, a phenomenon which is basically
rarely seen in E. coli, Klebsiella spp., H. inﬂuenzae, andM. catarrhalis
(Table 5 GNRa) (Table 5) [74,76,77]. Therefore, if adequately chosen
treatment parameters are improved, antimicrobial treatment could
be completed with careful follow up of patients' condition.
Although it is useful to recognize these pathogens, abbreviated as
SPACE (Serratia, Pseudomonas, Acinetobacter, Citrobacter, and
Enterobacter), as a representative microorganism group that causes
hospital-acquired pneumonia, the SPACE group is essentially a
common colonizer. Therefore it is important to bear in mind that
antimicrobial drug is not always indicated upon the isolation of
SPACE to avoid selection of antimicrobial resistant bacteria related
to unnecessary or long-term antimicrobial therapy [65,67].
b. Gram-positive bacteria
- - - Executive summary- - -
- In MRSA-infected patients, glycopeptides (VCM, TEIC) or
LZD should be selected [78,79] (AI).The therapeutic efﬁcacy of LZD is similar to those of
glycopeptides [50,80].
The penetration of LZD into the alveolar epithelium-
lining ﬂuid and intra-alveolar sputum is morefavorable. Therefore, use of LZD should be encouraged in
cases of restricted sputum expectoration, such as VAP
[51] (BII).
Exclusive use of a single drug may accelerate the acqui-
sition of resistance to the agent [81e83] (CI).
As DAP is inactivated by pulmonary surfactants, its use
should be avoided for MRSA pneumonia.- Glycopeptides should be selected as ﬁrst-line drug for
pneumonia caused by Corynebacterium sp [84] (AII).
- - - Explanation- - -
There is no signiﬁcant difference in the therapeutic efﬁcacy
for MRSA pneumonia between glycopeptides and LZD.
Several studies reported that the overall clinical efﬁcacy of
LZD, including the incidence of side effects, was superior to
VCM in patients with hospital-acquired pneumonia caused
by MRSA [85,86]. However, since the dosing of VCM in
these studies have been considered suboptimal, further
study is needed [51,87]. Some investigators have recom-
mended that, when MRSA is susceptible to CLDM or MINO
on a susceptibility test, LZD, a protein synthesis inhibitor
should be administered given the possible involvement of
the Panton-Valentine leukocidin [78,88]. If a prompt
improvement is achieved by the intravenous drip of LZD
600 mg q12h, or if the patient's condition is not critical,
switch from the intravenous administration to an oral
preparation of LZD, which shows high bioavailability [89],
is encouraged. As DAP is inactivated by pulmonary sur-
factants, it should not be used to treat MRSA pneumonia.
This may not apply to the treatment of septic pulmonary
embolism [90].
- - - Drugs to be recommended- - -
(1) MRSA
A First choices
- VCM, intravenous drip, 1 g/twice a day
- TEIC, intravenous drip, 400 mg for the ﬁrst 2 days/
twice a day for loading, 400 mg/once a day from
Day 3
* TDM should be conducted so that the trough levels of
VCM and TEIC range from 15 to 20 mg/mL [11].
- LZD, intravenous drip or oral administration, 600 mg/
twice a day
<> Second choices
- ABK, intravenous drip, 300 mg/once a day (A trough
level was established as 2 mg/mL using TDM.)
- ST combination drug (SMX at 400 mg/TMP at 80 mg),
oral administration, 2 tablets/twice a day or intrave-
nous drip, 960 mg/twice a day
- CLDM, intravenous drip, 600 mg/2e4 times a day (The
results of drug susceptibility testing must be
conﬁrmed).(2) MSSA
Refer to the section “2.1 Community-acquired
pneumonia- - - 2.1.2 Deﬁnitive therapy- - - [12] MSSA (2)
Hospital treatment” (p. 8).
(3) S. pneumoniae
Refer to the section “2.1 Community-acquired pneu-
monia- - - 2.1.2 Deﬁnitive therapy- - - [1] S. pneumoniae
(PC-susceptible) and [2] S. pneumoniae (PC-resistant)” (p.6).
(4) Corynebacterium sp.
VCM and TEIC should be administered, as described for
MRSA.
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- - - Drugs to be recommended- - -
(1) E. coli, Klebsiella spp., Proteus spp. (non-ESBL-producing
bacteria)
Refer to the section “2.1 Community-acquired pneu-
monia- - - 2.1.2 Deﬁnitive therapy- - - [7] Klebsiella spp.
[non-extended-spectrum b-lactamase (ESBL)-producing
bacteria] (2) Hospital treatment ” (p.7).
(2) E. coli, Klebsiella spp., Proteus mirabilis (ESBL-producing
bacteria)
Refer to the section “2.1 Community-acquired pneu-
monia- - - 2.1.2 Deﬁnitive therapy- - - [8] Klebsiella spp.
[ESBL-producing bacteria] (2) Hospital treatment” (p. 7).
(3) Enterobacter spp., Serratia spp., Citrobacter spp., Morganella
spp., Proteus vulgaris
A Third-generation cephems or quinolones should be
administered [50,51,68] (AII).
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a
day
- CTX, intravenous drip, 1e2 g/2e3 times a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 1000 mg/twice a day
<> If a strain is estimated to constantly express cepha-
losporinase (highly resistant to b-lactamase inhibitor-
containing b-lactams, oxyimino [¼3rd generation]
cephalosporin and cephamycin, through plasmid genes)
on an antimicrobial drug susceptibility test, fourth-
generation cephems or carbapenems should be
administered.
- CFPM, intravenous drip, 1e2 g/4 times a day
- CZOP, intravenous drip, 1e2 g/4 times a day
- MEPM, intravenous drip, 1 g/3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day(4) P. aeruginosa
 Anti-pseudomonal penicillins, third-generation or later
cephems, carbapenems, or new quinolones should be
administered [50,51] (AII).
 No marked enhancement of therapeutic effects related to
combination therapy with a b-lactam and aminoglycoside
has been conﬁrmed.
 Combination therapy with a b-lactam and new quinolone
(CPFX, LVFX)may be effective, but its effects have not been
investigated.
 When P. aeruginosa is resistant to several antimicrobial
drugs, combination therapy should be aggressively per-
formed [90,91] (AII).
 When performing combination therapy, the combination
effects of the drugs should be measured in vitro [50] (BIII).
- PIPC, intravenous drip, 2e4 g/4 times a day
- TAZ/PIPC, intravenous drip, 4.5 g/4 times a day
- CAZ, intravenous drip, 1e2 g/4 times a day
- CFPM, intravenous drip, 1e2 g/4 times a day
- CZOP, intravenous drip, 1e2 g/4 times a day
- AZT, intravenous drip, 1e2 g/4 times a day
- MEPM, intravenous drip, 1 g/3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- TOB, intravenous drip, 5 mg/kg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 1000 mg/twice a day
- LVFX, intravenous drip, 500 mg/once a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day* Combination therapy
the above b-lactam þ TOB (intravenous drip, 5 mg/
kg/once a day)
or þ CPFX (intravenous drip, 300 mg/twice a day)
or þ PZFX (intravenous drip, 1000 mg/twice a day)
* Multi-drug-resistant bacteria
CL (colistin): An initial dose (loading, 5 mg/kg) of CL
should be administered as a single dose. After 24 h,
administration at the following maintenance dose
should be started, and continued at 12-h or 8-
h intervals: 2.5  [(1.5  CLcre) þ 30] mg(5) Stenotrophomonas maltophilia
When this type of bacteria are isolated from airway
samples, they commonly represent colonization [51].
- MINO, intravenous drip or oral administration (during or
immediately after meals), 100 mg/twice a day
- ST combination drug (SMX at 400 mg/TMP at 80 mg), oral
administration, 3 to 4 tablets/3 times a day or intravenous
drip as TMP dose 240e320 mg/3 times a day(6) M. catarrhalis
Refer to the section “2.1 Community-acquired pneu-
monia- - - 2.1.2 Deﬁnitive therapy- - - [14] M. catarrhalis (2)
Hospital treatment” (p. 8).
(7) Acinetobacter baumannii
 When this type of bacteria are susceptible to SBT/ABPC,
this drug may be used as a ﬁrst-choice drug [51,67,92,93]
(AII).
 It has not been sufﬁciently investigated whether the ef-
fects of CVA/AMPC or TAZ/PIPC are similarly effective to
those of SBT/ABPC [92].
 Carbapenems may be effective.
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CAZ, intravenous drip, 1e2 g/4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- TOB, intravenous drip, 5 mg/kg/once a day
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day(8) H. inﬂuenzae
Refer to the section “2.1 Community-acquired pneu-
monia- - - 2.1.2 Deﬁnitive therapy- - - [3] H. inﬂuenza (ABPC-
susceptible), [4] H. inﬂuenza (b-lactamase-producing), [5]
H. inﬂuenza (b-lactamase-negative ampicillin-resistant
(BLNAR), and [6] H. inﬂuenza (b-lactamase-positive amoxi-
cillin clavulanate-resistant (BLPACR)” (p. 6e7).
- - - Explanation- - -
According to some investigators, enteric bacteria are clas-
siﬁed into 2 types: sensitive, Gram-negative rods, such as
E. coli, Klebsiella pneumoniae, and P. mirabilis, which are
susceptible to ﬁrst-generation cephalosporin, and resistant,
Gram-negative rods, such as Enterobacter spp., Serratia spp.,
and Citrobacter spp., which show an intrinsic or inducible
resistance to third-generation cephalosporin through chro-
mosomal AmpC genes [74,76,77]. In addition, the number of
extended spectrum of b-lactamase (ESBL)-producing strains
of E. coli, Klebsiella, and Proteus sp. that are resistant to all
cephalosporin has increased. Among resistant GNRs, such as
Enterobacter spp., strains that constantly produce AmpC-
type b-lactamase (cephalosporinase) (plasmid type) must
also be considered [76,77].
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susceptibility to antimicrobial agents differs among
P. aeruginosa, Stenotrophomonas spp., and Acinetobacter spp.
A study indicated that, in patients with P. aeruginosa pneu-
monia, monotherapy with a new quinolone might show
unfavorable bacteria-eradicating effects or lead to recru-
descence [90]. In some patients, combination therapy with a
b-lactam (PIPC, CAZ, CFPM, or carbapenems), which has an
anti-pseudomonal activity, and aminoglycoside or new
quinolone may be considered [51,90,94]. Most strains of
Stenotrophomonas spp. are susceptible to MINO or an ST
combination drug.
M. catarrhalis and Acinetobacter spp. are the frequent
types of Gram-negative coccus detected in patients with
early and late hospital-acquired pneumonia, respectively.
Many strains of the former produce b-lactamase. The latter
is a GNR existing in the hospital environment, and may be
resistant to many antimicrobial drugs. However, in Japan,
the multi-drug resistance of this type of bacteria has not
widely distributed. Carbapenems and new quinolones
should be selected. However, the vast majority of Acineto-
baccter strains are susceptible to SBT/ABPC. In particular, SBT
has an antimicrobial activity against this type of bacteria,
and their susceptibility to SBT/ABPC should routinely be
conﬁrmed. Primary test drugs for an antimicrobial suscep-
tibility of this type of bacteria (drugs appropriate for a
routine examination panel) are SBT/ABPC, CAZ, IPM/CS,
MEPM, GM, TOB, LVFX, and CPFX [95].
Pan-sensitive strains of H. inﬂuenzae are b-lactamase
(BL)-negative, ABPC-sensitive (BLNAS) strains. However,
there are various resistance patterns: BL-producing, ABPC-
resistant (BLPAR), BL-negative, ABPC-resistant (BLNAR),
and BL-producing, AMPC/CVA-resistant (BLPACR) strains.
BLNAS strains can be treated with ABPC, but SBT/ABPC
therapy is required to control BLPAR strains. The admin-
istration of CTRX or new quinolones is necessary for
BLNAR or BLPACR.
A randomized-controlled trial with multivariate analysis
has shown that factors for favorable bacteriological effects
included the absence of P. aeruginosa-related pneumonia
(<0.01), a higher body weight (<0.01), a low APACHE II
score (severity) (0.03), and CPFX therapy (0.04) [90].
Conditions suggesting the use of new quinolones include
allergy to b-lactams, the presence of or concern for ne-
phropathy (an aminoglycoside cannot be combined with a
b-lactam), necessity of covering obligate intracellular
pathogen, or situations in which switching to an oral
preparation is indicated [94]. An in vitro study indicated
that the alveolar epithelial lining ﬂuid (ELF) concentration
of LVFX reached as high as its serum concentration.
Furthermore, a prospective open-label study reported that
switching of intravenous drip to oral administration
decreased the ELF concentration, but it was within the
range at which many pathogens are deemed sensitive
based on the cumulative data of minimum inhibitory
concentrations for causative microorganisms [94].
2.3. Nursing and healthcare-associated pneumonia- - - Executive summary- - -
- Nursing and healthcare-associated pneumonia (NHCAP) is a
category independently deﬁned in Japan based on medical
circumstances.- The attending physician proposes a treatment category (Groups
A to D) by evaluating what treatment is necessary as the most
important item based on the patient's and his/her family's will
(Fig. 1) [96].
- Risk factors for resistant bacteria are categorized into two items,
and initial treatment options are recommended, assuming
target causative microorganisms (CIV).
- In patients in whom the general condition is unfavorable due to
complications or in terminal-stage patients, initial treatment
options are recommended considering side effects from the
perspective of innocent properties (CIV).
- In Group D, in which intensive care is required, combination
therapy with broad-spectrum (involving resistant bacteria and
Legionella) and potent antimicrobial drugs is recommended (BI).- - - Explanation- - -
[Characteristics and classiﬁcation of diseases]
In 2011, the Japanese Respiratory Society issued the “Guidelines
for the Management of Nursing and Healthcare-associated Pneu-
monia (NHCAP)” [96], considering medical circumstances in Japan
with reference to the entity of healthcare-associated pneumonia
(HCAP) proposed in the Untied States [51]. The deﬁnition of NHCAP
is shown in Table 6. As this committee has no objection to the entity
itself, the selection of drugs will be explained based on evidence to
avoid duplications with the above guidelines.
The mortality rate and frequency of resistant bacteria in pa-
tients with NHCAP are intermediate between community-acquired
pneumonia (CAP) and hospital-acquired pneumonia (HAP). How-
ever, NHCAP may be primarily regarded as being similar to geri-
atric pneumonia [97,98]. There is no fact that the rate at which
resistant bacteria are isolated increases with severity [97]. Even
when pneumonia is not severe, the host's activities of daily living
(ADL) and an underlying disease/immunodeﬁciency reduce the
prognosis in many cases [98]. As this type of pneumonia develops
in a variety of uneven populations, it is difﬁcult to simply deter-
mine severity classiﬁcation. Therefore, considering various condi-
tions, the entity of “treatment category”, involving the ethical
aspects of geriatric care, was introduced based on evaluation by
the attending physician who knows the patient well (Fig. 1).
Frequent basic conditions or concomitant diseases for NHCAP in
Japan include an advanced age, central nervous diseases, aspira-
tion, a reduction in ADL, and tubal feeding. Their factors are
aspiration pneumonia itself or risk factors, and HCAP in Japan may
overlap with aspiration pneumonia [99]. On the other hand, in
NHCAP patients, MRSA, P. aeruginosa, and anaerobes are more
frequently isolated in comparison with CAP patients. It is neces-
sary to switch therapeutic strategies, considering these causative
microorganisms. Refer to the next section “2.4 Aspiration pneu-
monia” (p.19).
[Type and frequency of causative microorganisms]
Concerning causative microorganisms in NHCAP patients,
resistant bacteria are frequently detected, differing from CAP pa-
tients. However, with respect to microorganisms that cause HCAP,
the distribution and frequency of Streptococcus pneumoniae and H.
inﬂuenzae, which are frequently isolated in CAP patients, as well as
MRSA, P. aeruginosa, and Gram-negative bacillus, which are
frequently detected in HAP patients, differ among countries, areas,
and institutions due to their variety (III). Concerning causative
microorganisms, a study reported that there was no marked dif-
ference between NHCAP and CAP [100]. On the other hand, a study
in the United States indicated that S. aureuswas frequently detected
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MNZ injecƟon or CLDM
New quinolone anƟbioƟcs
(CPFX*2) or PZFX*2))
or AZM for injecƟon
MRSA risk(+) :
VCM,TEIC, or LZD
or
or
or
Fig. 1. Recommendations of initial empiric antibiotic therapy [96].
Risk factors for involvement by drug-resistant pathogens.
-If no antibiotic therapy in the preceding 90 days or current tube feeding, the patient can be assumed to have no risk of involvement by drug-resistant pathogens.
-However, if past medical history indicates isolation of MRSA, the patient should be assumed to have risk of involvement by MRSA.
*1) Inappropriate when aspiration pneumonia is suspected, because it has insufﬁcient activity against anaerobic bacteria.
*2) Because of insufﬁcient activity against anaerobic bacteria, when used to treat suspected aspiration pneumonia, it should be used in combination with an antibiotic that has
activity against anaerobic bacteria (e.g., MNZ, CLDM, SBT/ABPC).
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advanced, as described for Japan, reported that aspiration pneu-
monia, H. inﬂuenzae, S. aureus, and Gram-negative bacillus were
more frequent than in patients with CAP [59]. As a result, the rate of
resistant bacteria increased, and inappropriate antimicrobial drugs
were selected in a high proportion of patients. In addition, the
mortality rate was higher than in CAP patients, suggesting the as-
sociation between the two factors.
Representative causative microorganisms with respect to the
presence or absence of risk factors for resistant bacteria are pre-
sented in Table 7 [96]. Of these, resistant bacteria, which are not
targeted in CAP patients, were isolated in approximately 20%.
However, the value was lower than in HAP patients. This is aTable 6
Deﬁnition of NHCAP [96].
1. Pneumonia diagnosed in a resident of an extended care facility or nursing home
2. Pneumonia diagnosed in a person who has been discharged from a hospital within
3. Pneumonia diagnosed in an elderly or disable d person who is receiving nursing ca
4. Pneumonia diagnosed in a person who is receiving regular endovascular treatment
therapy)
Standards for nursing care
Patients whose performance statues is PS 3 (capable of only limited self-care, conﬁned
Item 1 incudes patients on psychiatric wards.current status of Japan (III). However, we must consider that pa-
tients in whom isolated bacteria are unclear account for approxi-
mately 50%, with the involvement of aspiration as a background
factor [99]. In addition to bacteria commonly isolated in CAP pa-
tients, the frequency of enteric bacteria and anaerobes has
increased [102].
[Rules of antimicrobial drug therapy]
Risk factors for resistant bacteria in NHCAP patients include
“the previous use of antimicrobial drugs for 2 days or more
within 90 days” and “tubal feeding” (Table 8) [96] (II). A study
reported that, even among severe NHCAP patients who were
managed with a ventilator or in the ICU, resistant bacteria werethe preceding 90 days
re
as an outpatient (dialysis, antibiotic therapy, chemotherapy, immunosuppressant
to bed or a chair more than 50% of their waking hours) or more.
Table 7
Possible pathogens isolated from NHCAP patients [96].
When an NHCAP patient has no risk factors for involvement by
drug- resistant pathogens
 Pneumococcus
 MSSA
 Gram-negative enteric bacteria (including Klebsiella and E. coli)
 Haemophilus inﬂuenzae
 Oral Streptococci
 Atypical pathogens (particularly Chlamydophila)
When an NHCAP patient has a risk factor for involvement by
drug-resistant pathogens (the following will be considered in
addition to the above-mentioned pathogens)
 Pseudomonas aeruginosa
 MRSA
 Acinetobacter
 ESBL-producing enteric bacteria
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without a history of antimicrobial drug therapy [103]. Another
study indicated that tubal feeding was an independent risk factor
for infection with P. aeruginosa (odds ratio: 13.9) [104] (II). This is
the reason why Treatment Category C was established in the
Guidelines. Brieﬂy, patients who do not meet the above two items
are regarded as having no risk factor for resistant bacteria, and
assigned to Group B. Patients meeting 1 or 2 items or those in
whom MRSA was previously isolated are assigned to Group C.
Respective drugs to be recommended were separately estab-
lished. Patients in whom outpatient treatment is considered to be
appropriate are assigned to Group A, and those in whom the
attending physician considers ventilator or ICU management
necessary to Group D. Drugs to be recommended were added,
and a treatment category algorithm (Fig. 1) [96] was prepared.
Concerning HCAP treatment in Europe and the United States,
there is a gap between drugs used in clinical practice and those
recommended in guidelines [105] (II). Therefore, treatment
category-based empiric therapy in Japan may be acceptable in
clinical practice; future investigation is necessary.
[Administration period of antimicrobial drugs]
There is no evidence regarding the administration period of
antimicrobial drugs. An administration period of 7e10 days, which
is routinely adopted in the highest percentage of patients, is
appropriate (BIV). When administering antimicrobial drugs for a
longer period, equivalent-spectrum antimicrobial drugs should be
selected, or de-escalation of antimicrobial drugs should be per-
formed. In this case, fever, CRP, and leukocyte counts are often
used as indices of the treatment response. In cases of aspiration
pneumonia in which aspiration recurs during treatment despite
the efﬁcacy of antimicrobial drugs, it is necessary to evaluate
whether the effects of antimicrobial drugs are not obtained or
recurrence occurs.Table 8
Risk factors for involvement by drug-resistant pathogensa in NHCAP [96].
 History of antibiotic therapy for 2 or more days in the preceding 90 days
 Current tube feeding
The risk of MRSA should be taken into account whenever there is past history of
MRSA isolation.
When attempting to predict the isolation of drug-resistant pathogens based on the
presence of these risk factors, it should be borne in mind that their sensitivity and
negative predictive value are high, but their speciﬁcity and positive predictive value
are low.
a Drug-resistant pathogens include Pseudomonas aeruginosa, MRSA, Acineto-
bacter, ESBL-producing enteric bacteria, and Stenotrophomonas maltophilia.- - - Drugs to be recommended- - -
a. Empiric therapy (Fig. 1) [96]
(1) Cases in which there is no risk of resistant bacteria and
outpatient treatment is performed (Group A)
According to a study, Chlamydophila spp. and M. pneu-
moniae accounted for 34.7 and 9.3% of patients in whom
the type of microorganisms that cause NHCAP was clari-
ﬁed in Japan, respectively [98]. The results suggested that
Chlamydophila spp. is a target of treatment, as described
for CAP. Therefore, in Group A, combination therapy with a
b-lactam and macrolide or monotherapy with a respira-
tory quinolone should be performed (BII). In Group D, an
anti-P. aeruginosa drug should be combined with CPFX,
PZFX, or AZM for injection, considering Legionella or
Chlamydophila spp. pneumonia. However, concerning
combination therapy with a macrolide (CII) in patients
without “severe pneumonia requiring intensive care”, as
described below, the evidence level is not always high
from the perspectives of medical economics, side effects,
and resistant bacteria [106]. Some studies examined the
mortality rate with respect to the presence or absence of
treatment covering atypical pathogens, and reported that
the mortality rate was signiﬁcantly lower in the presence
of such treatment [17]. A recent meta-analysis also showed
a difference [107].
Respiratory quinolones were established as an option
(BII) based on many references describing that their ef-
fects are similar to or more potent than those of combi-
nation therapy with a b-lactam and macrolide. However,
this must be further examined, considering factors such as
severity and the presence or absence of concomitant
sepsis [108]. Furthermore, the prevalence of penicillin-
resistant Pneumococcus, which has been internationally
emphasized as an issue, and macrolide-resistant Pneu-
mococcus, which has been markedly observed in Japan,
was also a background factor for establishing respiratory
quinolones as an option [109]. The previous use of anti-
microbial drugs, which is often observed in patients with
NHCAP, is considered to be a risk factor for resistant
Pneumococcus [110]. A study reported that penicillin or EM
resistance in HCAP patients was more advanced than in
CAP patients [100]. A study indicated that the efﬁcacy of
oral therapy with LVFX was similar to that of CTRX in-
jection therapy in 619 patients with CAP [111]. Another
study reported that, among 680 patients with non-severe
HCAP, oral LVFX was useful in those with no description of
causative microorganisms [112]. However, when aspira-
tion pneumonia is suspected, GRNX or MFLX should be
selected, because the effects of LVFX on anaerobes are
weak. Furthermore, several studies suggested the useful-
ness of MFLX, which is not inﬂuenced by the kidney
function and does not require dose regulation, in elderly
patients with NHCAP [113,114].
As treatment is completed with a single, high dose,
compliance is favorable. AZM sustained-release prepara-
tions [115e117], which simultaneously cover bacteria and
atypical pathogens, and STFX, which shows a favorable
MIC for anaerobes, may also be recommended [118].
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times a
day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
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- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
<> Second choices
- MFLX, oral, 400 mg/once a day
- GRNX, oral, 400 mg/once a day
- STFX, oral, 100 mg/L to 2 times a day
or
- CTRX*1, intravenous drip, 2 g/once a day or 1 g/twice a
day
- CTX*1, intravenous drip, 1e2 g/2e3 times a day
þ one of the followings:
- AZM sustained-release preparation, oral, 2 g/single
dose
- CAM, oral, 200 mg/twice a day
*1) As the antimicrobial activity of the drug against an-
aerobes is insufﬁcient, it is inappropriate under a tentative
diagnosis of aspiration pneumonia.
(2) Cases in which there is no risk of resistant bacteria and
hospital treatment is performed (Group B)
In this category, we recommend monotherapy from the
perspectives of causative microorganisms resembling those
for CAP and side effect-based “innocent properties”. A study
reported that initial treatment with narrow-spectrum anti-
microbial drugs did not always lead to a poor prognosis
[119]. In particular, according to two articles [120,121], it is
not necessary to consider resistant bacteria in HCAP patients
in whom causative microorganisms are unclear; treatment
in accordance with CAP treatment is sufﬁcient (BII). How-
ever, an advanced age, central nervous diseases, aspiration,
and a reduction in ADL are the clinical characteristics of
aspiration pneumonia. The condition of NHCAP in Japan
overlaps with aspiration pneumonia [122]. Therefore, in
Group B, to which patients admitted for the ﬁrst time, with
no recent use of antimicrobial drugs, correspond, antimi-
crobial therapy with b-lactamase inhibitor-containing pen-
icillins is appropriate, as described for CAP. However, when
aspiration pneumonia is suspected, CTRX and LVFX should
be avoided (BIV). For the management of enteric bacteria,
candidate drugs for Group B, PAPM/BP, may be selected.
Actually, it is not necessary to consider P. aeruginosa in pa-
tients with CAP or non-ICU HAP. A study indicated that
ertapenem, which is not effective for P. aeruginosa, was
useful [123], as demonstrated for PAPM/BP. However,
another study reported that the widespread use of ertape-
nem induced the cross resistance of P. aeruginosa to other
carbapenems; the use of PAPM/BP alone should be avoided
[124] (BIV). In elderly persons, with a high risk of aspiration,
who are repeatedly admitted and discharged, Klebsiella is
often involved. TAZ/PIPC is more useful according to a study
[125] (BII). In patients in whom Gram-negative bacillus is
detected on Gram staining of sputum or those in whom the
involvement of enteric bacteria is suspected, PAPM/BP or
TAZ/PIPC should be selected (BIV).
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- CTRX*1, intravenous drip, 2 g/once a day or 1 g/twice a day
- CTX*1, intravenous drip, 1e2 g/2e3 times a day
- LVFX*1, intravenous drip, 500 mg/once a day
- PAPM/BP, intravenous drip, 0.5e1 g/2e4 times a day
*1) As the antimicrobial activity of the drug against anaer-
obes is insufﬁcient, it is inappropriate under a tentative
diagnosis of aspiration pneumonia.
(3) Cases in which there is a risk of resistant bacteria and hos-
pital treatment is performed (Group C)The target microorganisms include P. aeruginosa, MRSA,
and Acinetobacter spp. in addition to frequent microorgan-
isms that cause respiratory infection [97,99,103,126]. As
antimicrobial drugs, TAZ/PIPC, with an antimicrobial activity
against P. aeruginosa, fourth-generation cephems, carbape-
nems, and quinolones (CPFX, PZFX) are recommended. TAZ/
PIPC exhibits effects similar to those of IPM/CS and MEPM in
patients with nursing and healthcare-associated pneumonia
[127] (BII). PZFX also has an antimicrobial activity against
S. pneumoniae when used at a high dose (2 g/day). When
pneumonia related to atypical pathogens such as Chlamy-
dophila spp. is suggested, quinolones should be selected. As
the antimicrobial activities of fourth-generation cephems
and quinolones against anaerobes are weak, these drugs
should be combined with MNZ, CLDM, or SBT/ABPC.
Recently, the resistance of the Bacteroides fragilis group to
CLDM has advanced [128]. Therefore, in Europe and the
United States, MNZ is selected as a ﬁrst-choice antimicrobial
drug against anaerobes. However, the rate at which the B.
fragilis group is involved in oral anaerobes is low, and
combination therapy with CLDM may be selected [129,130].
Therefore, for combination therapy with fourth-generation
cephems, we recommend the two drugs. When there is a
risk of MRSA, such as previous admission, they should be
combined with VCM, TEIC, or LZD. If there is no abscess
formation, ABK is also effective.
A First choices
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
<> Second choices
- CFPM*2, intravenous drip, 1e2 g/2e4 times a day
- CPR*2, intravenous drip, 1e2 g/2e4 times a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
or
- CPFX*2, intravenous drip, 300 mg/twice a day
- PZFX*2, intravenous drip, 1000 mg/twice a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
*In addition to the above drugs, if MRSA infection is sus-
pected, antimicrobial drugs should be added in accordance
with the section “MRSA pneumonia”.
*2) As the antimicrobial activity of the drug against anaer-
obes is insufﬁcient, it should be combined with a drug with
an antimicrobial activity against anaerobes (MNZ, CLDM, or
SBT/ABPC) under a tentative diagnosis of aspiration
pneumonia.
(4) Severe cases requiring intensive care (Group D)
To cover L. pneumophila and atypical pathogens, which are
rare as causative microorganisms but may cause severe
conditions, Group-C antimicrobial drugs should be com-
bined with CPFX, PZFX, or AZM injection (BI). Concerning
the usefulness of combination therapy with a b-lactam and
macrolide injection for severe pneumonia, evidence has
been accumulated [131]. A study indicated that, in severe
community-acquired pneumonia patients with sepsis or
requiring ICU management, combination therapy with a b-
lactam and macrolide led to a more favorable prognosis
compared to that with a quinolone (I), suggesting that anti-
inﬂammatory actions are involved in the mechanism [132].
In addition, another study reported that, among pneumonia
K. Mikasa et al. / J Infect Chemother 22 (2016) S1eS65 S19patients with acute pulmonary disorder, both the ventilator
withdrawal and survival rates in a macrolide-treated group
were higher than in a non-macrolide-treated group [19] (I).
Several meta-analyses also support them [107,133].
A First choices
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
þ one of the followings:
- CPFX*2, intravenous drip, 300 mg/twice a day
- PZFX*2, intravenous drip, 1000 mg/twice a day
- AZM, intravenous drip, 500 mg/once a day
<> Second choices
- CFPM*2, intravenous drip, 1e2 g/2e4 times a day
- CPR*2, intravenous drip, 1e2 g/2e4 times a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
þ one of the followings:
- CPFX*2, intravenous drip, 300 mg/twice a day
- PZFX*2, intravenous drip, 1000 mg/twice a day
- AZM, intravenous drip, 500 mg/once a day
In addition to the above drugs,
*If MRSA infection is suspected, antimicrobial drugs should
be added in accordancewith the section “MRSA pneumonia”.
*2) As the antimicrobial activity of the drug against anaer-
obes is insufﬁcient, it should be combined with a drug with
an antimicrobial activity against anaerobes (MNZ, CLDM, or
SBT/ABPC) under a tentative diagnosis of aspiration
pneumonia.
b. Deﬁnitive therapy
Antimicrobial drugs against identiﬁed causative microor-
ganisms should be selected in accordance with the section
“2.2 Hospital-acquired pneumonia” (p. 8).
2.4. Aspiration pneumonia
- - - Executive summary- - -
- As oral indigenous bacteria, including anaerobes, cause aspira-
tion pneumonia, b-lactamase inhibitor-containing penicillins
are appropriate (BII).
- In cases of nosocomial onset, it is necessary to cover Gram-
negative bacillus, including P. aeruginosa.
- In cases of severe ventilator-associated pneumonia (VAP), the
selection of broad-spectrum antimicrobial drugs or combination
therapy with them should not be hesitated (AI).
- The detection rate of ESBL-producing Gram-negative bacillus
has increased, and antimicrobial drugs should be carefully
selected.
- It is important to prevent subclinical aspiration through oral
care and the prevention of gastroesophageal reﬂux, such as head
lifting (BII).
- To prevent aspiration pneumonia, it is also important to improve
the nutritional status and avoid the overuse of sleeping pills/
sedatives (BII).- - - Explanation- - -
[Characteristic and classiﬁcation of diseases]
Aspiration pneumonia occurs with a background factor,
dysphagia, which is frequently observed in the presence of areduction in ADL or systemic functions, especially cerebrovascular
disorder. Its onset is associated with dietary ingestion in elderly
persons [134]. Currently, aspiration pneumonia is accurately
deﬁned only in the Guidelines for the Management of Hospital-
acquired Pneumonia (HAP) in Adults, which were prepared by
the Japanese Respiratory Society [135]. The guidelines present
conditions that may cause dysphagia, which were proposed by the
Japanese Study Group on Aspiration Pulmonary Disease (Table 9,
modiﬁed) [136]. In our guidelines, we primarily explain antimi-
crobial drugs to be selected for patients with such conditions.
The above deﬁnition is also adopted in the Guidelines for the
Management of Nursing and Healthcare-associated Pneumonia
(NHCAP) [96]. In elderly persons admitted to long-term care beds
or nursing homes, risk factors include dysphagia and tubal
feeding according to international data on pneumonia that de-
velops in nursing homes [137e139]. In Japan, frequent underlying
diseases in patients with NHCAP also include central nervous
diseases and dementia, which are closely associated with aspi-
ration. The proportion of patients after percutaneous endoscopic
gastrostomy (PEG) is high [140]. However, among various types of
community-acquired pneumonia, a diagnosis of aspiration pneu-
monia is made based on onset factor-based classiﬁcation, and is
not equal to NHCAP diagnosed primarily based on the place of
onset or grade of nursing. According to data in Spain, aspiration
pneumonia accounts for 20.6% of patients with healthcare-
associated pneumonia (HCAP) requiring admission. This per-
centage was markedly higher than in those with community-
acquired pneumonia (CAP) requiring admission (3.6%), but cor-
responded to no more than 1/5 [100]. On the other hand, a
multicenter cooperative study involving inpatients with pneu-
monia in Japan, where the rapid aging of society is advanced,
reported that 60.1% of patients who were admitted with CAP had
aspiration pneumonia. Even in patients with CAP, which is not
classiﬁed as NHCAP, the involvement of aspiration cannot be
ignored [141]. Furthermore, the study indicated the involvement
of aspiration in 86.7% of patients, aged over 70 years, with CAP/
HAP [141]. In the future, the signiﬁcance of distinguishing aspi-
ration pneumonia among patients with NHCAP or HAP and
changing therapeutic strategies should be examined. However,
NHCAP more markedly affects ADL compared to CAP, and the
aspect of elderly pneumonia is emphasized; it may be signiﬁcant
to positively diagnose aspiration pneumonia and establish ther-
apeutic strategies different from those for CAP [142].
Concerning HAP, a reduction in the immune function is a
background factor. HAP has two aspects: pneumonia with a high
risk of resistant bacteria and that in which central nervous disease-
related aspiration is involved. In the Guidelines for the Manage-
ment of Hospital-acquired Pneumonia in Adults, which were pre-
pared by the Japanese Respiratory Society, Mendelson syndrome
and VAP are categorized as a group, and 3 classiﬁcations, involving
diffuse deglutition-related bronchiolitis, in which there are no
ﬁndings of pneumonia, are proposed. In addition, a ﬂow chart for
diagnosis is presented [135] (Fig. 2). With respect to the condition
and treatment of VAP, refer to a review described by Chastre et al.
[55] Management other than antimicrobial drug therapy should
also be considered, and bundle (Table 10)-based prevention should
be performed [143] (AII).
[Type and frequency of causative microorganisms]
Streptococcus pneumoniae, S. aureus, and Enterobacteriacae have
been reported. A study indicated that K. pneumoniae was frequent
[144]. The involvement of oral indigenous bacteria, such as Strep-
tococcus anginosus group. and anaerobes, has been suggested
[145,146]. In cases of nosocomial onset, Gram-negative bacillus,
including P. aeruginosa, must also be considered. Concerning E. coli,
Table 9
Conditions that may cause dysphagia [136] modiﬁed.
Old/acute cerebrovascular disorder
Degenerative nervous and neuromuscular diseases, Parkinson's disease
Consciousness disorder, dementia
Gastroesophageal reﬂux, after gastrectomy (especially total gastrectomy),
achalasia, scleroderma
Being bedridden
Laryngeal/pharyngeal tumors
Oral abnormalities (tooth occlusion disorder, inadaptation of dentures,
dry mouth)
Tracheotomy, nasogastric tube (tubal feeding)
Drugs that induce dry mouth, such as sedatives, sleeping pills,
and anticholinergic drugs
Table 10
Bundles for the prevention of ventilator-associated pneumonia.
(1) Upper body lifting
The head should be lifted at 30e45 .
(2) Discontinuation of sedatives
A sedative should be discontinued once a day to evaluate whether
or not extubation is possible.
(3) Prevention of gastrointestinal hemorrhage
(4) Prevention of deep venous thrombosis (DVT)
In addition to the above items, methods to prevent aspiration pneumonia include
oral care, the administration of drugs that improve the deglutition function, such as
ACE inhibitors and cilostazol, improvement in the nutritional status, eating/swal-
lowing rehabilitation, and anti-Pneumococcus vaccination.
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strains may increase in the future.
[Rules of antimicrobial drug therapy]
If appropriate antimicrobial drug therapy is not selected under a
diagnosis of aspiration-related pneumonia, insufﬁcient treatment
may lead to a fatal condition, or excessive treatment may increase
the number of resistant bacteria, showing negative effects. There
may be differences in options for empiric therapy between patients
with VAP (most patients show severe conditions) and those with
diffuse deglutition-related bronchiolitis, in whom the start of
treatment is not accelerated. On the other hand, approaches to
prevent pneumonia after aspiration or avoid aspiration are
important. Oral care, head lifting, and improvement in the nutri-
tional status must be considered, and the overuse of sleeping pills/
sedatives should be avoided (BII).
The best option for standard-type aspiration pneumonia is an
antimicrobial drug that exists an antimicrobial activity against both
aerobes and anaerobes. SBT/ABPC and TAZ/PIPC are effective for
anaerobes frequently isolated in the respiratory system, such as
Fusobacterium spp., Prevotella spp., and Peptostreptococcus spp.
[147,148]. As the resistance rates of these types of bacteria to the
two regimens are low, these regimens are also recommended as
ﬁrst choices in the guidelines established by the Japanese Associ-
ation for Anaerobic Infection Research [126].Fever, sputum, cough, tachypnea, tachyc
Chest X-ray
CT (images showing the presence of bilateral 
pneumonia in most cases)
High serum CRP level
VenƟlator-associated 
pneumonia,
Mendelson’s syndrome
AspiraƟon pneu
(common typ
Direct observaƟon of aspiraƟon Presence of funcƟonal
DefiniƟve cases Probable cas
Pneumonic findings present
Fig. 2. Diagnostic ﬂow chart for aspirHowever, a study reported that the previous administration of
antimicrobial drugs and ADL were correlated with the frequency
of Enterobacteriacae- or P. aeruginosa-related pneumonia [149]. A
retrospective study involving 90 patients with aspiration pneu-
monia showed that the frequency of K. pneumoniae-related
pneumonia was 25% [150]. Based on these studies, drugs to be
selected should be changed in accordance with the previous
administration of antimicrobial chemotherapeutic drugs in pa-
tients admitted to general or medical wards. Among patients with
hospital-acquired pneumonia, broad-spectrum drugs should be
selected in those with severe aspiration pneumonia or VAP (BII).
When causative microorganisms are identiﬁed and an improve-
ment in the condition is achieved, de-escalation should be
performed.
- - - Drugs to be recommended- - -
a. Empiric therapy
➀ No risk of resistant bacteria
Drugs with potent antimicrobial activities against oral an-
aerobes are presented. However, no article has provided
high-level evidence regarding aspiration pneumonia. As the
following drugs affect the intestinal ﬂora, antimicrobial drug-
associated diarrhea may occur. If symptom improvement is
delayed, patients must be promptly admitted, and dripardia
In elderly paƟents:
Anorexia, Decreased ADL,
Impaired consciousness , 
InconƟnence
monia 
e)
Diﬀuse aspiraƟon 
bronchioliƟs
 dysphagia Possibility of funcƟonal dysphagia
es Suspected case
No pneumonic findings
ation pulmonary disorders [96].
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should not be prolonged).
(1) Outpatient treatment
A First choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times
a day
- SBTPC, oral (375 mg), 2 tablets/3e4 times a day
<> Second choices
- MFLX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
- GRNX, oral, 400 mg/once a day(2) Hospital treatment
When a diagnosis of aspiration pneumonia is made,
SBT/ABPC is most frequently used in Japan [151]. Kaneko
et al. reported that the sensitivity of oral anaerobes that
may cause aspiration pneumonia, such as Peptos-
treptococcus spp., Prevotella spp., and Fusobacterium spp.,
to SBT/ABPC was 100%, similar to that to TAZ/PIPC [152].
The effects of CLDM on aspiration pneumonia or a
pulmonary abscess are similar to those of SBT/ABPC (BI)
[145]. SBT/ABPC and CLDM showed similar effects and
tolerance on aspiration pneumonia (67.5 and 63.5%,
respectively) [147]. Oral anaerobes, excluding Bacteroides
spp., are still susceptible to CLDM. A randomized clinical
trial (RCT) indicated that CLDM was more potent than
cephems [153].
A First choice
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
<> Second choice
- CLDM, intravenous drip, 600 mg/2e4 times a day➁ Cases in which there is a risk of resistant bacteria or severe
cases
In cases in which there is a risk of resistant bacteria or
severe cases, drugs should be selected in accordance with
options for Group C for NHCAP. Tubal feeding is a risk factor
for aspiration, and is also a risk factor for resistant bacteria
[97]. When the involvement of Enterobacteriacae, such as
K. pneumoniae and E. coli, is suggested, empiric therapy
should be selected in accordance with cases in which there is
a risk of resistant bacteria [55]. In Japan, the proportion of
ESBL-producing bacteria on sputum culture in patients with
respiratory infectious diseases is 5% or less [13], but the
number of ESBL-producing bacteria has slightly increased;
this must be considered in the future [154,155]. A study re-
ported that the clinical effects of TAZ/PIPC on non-ESBL-
producing K. pneumoniae were more potent than those of
SBT/ABPC; caution is needed [125]. It must be considered
that, in cases of aspiration pneumonia classiﬁed as HCAP,
Enterobacteriacae is isolated at a frequency that cannot be
ignored. Concerning aspiration pneumonia that occurs in
hospitals, some reviews proposed that antimicrobial drugs
should be selected, regarding the condition as hospital-
acquired pneumonia; empiric therapy may be selected in
accordance with the Guidelines for the Management of
Hospital-acquired Pneumonia, which were published by the
Japanese Respiratory Society [156,157]. According to a study,
BIPM, which does not cause kidney dysfunction in elderly
patients, is also effective (CIV); therefore, it is presented as an
option for cases in which there is a risk of resistant bacteria
[158].
The mortality rate in patients with VAP is high. If causative
microorganisms cannot be initially covered, the mortalityrate may increase [51]. Therefore, drugs should be selected,
regarding the condition as severe aspiration pneumonia.
Three studies reported that, in a group in which TAZ/PIPC
was selected as a drug to be combined with aminoglycosides
for VAP treatment, the mortality rate was lower than in a
group in which CAZ was selected [159e161]. In particular,
when pneumonia was caused by P. aeruginosa, the clinical
effects of TAZ/PIPC were more potent than those of IPM/CS
(BII). For monotherapy, information on the culture of pro-
tected specimen brush (PSB) samples or broncho-alveolar
lavage (BAL) ﬂuid is strongly recommended [70,162]. On
the other hand, an observational study indicated that three-
drug therapy (two anti-P. aeruginosa drugs þ an anti-MRSA
drug) deteriorated the prognosis; an RCT should be con-
ducted in the future [60]. Therefore, if there is a risk of
resistant bacteria, at least broad-spectrum antimicrobial
drugs must be used for empiric therapy. However, assuming
causative microorganisms with reference to Gram staining
reactions, minimum necessary antimicrobial drugs should
be selected based on local factors (antimicrobial drug sus-
ceptibility pattern of each type of bacteria in each hospital).
Recently, the entity of ventilator-associated tracheo-
bronchitis (VAT) was proposed, and the disadvantages of
aggressive treatment have been discussed [163]. In a
multicenter cooperative study, patients with VAT, which
occurred in the ICU, were divided into two groups with and
without antimicrobial drug therapy, and the results were
compared. In the former, the incidence of VAP was signiﬁ-
cantly lower, and the mechanical ventilation-free period was
signiﬁcantly longer. In addition, the ICU mortality rate was
signiﬁcantly lower. On the other hand, there was no signif-
icant difference in the appearance of resistant bacteria be-
tween the two groups [164].
A First choices- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
<> Second choices
- CFPM, intravenous drip, 1e2 g/2e4 times a day
- CPR, intravenous drip, 1e2 g/2e4 times a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
or
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
- SBT/ABPC, intravenous drip, 1.5e3 g/3e4 times a day
*If MRSA infection is suspected, antimicrobial drugs should be
administered in accordance with the section “MRSA pneu-
monia” in addition to the above drugs.
[Administration period of antimicrobial drugs]
It is recommended that the treatment period of hospital-
acquired pneumonia should be 7e10 days. However, the
treatment period should be 14 days in patients with pneumonia
related to non-glucose-fermenting bacteria such as
P. aeruginosa [2] (BII). Concerning VAP, a study reported that
there was no difference in the clinical effects between 8 and 15
days [57].
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To control identiﬁed causative microorganisms, antimicrobial
drugs should be selected in accordance with the section “Hos-
pital-acquired pneumonia”. If MRSA infection is suspected,
antimicrobial drugs should be selected in accordance with the
section “MRSA pneumonia”.
2.5. Fungal/viral pneumonia
a. Invasive pulmonary aspergillosis (IPA)
- - - Executive summary- - -
- In the management of IPA, effective treatment should be
started as early as possible [165] (AII).
- Initial treatment with VRCZ [166] (AI) or L-AMB [167] (AI)
should be performed.
- CPFG, MCFG, and ITCZ are recommended as alternative
drugs, depending on interactions with drugs that are used to
treat an underlying disease or the organ disorder [168e170]
(BII).
- In severe or refractory cases in which the efﬁcacy of initial
treatment is not sufﬁcient, combination therapy with an
antifungal drug should also be considered [171e173] (BII).
- As the effects of combination therapy with an azole and
AMPH-B preparation antagonize in some strains, a combi-
nation of these drugs should be avoided [174] (AIII).
- For the target treatment of this disease, an antifungal drug of
which the class is different from that of a drug used for
preventive administration should be used (BIII).
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease develops in severe immunocom-
promised hosts such as patients received chemotherapy for
leukemia or hematopoietic stem cell/organ transplantation.
Symptoms such as fever that does not respond to broad-
spectrum antimicrobial drugs, cough, dyspnea, sputum,
and bloody sputum/hemoptysis are observed.
- Laboratory ﬁndings: Chest X-ray shows an inﬁltrative
shadow (typically, a wedge shadow involving the pleura as
the base). On thoracic CT, inﬁltrative and nodular shadows
(with a halo sign in some cases) are observed. In the recovery
phase of neutrophils, an air crescent sign is noted. An in-
crease in the inﬂammatory marker such as the CRP level,
Aspergillus galactomannan antigen-positive reactions, and
an increase in the (1 / 3)-b-D-glucan level are useful for
diagnosis. However, neither the sensitivity nor speciﬁcity is
sufﬁcient. The results should be carefully evaluated.
- Causative microorganisms: Aspergillus fumigatus is
frequently detected, but, recently, an increase in the number
of patients with non-fumigatus Aspergillus-related IPA has
been indicated.
- Speciﬁc condition: Lesions are sometimes formed in the
nasal sinus and brain; caution is needed.
- Early diagnosis: Early treatment is important for successful
treatment for this disease.
- - - Drugs to be recommended- - -
A study reported that, in a group in which VRCZ was used
for the initial treatment of IPA, the results of treatment were
more favorable than in a group in which d-AMPH was used
[166]. Furthermore, another study indicated that therapy
with L-AMB at 3 mg/kg/day was safer than that at 10 mg/kg/day, although there was no signiﬁcant difference in the
clinical efﬁcacy [167]. CPFG, MCFG, and ITCZ also have anti-
Aspergillus activities, and can be used. It is important to
consider different strategies in accordance with the
appearance of the host's allergy or adverse events and in-
teractions with drugs used to treat an underlying disease.
A First choices
- VRCZ, intravenous drip, 6.0 mg/kg/twice a day on Day 1
(loading dose), 3.0e4.0mg/kg/twice a day on Day 2 or later
- L-AMB, intravenous drip, 2.5e5.0 mg/kg/once a day
<> Second choices
- CPFG, intravenous drip, 70 mg/once a day on Day 1
(loading dose), 50 mg/once a day on Day 2 or later
- MCFG, intravenous drip, 150e300 mg/once a day
- ITCZ, intravenous drip, 200mg/twice a day on Days 1 and 2
(loading dose), 200 mg/once a day fromDay 3 until Day 14.
If treatment is further continued, ITCZ capsules (200 mg)
should be administered immediately after meals twice a
day, or ITCZ oral solution (20 mL) (200 mg as ITCZ) should
be administered after fasting once a day.
b. Chronic progressive pulmonary aspergillosis (CPPA)
- - - Executive summary- - -
- In Japan, various disease types such as aspergilloma with
inﬁltration and enlargement of an existing cavity are
included. CPPA includes various diseases such as chronic
necrotizing pulmonary aspergillosis (CNPA), chronic cavitary
pulmonary aspergillosis (CCPA), and chronic ﬁbrosing pul-
monary aspergillosis (CFPA). It refers to a series of syndrome
for which the administration of antifungal drugs is essential.
- Treatment should be startedwith injection. If symptoms and
ﬁndings are stabilized, injection should be switched to oral
drugs.
- Initial treatment with MCFG or CPFG should be performed
[175,176] (AI).
- Initial treatment with ITCZ, VRCZ, or L-AMB can also be
selected in accordance with the host's underlying disease or
drugs used to treat the underlying disease.
- For maintenance therapy, ITCZ and VRCZ oral preparations
are recommended (AIII).
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease develops in hosts with organic
diseases such as a cavity or cystic disease of the lung or
bronchus. Symptoms such as fever, sputum, bloody sputum/
hemoptysis, and dyspnea are observed.
- Laboratory ﬁndings: Chest X-ray and CT show an inﬁltrative
shadow, enlargement of a cavity, thickening of the cavity
wall/pleura, and a niveau in the cavity. There is an increase in
the CRP level in many patients. Most patients are positive for
anti-Aspergillus precipitating antibody. Neither Aspergillus
galactomannan antigen nor b-D-glucan is a clue to diagnosis.
- Causative microorganisms: A. fumigatus is frequently
detected. Non-fumigatus Aspergillus-related CPPA is also
often observed.
- - - Drugs to be recommended- - -
A clinical study in Japan indicated that there was no
marked difference in the efﬁcacy of treatment between
MCFG- and VRCZ-treated groups, whereas MCFG was safer
[175]. Another study reported that there was no difference
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phase of severe symptoms such as fever and bloody sputum,
treatment should be started using these injections. Subse-
quently, if the condition becomes stable, switching to oral
preparations can be considered. Currently, there are no
criteria for the completion of treatment.
(1) Initial treatment
A First choices
- MCFG, intravenous drip, 150e300 mg/once a day
- CPFG, intravenous drip, 70 mg/once a day on Day 1
(loading dose), 50 mg/once a day on Day 2 or later
- VRCZ, intravenous drip, 6.0 mg/kg/twice a day on Day 1
(loading dose), 3.0e4.0 mg/kg/twice a day on Day 2 or
later
<> Second choices
- ITCZ, intravenous drip, 200 mg/twice a day on Days 1
and 2 (loading dose), 200 mg/once a day from Day 3
until Day 14. If treatment is further continued, refer to
the section “(2) Maintenance therapy”.
- L-AMB, intravenous drip, 2.5e5.0 mg/kg/once a day(2) Maintenance therapy
A First choices
- ITCZ oral solution, oral, 20 mL (200 mg as ITCZ)/once a
day (administered after fasting)
- (Switching from ITCZ injection) ITCZ capsules, oral,
200 mg/twice a day (administered immediately after
meals)
- (Switching from drugs other than ITCZ injection or
favorable conditions) ITCZ capsules, oral, 200 mg/once
a day (administered immediately after meals)
- VRCZ tablets
 (Body weight: 40 kg or more) oral, 300 mg/twice
a day on Day 1 (loading dose), 150 or 200 mg/twice a
day (administered between meals) on Day 2 or later
 (Body weight: less than 40 kg) oral, 150 mg/twice
a day on Day 1 (loading dose), 100 mg/twice a day
(administered between meals) on Day 2 or laterc. Pulmonary aspergilloma
- - - Executive summary- - -
- The purpose of treatment is the prevention or treatment of
hemoptysis. When there are no symptoms, follow-up is
continued without treatment in some cases.
- As a rule, resection should be performed for radical treatment
[177].
- When treatment is necessary, resection should be considered, if
possible, by comprehensively evaluating the age, pulmonary
function, anddegreeof pulmonarydestruction/pleural adhesion.
- When resection is considered to be impossible, antifungal
therapy should be performed if necessary.
- Oral treatment with ITCZ or VRCZ is recommended (BIII).
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease develops in hosts with preexisting
cavities such as old pulmonary tuberculosis, pulmonary cysts,
and bronchiectasis. The condition is asymptomatic in some
patients, whereas symptoms such as sputum and bloody
sputum/hemoptysis are observed in others.
- Laboratory ﬁndings: Chest X-ray and CT show a cavity, intra-
cavitary fungas balls, and thickening of the cavity wall/pleura.
Anti-Aspergillus precipitating antibodyepositive reactions areobtained. The enhancement of the inﬂammatory marker is
noted in some cases.
- Causativemicroorganisms: A. fumigatus is frequently detected.
- Pulmonary aspergilloma is classiﬁed into two types: simple
and complex aspergilloma based on the grade of difﬁculty in
resection. The former refers to aspergilloma formation in a
focus with a thinwall, such as a cyst, without accessory lesions
at the periphery. The latter refers to aspergilloma formation in
a cavity derived from a strongly destructed existing structure
of the lung, such as old pulmonary tuberculosis and bronchi-
ectasis, with marked destructive lesions or pleural adhesion at
the periphery of the cavity.
- - - Drugs to be recommended- - -
Resection should be selected as a ﬁrst choice. When resec-
tion is impossible, medical treatment can be considered.
In the treatment of aspergilloma, oral drugs are usually
selected. Although there is no evidence, ITCZ capsules/oral
solution and VRCZ tablets should be used.
- ITCZ capsules, oral, 200 mg/once a day (administered imme-
diately after meals)
- ITCZ oral solution, oral, 20 mL (200 mg as ITCZ)/once a day
(administered after fasting)
- VRCZ tablets
 (Body weight: 40 kg or more) oral, 300 mg/twice a day on
Day 1 (loading dose), 150 or 200 mg/twice a day (adminis-
tered between meals) on Day 2 or later
 (Body weight: less than 40 kg) oral, 150 mg/twice a day on
Day 1 (loading dose), 100 mg/twice a day (administered
between meals) on Day 2 or later
d. Primary pulmonary cryptococcosis
- - - Executive summary- - -
- No study has prospectively examined treatment for pulmo-
nary cryptococcosis in patients without underlying diseases.
- FLCZ oral preparations should be selected [178] (AII).
- ITCZ capsules/oral solution and VRCZ tablets can also be used
(BIII).
- In severe cases, drugs should be selected in accordance with
cases in which underlying diseases are present (BIV).
- Cryptococcus glucuronoxylomannan antigen is useful for the
diagnosis of this disease, but cannot be used to evaluate the
treatment response or as an index for the completion of
treatment.
- To conﬁrm the presence or absence of inﬂammation
involving the central nervous system, glucuronoxylomannan
antigen or Cryptococcus cells in cerebrospinal ﬂuid should be
investigated, even when there is no marked meningeal irri-
tation sign (BIII).
- If meningitis is present, initial treatment with an AMPH-B
preparation, such as L-AMB, and 5-FC should be performed
for 2 weeks or more. Subsequently, treatment should be
continued using FLCZ or F-FLCZ.
- In Japan, Cryptococcus gattii infection has also been reported.
If possible, causative fungus must be isolated/identiﬁed.
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease is often asymptomatic, and is
detected on a health checkup in many cases.
- Laboratory ﬁndings: Chest X-ray and CT show solitary or
multiple nodular and inﬁltrative shadows.
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enhancement of the inﬂammatorymarker inmany cases, but
glucuronoxylomannan antigen-positive reactions are
detected.
- Causative microorganisms: This disease is caused by Crypto-
coccus neoformans. Recently, infection with C. gattii has been
reported inVancouver, Canada and theNortharea of theWest
Coast of the United States of America; caution is needed.
- C. gattii is primarily distributed in the tropical and subtropical
zones. Infection in humans has been considered to be rare.
However, since 1999, patients infectedwith C. gattiihave been
reported in the Paciﬁc Coast of North America. Even healthy
adults are infectedwith C. gattii, and themortality rate is high.
- - - Drugs to be recommended- - -
Although there is no evidence regarding pulmonary cryp-
tococcosis, FLCZ tablets, which have a potent activity against
Cryptococcus, are frequently selected when the patient's con-
dition is stable in the absence of an underlying disease. Azoles
other than this drug can also be selected.
A First choice
- FLCZ, oral, 400e800 mg/once a day on Days 1 and 2
(loading dose), 200e400 mg/once a day on Day 3 or later
<> Second choices
- ITCZ capsules, oral, 200 mg/once a day (administered
immediately after meals)
- ITCZ oral solution, oral, 20 mL (200 mg as ITCZ)/once a day
(administered after fasting)
- VRCZ tablets
 (Body weight: 40 kg or more) oral, 300 mg/twice a day
on Day 1 (loading dose), 150 or 200 mg/twice a day
(administered between meals) on Day 2 or later
 (Body weight: less than 40 kg) oral, 150 mg/twice a day
on Day 1 (loading dose), 100 mg/twice a day (adminis-
tered between meals) on Day 2 or latere. Pulmonary cryptococcosis- - - in the presence of an underlying
disease (non-HIV infection)- - -
- - - Executive summary- - -
- Initial treatment with F-FLCZ injection should be performed
[179] (AIII).
- ITCZ and VRCZ injections can also be used (BIII).
- In severe cases, treatment with L-AMB þ 5-FC should be
selected [179] (AIII).
- Cryptococcus antigen is useful for diagnosis, but cannot be
used to evaluate the treatment response or as an index for
the completion of treatment.
- To conﬁrm the presence or absence of inﬂammation
involving the central nervous system, glucuronoxylomannan
antigen or Cryptococcus cells in cerebrospinal ﬂuid should be
investigated, even when there is no marked meningeal irri-
tation sign (BIII).
- If meningitis is present, initial treatment with an AMPH-B
preparation, such as L-AMB, and 5-FC should be performed
for 2 weeks or more. Subsequently, treatment should be
continued using FLCZ or F-FLCZ.
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease develops as opportunistic infection
in hosts with malignant tumors or renal failure, those
receiving steroids or immunosuppressive drugs, andpatients with AIDS. The symptoms of this disease are more
marked than those of primary pulmonary cryptococcosis:
fever, general malaise, cough, sputum, bloody sputum, dys-
pnea, and thoracic pain.
- Laboratory ﬁndings: Chest X-ray and CT show solitary or
multiple nodular and inﬁltrative shadows. Cavitary lesions
are observed in a lot of cases. Cryptococcus glucuronox-
ylomannan antigen-positive reactions are detected.
- Causative microorganisms: This disease is caused by
C. neoformans.
- Speciﬁc condition: If this disease develops in AIDS patients, it
may deteriorate to a systemic infectious disease in the early
stage, particularly causing meningoencephalitis. Therefore,
treatment in accordance with Cryptococcus encephalome-
ningitis should be performed.
- - - Drugs to be recommended- - -
Pulmonary cryptococcosis in the host with an underlying
disease more frequently leads to a severe condition
compared to primary pulmonary cryptococcosis. Although
there is no evidence, azoles with anti-Cryptococcus activities
should be used for initial treatment. When azoles cannot be
used, or when clinical effects are not satisfactory, combina-
tion therapy with L-AMB and 5-FC should be considered.
A First choices
- F-FLCZ, intravenous drip, 800 mg/once a day on Days 1 and
2 (loading dose), 400 mg/once a day on Day 3 or later
- ITCZ, intravenous drip, 200mg/twice a day on Days 1 and 2
(loading dose), 200 mg/once a day fromDay 3 until Day 14.
If treatment is further continued, ITCZ capsules (200 mg)
should be administered immediately after meals twice a
day, or ITCZ oral solution (20 mL) (200 mg as ITCZ) should
be administered after fasting once a day.
- VRCZ, intravenous drip, 6.0 mg/kg/twice a day on Day 1
(loading dose), 3.0e4.0mg/kg/twice a day on Day 2 or later
<> Second choice
- L-AMB, intravenous drip, 2.5e6.0 mg/kg/once a dayþ 5-FC
tablets, oral, 25 mg/kg/4 times a day
f. Pulmonary zygomycosis
- - - Executive summary- - -
- When this disease is suspected, an effective antifungal drug
should be administered as early as possible (A).
- This disease may develop as breakthrough infection during
azole therapy (BII).
- Treatment with high-dose L-AMB should be performed [180]
(AII).
- If the lesion is localized, resection should be considered.
- Combination therapy with an iron chelating agent and L-AMB
should be avoided [181] (AI).
- - - Explanation- - -
[Characteristics of the disease]
- Symptoms: This disease develops as opportunistic infection in
patients with severe diabetes, those after organ/hematopoi-
etic stem cell transplantation, those with neutropenia, and
those with malignant tumors. It rapidly exacerbates, showing
an unfavorable prognosis. In some patients, autopsy leads to a
deﬁnitive diagnosis. Fever, dyspnea, and bloody sputum/he-
moptysis are often observed.
-Laboratory ﬁndings: Thoracic CT shows inﬁltrative/nodular
(±halo sign) shadows and air crescent signs. In some
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nosis cannot be applied.
- Causative microorganisms: In many cases, this disease is
caused by 4 classes of Mucoraceae: Rhizopus, Rhizomucor,
Mucor, and Absidia. The most frequent type is Rhizopus oryzae.
Recently, an increase in the incidence of infection with Cun-
ninghamella has also been indicated.
- Speciﬁc condition: Nasal/brain-type, dermal, and dissemi-
nated zygomycosis is observed.
- - - Drugs to be recommended- - -
Currently, only AMPH preparations may be clinically useful
for treating zygomycosis among antifungal drugs that are
available in clinical practice in Japan. As high-dose therapy
must be started as early as possible, not d-AMPH but L-AMB
should be selected.
- L-AMB, intravenous drip, 5 mg/kg/once a day
Precautions for the use of antifungal drugs (Conﬁrm the
package inserts.)
➀ VRCZ
Vision disorder, liver dysfunction, and neurological/
mental adverse events may occur.
Combination therapy with RFP, RBT, efavirenz, ritonavir,
carbamazepine, long-acting barbiturate, pimozide, quini-
dine sulfate, ergot alkaloid, or triazolam is contraindicated.
This drug is also contraindicated for pregnant women. As a
rule, it is contraindicated for patients with a Ccr of <30 mL/
min (injection only).
As the blood concentration of VRCZ may vary, TDM
should be conducted. In patients with mild to moderate
liver dysfunction, the dose should be regulated.
➁ ITCZ
Hepatopathy and congestive heart failure may occur.
Combination therapy with pimozide, quinidine, bepridil,
simvastatin, triazolam, azelnidipine, ergotamine, nisoldi-
pine, dihydroergotamine, vardenaﬁl, eplerenone, blo-
nanserin, sildenaﬁl, tadalaﬁl, aliskiren, dabigatran(ITCZ
oral only), rivaroxaban, ergometrine, or methylergome-
trine is contraindicated. This drug is contraindicated for
patients with severe liver diseases, pregnant women. Pa-
tients with a Ccr of <30 mL/min are also contraindicated
(injection only).
➂ FLCZ
Hepatopathy and a prolongation of QT may occur.
Combination therapy with triazolam, ergotamine, dihy-
droergotamine, quinidine, or pimozide is contraindicated.
This drug is also contraindicated for pregnant women.
➃ F-FLCZ
Combination therapy with triazolam, ergotamine, dihy-
droergotamine, quinidine, or pimozide is contraindicated.
This drug is also contraindicated for pregnant women.
➄ L-AMB
Adverse events such as nephropathy, hypopotassiumemia,
and fever may occur.
This drug is contraindicated during leukocyte transfusion.
➅ CPFG
This drug is safe, but hepatopathy may occur.
Caution is needed for combination therapy with cyclo-
sporin, tacrolimus, RFP, efavirenz, nevirapine, phenytoin,
dexamethasone, or carbamazepine.
➆ MCFG
This drug is safe, but hepatopathy may occur.➇ 5-FC
Anorexia and myelopathy may occur.
Combination therapy with tegafur-/gimeracil-/oteracil
potassium-containing drugs is contraindicated. Even after
the discontinuation of tegafur-/gimeracil-/oteracil
potassium-containing drugs, combination therapy should
be avoided within 7 days. This drug is also contraindicated
for pregnant women.g. Pneumocystis jirovecii pneumonia (PCP)
- - - Executive summary- - -
- Initial treatment with an ST combination drug should be
performed [182] (AI).
- When an ST combination drug cannot be used, treatment
with pentamidine or atovaquone should be performed (AI).
- To HIV-infected patients with respiratory failure (PaO2:
<70 mmHg or A-aDO2: >35 mmHg in room air), corticoste-
roids should be administered for adjuvant therapy [183] (AI).
- Even in the absence of HIV infection, corticosteroids is rec-
ommended to patients with respiratory failure (PaO2:
<70 mmHg or A-aDO2: >35 mmHg in room air) for adjuvant
therapy (AIII).
- - - Explanation- - -
[Characteristic of the disease]
- Symptoms: This disease develops as opportunistic infection
in patients taking steroids or immunosuppressive drugs over
a long period and those infected with HIV. Three major signs
consist of fever, dry cough, and dyspnea. The mode of PCP
onset in HIV-infected patients is slower than in non-HIV-
infected patients. In the former, fever and hypoxemia are
relatively mild, and the mortality rate is low.
- Laboratory ﬁndings: Typical chest X-ray and CT ﬁndings
include a diffuse, ground glass opacity extending from the
pulmonary hilum to the bilateral sides. On CT, a ground glass
opacity expanding like a map is observed in some cases. In
addition, various shadows such as multiple nodes/cysts are
detected. The levels of CRP, LDH, KL-6, and (1 / 3)-b-D-
glucan increase. A deﬁnitive diagnosis is made by conﬁrming
Pneumocystis jiroveciil cells using Diff-Quick or Grocott
staining of sputum/BALF.
- - - Drugs to be recommended- - -
ST combination drugs are used as a gold standard of PCP
treatment. However, there have been a large number of
patients in whom treatment was discontinued due to their
side effects. Recently, atovaquone also became available in
Japan as a second-choice drug. In patients with mild PCP,
atovaquone tablets were as effective as ST combination
drugs. In those with moderate PCP, ST combination drugs
were more effective, but there was no signiﬁcant difference
due to a small number of subjects. In atovaquone-treated
patients, the incidence of adverse events for which admin-
istration was discontinued was lower than in ST combina-
tion drug-treated patients, suggesting that the tolerance is
high [184].
A First choices
The administration period should be 21 days in HIV-
infected patients and 14 days in non-HIV-infected patients.
A target daily dose of trimethoprim should be 15e20 mg/kg.
- ST combination drug, oral, 3 to 4 tablets/3 times a day
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trimethoprim/3 times a day (infused over 1e2 h)
<> Second choices
- Pentamidine, intravenous drip, 4 mg/kg/once a day
(infused over 1e2 h)
- Atovaquone oral suspension, 5 mL (750 mg as atova-
quone)/twice a day for 21 days (orally administered after
meals)
* Adjuvant therapy
In patients with a PaO2 of <70 mmHg or A-aDO2 of
>35 mmHg in room air, one of the above drugs should be
combined with a corticosteroid from the start of treat-
ment. However, the dose may be reduced or adminis-
tration may be discontinued in the early phase in
accordance with symptoms.When the respiratory state is
extremely unfavorable, pulse therapy should also be
considered.
Prednisolone Days 1e5: Oral, 30e40 mg/twice a day
Days 6e10: Oral, 15e20 mg/twice a day
Days 11e21: Oral, 7.5e10 mg/twice a day
- - - Precautions for each drug- - - (Conﬁrm the package
inserts.)
➀ ST combination drug (Baktar tablets)
Fever, exanthema, digestive symptoms, hepatopathy,
nephropathy, and blood disorder may occur.
This drug may interact with methotrexate, sulfadoxine,
pyrimethamine, diaphenylsulfone, sulfonyl amide/sulfo-
nylurea oral drugs for diabetes, warfarin, phenytoin,
cyclosporin, zidovudine, digoxin, tricyclic antidepres-
sants, and lamivudine.
This drug is contraindicated for neonates, low-birth-
weight infants, pregnant women, and patients with G-6-
PD deﬁciency. In patients with renal dysfunction, dose
reduction must be considered.
➁ Pentamidine
Side effects such as hypoglycemia, hypotension, ne-
phropathy, taste disorder, numbness of the tongue/lips,
ventricular arrhythmia, exanthema, and fever may occur.
Combination therapy with zalcitabine, PFA, or amiodar-
one is contraindicated. This drug is contraindicated for
patients with severe ventilatory disturbance.
➂ Atovaquone
Nausea/vomiting, exanthema, and diarrhea may occur.
This drug should be carefully administered to patients
with severe kidney or liver dysfunction. This drug may
interact with RFP, RBT, tetracycline, metoclopramide,
zidovudine, acetaminophen, benzodiazepines, aciclovir,
opioid analgesic drugs, cephalosporin antibiotics, antidi-
arrheal drugs/laxatives, and indinavir.h. Cytomegalovirus (CMV) pneumonia
- - - Executive summary- - -
- In the ﬁeld of transplantation, preemptive treatment with
GCV should be conducted through CMV antigenemia test
monitoring.
- The efﬁcacy of preemptive treatment with vGCV or PFA is
similar to that of GCV.
- If a diagnosis of CMV pneumonia is made, treatment with
GCV should be promptly started [185] (AII).
- vGCV and PFA are recognized as alternative drugs for GCV
[186,187] (BII).
- Combination therapy with an antiviral drug and high-dose
immunoglobulin should be performed [188] (AIII).- - - Explanation- - -
[Characteristic of the disease]
- Symptoms: In most healthy adults, latent infection persists
after the initial infection with CMV during childhood.
However, when cellular immunodeﬁciency occurs, this
disease develops, leading to a severe condition. It
frequently occurs after hematopoietic stem cell/organ
transplantation or in patients with AIDS. Symptoms such as
fever, general malaise, dry cough, dyspnea, and tachypnea
are observed.
- Laboratory ﬁndings: Chest X-ray and CT show ground glass
opacity extending from the pulmonary hilum to the bilateral
sides. On CT, a microgranular shadow and thickening of the
interlobular septa are sometimes observed. In the initial
phase, there is no abnormal shadow on chest X-ray in about
one-third of patients; caution is needed. Leukopenia,
thrombopenia, atypical lymphocytes, and hypoxemia are
noted. A deﬁnitive diagnosis is made by verifying inclusion
cells, which are called owl's eyes, on histopathological ex-
amination. For clinical diagnosis, the antigenemia method is
commonly used.
- In severely immunosuppressed patients, such as those after
transplantation, empiric therapy is sometimes necessary.
- Speciﬁc condition: This disease causes retinitis, gastroen-
teritis, hepatitis, or encephalitis in some cases. Other types
of opportunistic infection, such as Pneumocystis pneumonia,
may concomitantly occur.
- - - Antimicrobial drugs to be recommended- - -
A ﬁrst-choice drug for CMV pneumonia treatment is GCV,
which has been frequently used. PFA has been used to treat
CMV infection in AIDS patients, but experience on its use is
limited in patients after hematopoietic stem cell
transplantation.
(1) Initial administration
A First choice
- GCV, intravenous drip, 5 mg/kg (over 1 h or more)/
every 12 h for 2e3 weeks þ anti-CMV high-titer
gamma globulin, intravenous drip, 2.5e5 g/once a
day for the ﬁrst 3 days
<> Second choices
- PFA, intravenous drip, 60 mg/kg (over 1 h or more)/3
times a day, every 8 h for 2e3 weeks or more þ anti-
CMV high-titer gamma globulin, intravenous drip,
2.5e5 g/once a day for the ﬁrst 3 days
or
- PFA, intravenous drip, 90 mg/kg (over 2 h or more)/
twice a day, every 12 h for 2e3 weeks or more þ anti-
CMV high-titer gamma globulin, intravenous drip,
2.5e5 g/once a day for the ﬁrst 3 days(2) Maintenance administration
A First choices
- GCV, intravenous drip, 5mg/kg (over 1 h ormore)/once
a day, 7 days a week
or
- GCV, intravenous drip, 6mg/kg (over 1 h ormore)/once
a day, 5 days a week* This regimen should be completed after con-
ﬁrming the disappearance of clinical symptoms and
negative reactions on two consecutive CMV anti-
genemia tests.
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- PFA, intravenous drip, 90e120 mg/kg (over 2 h or
more)/once a day
(In clinical practice in Japan, there have been few
case reports on once-a-day administration at 120 mg/
kg as maintenance therapy. A dose exceeding 120 mg/
kg should be avoided. For administration at 120 mg/kg,
twice-a-day administration at 60 mg/kg is commonly
selected.)* This regimen should be completed after con-
ﬁrming the disappearance of clinical symptoms and
negative reactions on two consecutive CMV anti-
genemia tests.
- - - Precautions for each drug- - - (Conﬁrm the
package inserts.)➀ GCV
Severe leukopenia, neutropenia, anemia, thrombope-
nia, pancytopenia, aplastic anemia, and bone marrow
suppression may occur. An animal experiment showed
that this drug induced transient or irreversible sper-
matogenic dysfunction and reduced fertility. In humans,
this drug may cause spermatogenic dysfunction. An an-
imal experiment demonstrated the teratogenicity,
mutagenicity, and carcinogenicity of this drug. In the
presence of renal hypofunction, it is necessary to regu-
late the dose.
This drug is contraindicated for patients with marked
bonemarrow suppression (neutrophil count: <500/mm3
or platelet count: <25,000/mm3) and pregnant women.
It may interact with didanosine, zidovudine, IPM/CS,
bone marrow-suppressing and kidney function-affecting
drugs, zalcitabine, ST combination drugs, cyclosporin,
probenecid, and mycophenolate mofetil.
➁ VGCV
This is a prodrug of GCV.
➂ PFA
Acute renal failure, shock, heart failure, thrombo-
phlebitis, and convulsion may occur.
It is necessary to regulate the dose in accordance with
the kidney function. Combination therapy with pent-
amidine is contraindicated. This drug is contraindicated
for patients with a Ccr of <0.4 mL/min/kg.Fever, c
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Fig. 3. Differentiation of major childhood3. Pneumonia (Children)
3.1. Community-acquired pneumonia- - - Executive summary- - -
For the treatment of community-acquired pneumonia in chil-
dren, antimicrobial drugs should be selected, considering age and
severity.
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Patients with acute respiratory infectious disease symptoms,
such as fever, nasal discharge, pharyngeal pain, and cough, and the
appearance of a new inﬁltrative shadow in the lung on imaging
examinations such as chest X-ray and CT are regarded as having
pneumonia [189]. In patients with pneumonia, thoracic ausculta-
tion ﬁndings often include accessory murmurs and the attenuation
of respiratory sounds. Most patients with respiratory infectious
diseases consult hospitals with fever and cough. The lesion site of
the airway is estimated based on symptoms and physical ﬁndings
(Fig. 3) [189]. In addition to thoracic ﬁndings, it is necessary to
check the presence or absence of dyspnea signs, such as tachypnea,
nasal alar breathing, retractive breathing, shoulder breathing,
orthopnea, groaning, and cyanosis. To consider the need of
antimicrobial-drug administration and options of antimicrobial
drugs, pneumonia is classiﬁed into three types: bacterial, viral, and
atypical pneumonia based on causative microorganisms [189].
[Type and frequency of causative microorganisms]
Microorganisms that cause childhood community-acquired
pneumonia differ among ages. According to the data on investiga-
tion of causative microorganisms based on lavage sputum culture
in Japan, bacterial and viral pneumonia is frequent in infants/chil-
dren aged 1 year or younger. In those aged 2e6 years, the in-
cidences of bacterial, viral, and atypical pneumonia are similar. In
those aged over 6 years, the incidence of atypical pneumonia is the
highest [189] (Fig. 4). In a similar proportion of children with bac-
terial pneumonia, non-capsule H. inﬂuenzae and Streptococcus
pneumoniae are involved, respectively. Mixed infectionwith viruses
is often observed. In Europe and the United States, lavage sputum
culture is not conducted, and data on causative microorganisms areough
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Fig. 4. Causative microorganisms with respect to age in children with community-acquired pneumonia [190].
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(Table 11) [189]. In children, it is not easy to investigate causative
microorganisms. In institutions in which it is impossible to inves-
tigate causative microorganisms, treatment must be performed
based on the statistical frequency of causative microorganisms
described below. However, in those in which investigation is
possible, the etiology should be investigated if possible.
[Rules of antimicrobial drug therapy]
It is important to improve the efﬁcacy of treatment by accurately
predicting causative microorganisms and selecting an appropriate
antimicrobial drug and its administration method. Whether or not
an antimicrobial drug should be indicated must be comprehen-
sively evaluated by differentiating bacterial, viral, and atypical
pneumonia with reference to age, severity, clinical symptoms,
physical ﬁndings, laboratory data, and X-ray ﬁndings [189]. As a
rule, a single antimicrobial drug should be selected. When the type
of microorganisms that caused pneumonia is identiﬁed, an anti-
microbial drug should be selected through de-escalation, consid-
ering drug susceptibility and pharmacokinetics.
[Clinical symptoms, physical ﬁndings]
Wet cough and tachypnea are frequently observed in children
with bacterial pneumonia. The proportion of labored breathing-
free patients is high in children with Mycoplasma pneumonia
[191,192]. Auscultation ﬁndings include intermittent accessory
murmurs (rales) regardless of the type of pneumonia. In children
with Mycoplasma pneumonia, the proportion of those in whom
auscultation ﬁndings are not marked is signiﬁcantly higher than in
other groups. In children with Chlamydia pneumonia, fever is mild,
and cough is protracted. Thus, clinical symptoms and physical
ﬁndings show characteristics related to causative microorganisms,but it is difﬁcult to identify causative microorganisms based on
clinical symptoms and physical ﬁndings alone in individual pa-
tients [193e195].
[Laboratory ﬁndings]
Concerning laboratory ﬁndings on admission in children with
bacterial and viral pneumonia, there are signiﬁcant differences in
the leukocyte count, CRP level, and erythrocyte sedimentation
rate between the two groups (p < 0.01). However, measurements
overlapping in about one-third of patients are presented [195]
(Fig. 5). Brieﬂy, it is impossible to accurately differentiate bac-
terial from viral pneumonia based on inﬂammatory responses
reﬂected by the leukocyte count, CRP level, and erythrocyte
sedimentation rate. Mycoplasma pneumonia is characterized by
increases in the CRP level and erythrocyte sedimentation rate,
but many patients show normal leukocyte counts or a slight
decrease in this parameter. Furthermore, it is difﬁcult to differ-
entiate Mycoplasma from viral pneumonia based on laboratory
data [196].
[Chest X-ray]
Chest X-ray ﬁndings show characteristics related to causative
microorganisms to some degree, but it is difﬁcult to identify caus-
ative microorganisms in individual patients [197].
[Classiﬁcation of severity]
It is important to evaluate the severity of pneumonia, for
selecting outpatient or hospital treatment and reviewing the ne-
cessity of antimicrobial drugs and route of administration (oral or
intravenous). The classiﬁcation of severity in the Guidelines for the
Management of Respiratory Infectious Diseases in Children in Japan
2011 is presented [189] (Table 12). However, a consensus regarding
Table 11
Age-related distribution of microorganisms that cause pneumonia in children [189].
Immediately after birth to 20 days after birth Streptococcus group B
Gram-negative enteric bacteria
Cytomegalovirus
Listeria monocytogenes
3 weekse3 months Chlamydia trachomatis
RS virus
Parainﬂuenza virus 3
Pneumococcus
Bordetella pertussis
Staphylococcus aureus
4 monthse4 years RS virus
Parainﬂuenza virus
Inﬂuenza virus
Adenovirus
Rhinovirus
Pneumococcus
Haemophilus inﬂuenzae
Mycoplasma pneumoniae
Mycobacterium tuberculosis
5e15 years Mycoplasma pneumoniae
Chlamydia pneumoniae
Pneumococcus
Mycobacterium tuberculosis
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reached in Japan or internationally. This should be examined in the
future.
[Standards for outpatient/hospital treatment]
As a rule, outpatient treatment should be performed in mild-
status patients evaluated according to the severity classiﬁcation,
and hospital treatment in mild-status patients with dehydration. In
addition, it is necessary to determine admission when outpatient
treatment does not lead to an improvement in symptoms or
considering social adaptation [189] (Table 13).
[Initial antimicrobial drug therapy]
When examining children with pneumonia, treatment must be
started without any precise information about causative microor-
ganism in many cases. Basically, empiric therapy should be per-
formed, considering the severity of pneumonia and causative
microorganisms.Fig. 5. Inﬂammatory response on admissio- The type of causative microorganisms depends on age and
severity. Therefore, the necessity of antimicrobial drugs should
be examined, and selected, considering age and severity. In
addition, bacterial, viral, or atypical pneumonia should be
differentiated, and comprehensively evaluated in reference to
clinical symptoms, physical ﬁndings, laboratory ﬁndings, and X-
ray ﬁndings [189].
- Recently, the number of drug-resistant strains of S. pneumoniae,
H. inﬂuenzae, M. catarrhalis, and M. pneumoniae, which cause
pneumonia, has increased [198e201] (Figs. 6 and 7) [189,199].
For pneumonia treatment, it is important to perform antimi-
crobial drug therapy, considering resistant microorganisms.
- When bacterial pneumonia is suspected, antimicrobial drug
therapy that covers S. pneumoniae must be considered, as
S. pneumoniae shows the strongest pathogenicity. Concerning
treatment for S. pneumoniae pneumonia, resistance criteria have
been established, assuming meningitis treatment. However, in
January 2008, the Criteria for the Drug Susceptibility of
S. pneumoniae, which were prepared by the Clinical and Labo-
ratory Standards Institute (CLSI) (U.S.A.), were revised, and it
was recommended that strains, isolated from S. pneumoniae-
infected patients other than those with meningitis, with a PCG-
MIC or AMPC-MIC of 2 mg/mL or less should be regarded as
susceptible (Fig. 8) [203]. Currently, the susceptibility of
S. pneumoniae isolated as causative microorganisms, that is,
PCG-MIC, is 2 mg/mL or less in most strains. Brieﬂy, the drug
resistance of S. pneumoniae is not problematic in patients with
respiratory infectious diseases. S. pneumoniae infection can be
managed with standard-dose synthetic penicillins (AMPC,
ABPC).
- Concerning treatment for H. inﬂuenzae pneumonia, strains for
which the MIC is evaluated as 1 mg/mL or less using the
microliquid dilution method should be regarded as susceptible,
those for which the MIC is 2 mg/mL as intermediate, and those
for which the MIC is 4 mg/mL or more as resistant according to
the Criteria for the ABPC Resistance of H. inﬂuenzae, which were
prepared by the CLSI.
In particular, acute bronchitis/pneumonia related to interme-
diately susceptible H. inﬂuenzae (MIC: 2 mg/mL) can be managed
with oral AMPC or ABPC intravenous injection therapies [204].
Recently, the number of ABPC-susceptible strains has annually
decreased [198,200]. The proportion of BLNAR strains (MIC: 4 mg/n in children with pneumonia [196].
Table 12
Classiﬁcation of the severity of community-acquired pneumonia in children [189].
Mild Moderate Severe
General condition Favorable Unfavorable
Cyanosis Absent Present
Respiratory rate Normal Polypnea
Labored breathing*1
(groaning, nasal alar breathing,
retractive breathing)
Absent Present
Shadow on chest X-ray 1/3 or smaller of the unilateral lung 2/3 or larger of the unilateral lung
Pleural effusion Absent Present
SpO2 >96% <90%*2
Circulatory failure Absent Present*2
Artiﬁcial respiration management Unnecessary Necessary*2
Criteria Meeting all of the above criteria Neither mild nor severe cases *2: Meeting one of the above criteria
*1 Respiratory rate with respect to age (times/min): Neonates <60, Infants <50, Children <40, School children <30.
Table 13
Standards for admission due to community-acquired pneumonia in children [189].
1. Moderate or severe according to the severity classiﬁcation
2. Less than 1 year
3. The oral administration of drugs is impossible.
4. Oral antimicrobial drug treatment does not lead to an improvement.
5. Presence of an underlying disease
6. Dehydration
7. Cases in which the attending physician considers admission
necessary despite a mild condition
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selection. When the involvement of BLNAR strains is suspected,
high-dose AMPC or new oral cephems may be necessary at
outpatient clinics [208].
The efﬁcacy of outpatient antimicrobial drugs for BLNAR strains,
which will increase in the future, should be carefully monitored.
Concerning hospital treatment, the clinical effects of ABPC intra-
venous injection for 3e4 days until the results of a susceptibility
test were clariﬁed were investigated, and approximately 80% of
patients responded to this therapy. There was no exacerbation in
any patient [189]. In non-responders or patients in whom clinical
effects are insufﬁcient, it is necessary to switch the antimicrobial
drug. PIPC, CTX, and CTRX have stable antimicrobial activities.
When reviewing the clinical effects of PIPC on childhoodFig. 6. Increases in the number of resistant strains of S. pneumoniae anbronchopulmonary infection, the response rate was 95%; the re-
sults were satisfactory [205].
- Concerning treatment for M. catarrhalis pneumonia,
M. catarrhalis produces b-lactamase. However, when examining
the clinical course, AMPC is effective [205,206]. This is because
the enzymatic activity of b-lactamase produced byM. catarrhalis
is low [207].
- Concerning treatment for Mycoplasma pneumonia, a recent in-
crease in the number of macrolide-resistant M. pneumoniae
strains must be considered [202]. In Japan, an outbreak of
M. pneumoniae infection occurred in mid-2011, and persisted
until 2012. The outbreak involved a large number of patients
with macrolide-resistant M. pneumoniae infection. Diagnosis
and treatment were confused [209,210]. Concepts regarding the
diagnosis and treatment of childhood Mycoplasma pneumonia
proposed by the Committee to Prepare the Guidelines for the
Management of Respiratory Infectious Diseases in Children and
Vaccination/Infection Control Committee, Japan Pediatric Soci-
ety as of February 19, 2013 are presented [211] (Table 14).
[Evaluation of the treatment response and administration period]
The administration period of antimicrobial drugs is shown in
Table 15 [211].d H. inﬂuenzae derived from respiratory infectious diseases [199].
Fig. 7. Increase in the number of macrolide-resistant M. pneumoniae strains [189].
Fig. 8. Changes in the criteria for the drug susceptibility of Pneumococcus established
by the Clinical and Laboratory Standards Institute (CLSI) [203].
Table 15
Administration period of major antimicrobial drugs to be used for the treatment of
Mycoplasma/Chlamydia pneumonia211).
Antimicrobial drug Administration period
Erythromycin ethylsuccinate 14 days
Clarithromycin 10 days
Azithromycin 3 days
Tosuﬂoxacin tosilate hydratea 7e14 days
Minocycline 7e14 days
a Indications for tosuﬂoxacin tosilate granules for children include pneumonia.
However, Mycoplasma pneumoniae is not included in bacterial types for which this
preparation may be indicated.
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should be administered for 3e7 days. The treatment response
should be evaluated after 2e3 days. In children, disease progression
is often prompt, and the ﬁrst evaluation should be performed after
2 days in younger and severe-status children, and not after 3 days
[189]. If an improvement in clinical symptoms or laboratory data is
achieved, the same antimicrobial drug should be continued until an
appropriate antimicrobial drug and drug susceptibility are clariﬁed.
With respect to the administration period of antimicrobial drugs,
factors such as the type of causative microorganisms and patient
background differ among individual patients; therefore, it is difﬁ-
cult to establish standardized criteria. As M. pneumoniae and C.Table 14
Concepts regarding the diagnosis and treatment of childhood Mycoplasma pneumonia [2
1. As it is often difﬁcult to make a diagnosis of Mycoplasma pneumoniae infection ba
the Mycoplasma pneumoniae nucleic acid identiﬁcation test (LAMP method) shoul
2. As ﬁrst-choice drugs for Mycoplasma pneumonia, macrolides should be used.
3. The effects of macrolides can be evaluated based on pyretolysis within 2e3 days af
4. To treat pneumonia that does not respond to macrolides, the administration of tosu
However, as a rule, tetracyclines are contraindicated for children aged 7 years or yo
5. These antimicrobial drugs should be administered in accordance with administratio
6. In patients with severe pneumonia, systemic steroid therapy must be considered. Hpneumoniae slowly proliferate, the treatment period is prolonged
(Table 15). In patients infected with general bacteria, the adminis-
tration of antimicrobial drugs can be discontinued 3 days after
pyretolysis [189]. However, further antimicrobial drug therapy is
necessary to treat S. aureus pneumonia.
[Management for non-responders to antimicrobial drugs]
When there are no therapeutic effects of antimicrobial drugs on
pneumonia, whether or not a diagnosis of pneumonia is correct
should be initially investigated [189]. The possibility of diseases
other than pneumonia, with a pneumonia-like shadow, must be
reviewed (Table 16). If it can be ruled out, whether or not the ex-
pected type of pathogenic microorganisms is correct should be
examined. If the type of causative microorganisms is the same as
expected, the possibility of resistant microorganisms should be
considered. New therapeutic strategies should be devised carefully
and promptly. When the condition further exacerbates despite
treatment switching, additional examination should be conducted.11].
sed on serum antibody titer-positive ﬁndings in the acute stage alone,
d be conducted to make a deﬁnitive diagnosis in the acute stage.
ter administration.
ﬂoxacin or tetracyclines should be considered if necessary.
unger.
n periods recommended for individual drugs.
owever, easy steroid administration should be avoided.
Table 16
Conditions with pneumonia-like shadows related to factors other than pneumonia
[189].
➀ Heart failure, pulmonary edema
➁ Lung tumor
Metastatic tumor: Wilms' tumor, osteosarcoma, Ewing's sarcoma,
rhabdomyosarcoma, lymphoma
Primary thoracic tumor: Pulmonary blastoma, lung cancer,
neuroblastoma, teratoma
➂ Congenital disease: Bronchial atresia, sequestration of
the lung, pulmonary arteriovenous malformation
➃ Diffuse lung disease: Drug-induced pneumonia, idiopathic
interstitial pneumonia, hypersensitivity pneumonitis,
eosinophilic pneumonia, collagen disease-related pulmonary lesions
➄ Pulmonary infarction
➅ Alveolar proteinosis, pulmonary hemosiderosis
➆ Intra-tracheal/-bronchial foreign bodies
➇ Radiation pneumonitis
➈ ARDS
➉ Others
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1. Empiric therapy
➀ Two months after birth to 5 years(1) Outpatient clinic (Mild)
A First choices
1) Cases in which there is no risk of resistant
bacteria
- AMPC, oral, 10e15 mg/kg/3 times a day
- SBTPC, oral, 10 mg/kg/3 times a day
- CDTR-PI, oral, 3 mg/kg/3 times a day
- CFPN-PI, oral, 3 mg/kg/3 times a day
- CFTM-PI, oral, 3 mg/kg/3 times a day
2) Cases in which infection with resistant bacteria is
suspected
i) Two years or younger, ii) Pretreatment with an
antimicrobial drug (within 2 weeks), iii) Concomitant
development of otitis media, iv) History of pneu-
monia/repeated otitis media
- AMPC, oral, 20e30 mg/kg/3 times a day
- CVA/AMPC (1:14 preparation), oral, 48.2 mg/
kg/twice a day
- CDTR-PI, oral, 6 mg/kg/3 times a day
- CFPN-PI, oral, 6 mg/kg/3 times a day
- CFTM-PI, oral, 6 mg/kg/3 times a day
3) Cases inwhich onset/recurrence/recrudescence is
observed despite previous treatment 2)
- TBPM-PI, oral, 4e6 mg/kg/twice a day
- TFLX, oral, 6 mg/kg/twice a day
<> Second choices
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day(2) Admission (Moderate, general ward)
A First choices
- ABPC, intravenous injection or drip, 50 mg/kg/3
times a day
- PIPC, intravenous injection or drip, 50 mg/kg/3
times a day
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/
3 times a day
* WhenM. pneumoniae, Chlamydia trachomatis, or
C. pneumoniae infection is strongly suspected, one of
the above regimens should be combined with a mac-
rolide [With respect to the administration method/
dose, refer to the section “➁ Six years or older- - -
(1) Outpatient clinic (Mild)”.].<> Second choices
- CTX, intravenous injection or drip, 40 mg/kg/3
times a day
- CTRX, intravenous injection or drip, 25e60 mg/kg/
once to twice a day (50e60 mg/kg/day)
(3) Admission (Severe, ICU)- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
* When legionellosis cannot be ruled out, one of the
above regimens should be combined with a macrolide
[With respect to the administration method/dose,
refer to the section “➁ Six years or older- - -
(2) Admission (Moderate, general ward)”.].➁ Six years or older
(1) Outpatient clinic (Mild)
A First choices
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
<> Second choices
- AMPC, oral, 10e15 mg/kg/3 times a day
- SBTPC, oral, 10 mg/kg/3 times a day
- CDTR-PI, oral, 3 mg/kg/3 times a day
- CFPN-PI, oral, 3 mg/kg/3 times a day
- CFTM-PI, oral, 3 mg/kg/3 times a day
- MINO, oral, 1e2 mg/kg/twice a day (In children
aged 7 years or younger, the use of this drug is limited
to those in whom other drugs cannot be used or non-
responders to other drugs.)(2) Admission (Moderate, general ward)
A First choices
1) Cases in which bacterial pneumonia is suspected
- ABPC, intravenous injection or drip, 50 mg/kg/3
times a day
- PIPC, intravenous injection or drip, 50 mg/kg/3
times a day
- SBT/ABPC, intravenous injection or drip, 75 mg/
kg/3 times a day
- CTX, intravenous injection or drip, 40 mg/kg/3
times a day
- CTRX, intravenous injection or drip, 25e60 mg/
kg/once to twice a day (50e60 mg/kg/day)
2) Cases in which atypical pneumonia is suspected
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- EM, intravenous drip, 10 mg/kg/3e4 times a day
-MINO, oral or intravenous drip,1e2mg/kg/twice
a day (In children aged 7 years or younger, the use of
this drug is limited to those in whom other drugs
cannot be used or non-responders to other drugs.)
3) Cases in which it is impossible to differentiate
bacterial from atypical pneumonia
One drug each should be selected from choices 1) and 2),
and combined.
(3) Admission (Severe, ICU)
A First choices
- PAPM/BP, intravenous drip, 20mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a
day
* When legionellosis cannot be ruled out, one of
the above regimens should be combined with a mac-
rolide [With respect to the administration method/
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Admission (Moderate, general ward)”.].2. Deﬁnitive therapy
➀ S. pneumoniae▪ PCG MIC  2 mg/mL
- AMPC, oral, 10e15 mg/kg/3 times a day
- ABPC, intravenous injection or drip, 30e50 mg/kg/3e4
times a day▪ PCG MIC  4 mg/mL
- FRPM, oral, 10 mg/kg/3 times a day
- TBPM-PI, oral, 4e6 mg/kg/twice a day
- CTX, intravenous injection or drip, 40 mg/kg/3 times a
day
- CTRX, intravenous injection or drip, 25e60 mg/kg/once
to twice a day (50e60 mg/kg/day)
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day➁ H. inﬂuenzae
▪ BLNAS
- AMPC, oral, 10e15 mg/kg/3 times a day
- ABPC, intravenous injection or drip, 50 mg/kg/3e4
times a day▪ BLPAR
- CVA/AMPC (1:14 preparation), oral, 48.2 mg/kg/twice a
day
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3
times a day
- CTX, intravenous injection or drip, 40 mg/kg/3 times a
day
- CTRX, intravenous injection or drip, 25e60 mg/kg/once
to twice a day (50e60 mg/kg/day)▪ BLNAR
- CDTR-PI, oral, 6 mg/kg/3 times a day
- TFLX, oral, 6 mg/kg/twice a day
- PIPC, intravenous injection or drip, 50 mg/kg/3 times a
day
- CTX, intravenous injection or drip, 40 mg/kg/3 times a
day
- CTRX, intravenous injection or drip, 25e60 mg/kg/once
to twice a day (50e60 mg/kg/day)▪ BLPACR
- CDTR-PI, oral, 6 mg/kg/3 times a day
- TFLX, oral, 6 mg/kg/twice a day
- CTX, intravenous injection or drip, 40 mg/kg/3 times a
day
- CTRX, intravenous injection or drip, 25e60 mg/kg/once
to twice a day (50e60 mg/kg/day)
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
➂ M. catarrhalis
- CVA/AMPC (1:14 preparation), oral, 48.2 mg/kg/twice a day
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- SBT/ABPC, intravenous injection or drip, 75mg/kg/3 times a
day
➃ Streptococcus pyogenes (Group A b-Streptococcus)
- PCG, intravenous drip, 50,000 units/kg/4 times a day
- ABPC, intravenous injection or drip, 30e50 mg/kg/3e4
times a day
➄ Staphylococcus aureus
▪ MSSA
- ABPC/MCIPC, intravenous injection or drip, 40 mg/kg/3
times a day- CEZ, intravenous injection or drip, 30mg/kg/3 times a day
▪ MRSA
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
- LZD, intravenous drip or oral, 10 mg/kg/every 8 h, 3 times
a day
➅ Bordetella pertussis
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- PIPC, intravenous injection or drip, 50 mg/kg/3 times a day
➆ Legionella
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- EM, intravenous drip, 10 mg/kg/3e4 times a day
➇ M. pneumoniae
▪ Macrolide-susceptible
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- EM, intravenous drip, 10 mg/kg/3e4 times a day
▪ Macrolide-resistant
- MINO, oral or intravenous drip, 1e2 mg/kg/twice a day
(In children aged 7 years or younger, the use of this drug
is limited to those in whom other drugs cannot be used
or non-responders to other drugs.)
- TFLX, oral, 6 mg/kg/twice a day
➈ Chlamydia (C. trachomatis, C. pneumoniae, Chlamydia psittaci)
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day for 3 days
- CAM, oral, 7.5 mg/kg/twice a day
- EM, intravenous drip, 10 mg/kg/3e4 times a day
- MINO, oral or intravenous drip, 1e2 mg/kg/twice a day (In
children aged 7 years or younger, the use of this drug is
limited to those in whom other drugs cannot be used or
non-responders to other drugs.)
3.2. Hospital-acquired pneumonia (including ventilator-associated
pneumonia: VAP)- - - Executive summary- - -
For the treatment of hospital-acquired pneumonia in children,
antimicrobial drugs should be selected, considering severity and
the involvement of resistant bacteria. Empiric therapy should be
started by combining two drugs if necessary, considering various
resistant microorganisms, differing from that for community-
acquired pneumonia (BIII).
[Characteristics and classiﬁcation of the disease]
Hospital-acquired pneumonia is deﬁned as pneumonia that
newly develops 48 h or more after admission. Ventilator-associated
pneumonia is deﬁned as pneumonia that develops 48 h or more
after endotracheal intubation [211]. These conditions may become
severe due to an underlying disease, reduced immune capacity, or
the deterioration of the general condition, and are caused by drug-
resistant microorganisms in many cases; treatment is difﬁcult in
most cases.
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Not only microorganisms acquired in the community but also
those existing in the hospital environment cause hospital-acquired
pneumonia in children, as reported in the adult ﬁeld. Bacteria that
cause community-acquired pneumonia (S. pneumoniae,
H. inﬂuenzae), enteric bacteria (E. coli, K. pneumoniae), S. aureus,
non-glucose-fermenting bacteria, such as P. aeruginosa, and Aci-
netobacter spp., and anaerobes cause hospital-acquired pneumonia
[212]. In addition, not only general bacteria but also fungus and
viruses sometimes cause hospital-acquired pneumonia in patients
with immunodeﬁciency. Among patients with nosocomial infec-
tion, causative microorganisms differ, and drug-resistant microor-
ganisms are involved in many cases. In children, it is not easy to
investigate causative microorganisms, but, if drug susceptibility is
clariﬁed, it contributes to successful treatment. Therefore, lavage or
aspiration sputum culture should be conducted to investigate the
etiology, if possible [189,211].
[Rules of antimicrobial drug therapy]
Basically, empiric therapy should be performed, considering
the severity of pneumonia, an underlying disease, and causative
microorganisms. In particular, the involvement of drug-resistant
microorganisms, such as MRSA, extended-spectrum b-lactamase
(ESBL)-producing bacteria, and multi-drug-resistant
P. aeruginosa (MDRP), must always be considered for treat-
ment. Empiric therapy should be started by combining two drugs
if necessary, considering various resistant microorganisms,
differing from that for community-acquired pneumonia [211]. As
the state of resistant bacteria differs among institutions, anti-
microbial drug options should be customized based on records
on antimicrobial drug susceptibility (antibiograms) at each
institution.
A consensus regarding the administration period of antimi-
crobial drugs has not been reached. With respect to the
administration period of antimicrobial drugs, factors such as the
type of causative microorganisms and patient background differ
among individual patients with nosocomial infection; therefore,
it is difﬁcult to establish standardized criteria. However, when
complications such as severe immunodeﬁciency, pulmonary
suppuration, lung abscess, and pleuritis are absent, antimicrobial
drugs should be administered for 5 days after pyretolysis (7e10
days) [50]. Considering an underlying disease or the immune
state, ﬂexible management must be performed. In children,
disease progression is often prompt, and the ﬁrst evaluation
should be performed after 2 days in younger and severe-status
children, and not after 3 days [189]. If an improvement in clin-
ical symptoms or laboratory data is achieved, the same antimi-
crobial drug should be continued until an appropriate
antimicrobial drug and drug susceptibility are clariﬁed. When
the type of microorganisms that caused pneumonia is identiﬁed,
a target-focused antimicrobial drug should be selected through
de-escalation, considering drug susceptibility and pharmacoki-
netics [211].
Concerning multi-drug-resistant microorganisms, it is impor-
tant to promote standard preventive strategies and those to control
nosocomial infection, such as the prevention of droplet/contact
infection, thoroughly. Furthermore, oral care and devised postures
(if there is no medical contraindication, the head should be lifted at
30e45.) are necessary to prevent VAP [211].
In this article, the classiﬁcation of severity (Table 12, p. 30) in
the Guidelines for the Management of Respiratory Infectious Dis-
eases in Children in Japan 2011 was used [189] (Refer to the sec-
tion “3. Pneumonia (Children), 3.1 Community-acquired
pneumonia”.).- - - Drugs to be recommended- - -
1. Empiric therapy
(1) Mild (General ward)
A First choices
- CAZ, intravenous injection or drip, 50 mg/kg/3 times a
day
- CZOP, intravenous injection or drip, 40 mg/kg/3e4
times a day
- CPR, intravenous injection or drip, 40mg/kg/3e4 times
a day
If necessary, one of the above regimens should be com-
bined with one of the following drugs:
1) Cases in which anaerobe infection is suspected (such as
aspiration pneumonia)
- CLDM, intravenous drip, 10 mg/kg/3 times a day
2) Cases in which MRSA infection is suspected
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
(2) Moderate (General ward, including VAP)
A First choices
- CAZ, intravenous injection or drip, 50 mg/kg/3 times a
day
- CZOP, intravenous injection or drip, 40 mg/kg/3e4
times a day
- CPR, intravenous injection or drip, 40mg/kg/3e4 times
a day
þ one of the followings:
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
(3) Severe (ICU, including VAP)
A First choices
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
þ one of the followings:
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
[Note] When legionellosis cannot be ruled out in the severest
cases, one of the above regimens should be combined with a
macrolide (With respect to the administrationmethod/dose, refer
to the section “3.1 Community-acquired pneumonia- - - ➁ Six
years orolder- - - (2) Admission (Moderate, generalward)” (p. 33).
2. Deﬁnitive therapy
➀ Enteric bacteria (E. coli, K. pneumoniae, Proteus spp.)
A Non-ESBL-producing bacteria
- CTX, intravenous injection or drip, 40 mg/kg/3e4 times
a day
- CTRX, intravenous injection or drip, 50 mg/kg/twice a
day
▪ ESBL-producing bacteria
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
➁ Enterobacter spp., Serratia spp., Citrobacter spp.
- CPR, intravenous injection or drip, 40 mg/kg/3e4 times a
day
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- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
➂ P. aeruginosa
- CAZ, intravenous injection or drip, 50 mg/kg/4 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
If necessary, one of the above regimens should be com-
bined with one of the following drugs:
- AMK, intravenous drip, 5e7.5 mg/kg/twice a day
- TOB, intravenous drip, 2e3 mg/kg/twice a day
➃ Stenotrophomonas maltophilia
- ST combination drug, intravenous drip or oral, SMX 25 mg/
TMP 5 mg/kg/3e4 times a day
- MINO, intravenous drip,1e2mg/kg/twice a day (In children
aged 7 years or younger, the use of this drug is limited to
those in whom other drugs cannot be used or non-
responders to other drugs.)
➄ Acinetobacter baumannii
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3e4
times a day
[Note] If there is no susceptibility, combination therapy with
aminoglycosides should be reviewed using the checker-
board method. CL administration should also be considered.
➅ S. aureus
▪ MSSA
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3e4
times a day
- CEZ, intravenous injection or drip, 50 mg/kg/3 times a
day
▪ MRSA
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
- LZD, intravenous drip or oral, 10 mg/kg/every 8 h, 3 times
a day
➆ Anaerobes
- SBT/ABPC, intravenous injection or drip, 75mg/kg/3 times a
day
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- CLDM, intravenous drip, 10 mg/kg/3 times a day3.3. Pneumonia in the presence of immunodeﬁciency/blood
diseases- - - Executive summary- - -
In children with immunodeﬁciency-/blood disease-related
pneumonia, antimicrobial drugs should be selected, considering
an underlying disease, the grade of immunodeﬁciency, and
involvement of various causative microorganisms. Initial antimi-
crobial drug therapy should be started by combining two drugs ifnecessary, considering various causative microorganisms, differing
from that for community-acquired pneumonia (BIII).
[Characteristics and classiﬁcation of the disease]
As immunodeﬁciency-/blood disease-related pneumonia in
children often develops in hospitals, it has the characteristics of
hospital-acquired pneumonia in many cases. It may become severe
due to the patient's unfavorable conditions, such as an underlying
disease, reduced immune capacity, and the deterioration of the
general condition. Even non-pathogenic microorganisms may
cause pneumonia in many cases. Furthermore, drug-resistant mi-
croorganisms often cause pneumonia; treatment is difﬁcult in
many cases [213,214]. To achieve multidisciplinary, comprehensive
treatment to save children, it is necessary to cooperate with other
special ﬁelds.
[Type and frequency of causative microorganisms]
Not only microorganisms acquired in the community in the
presence of various immunodeﬁciency states but also non-
pathogenic microorganisms existing in the hospital environment
cause immunodeﬁciency-/blood disease-related pneumonia in
children. Bacteria that cause community-acquired pneumonia
(S. pneumoniae, H. inﬂuenzae), enteric bacteria (E. coli,
K. pneumoniae), S. aureus, non-glucose-fermenting bacteria, such as
P. aeruginosa, and Acinetobacter spp., and anaerobes cause this type
of pneumonia. In addition, not only general bacteria but also fungus
and viruses often cause this type of pneumonia. Furthermore, drug-
resistant microorganisms are involved in many cases, as indicated
for hospital-acquired pneumonia [213,214].
[Type of immunodeﬁciency, causative microorganisms to be
monitored, and precautions for diagnosis]
➀ Humoral immunodeﬁciency: As bacterial opsonization and
complement activation are affected, patients with humoral
immunodeﬁciency are prone to be infected with general bac-
teria. Among immunodeﬁciency patients with hyper-IgM-emia,
Pneumocystis pneumonia should be considered in those with
conditions related to CD40 ligand abnormalities.
➁ Cellular immunodeﬁciency: In addition to infectionwith general
bacteria, infection with intracellular parasitic bacteria, fungus,
or Protozoa may become severe, and be protracted. As the dif-
ferentiation and induction of B and killer T cells by CD4-positive
lymphocytes are affected, the eradication of virus-infected cells
is inhibited (Table 17) [215].
➂ Neutrophil abnormalities: Neutrophil abnormalities are classi-
ﬁed into two types: neutropenia and neutrophil functional
disorders. Patients with a peripheral blood absolute neutrophil
count (ANC) of <500/mL or those in whom the ANC is estimated
to reach <500/mL within 48 h are regarded as having neu-
tropenia [215]. Of these, the risk is higher in patients with an
ANC of 100/mL or less inwhom the period is estimated to exceed
7 days. Many patients with neutropenia do not show purulent
sputum or abnormal ﬁndings on chest X-ray even in the pres-
ence of pneumonia. Therefore, when fever persists, thoracic CT
should be performed in the early stage. All microorganisms
including general bacteria (gram-positive bacteria, gram-
negative bacteria), fungus, and viruses may cause pneumonia.
In particular, in addition to neutropenia early after homologous
hematopoietic stem cell transplantation, infection-prone fea-
tures associated with humoral/cellular immunodeﬁciency
related to the administration of immunosuppressives persist
over a long period. Furthermore, the concomitant development
Table 17
Rate of decrease in the number of CD4-positive lymphocytes and risk of infection
with causative microorganisms [214].
CD4-positive Causative microorganisms
200e500/mL General bacteria, Mycobacterium tuberculosis
50e199/mL Cryptococcus, Toxoplasma
49/mL Cytomegalovirus, nontuberculous Mycobacteria
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tor for the onset of pneumonia. In addition, non-infectious
pulmonary disorder related to drugs/radiation for pretreat-
ment may occur, and it is important to differentiate it from in-
fectious diseases (Fig. 9) [214,216].
A representative neutrophil functional disorder, chronic gran-
ulomatosis, induces active oxygen production disorder of neu-
trophils, affecting bactericidal actions. Therefore, patients with
this disorder are prone to be infected with non-H2O2-producing
catalase-positive bacteria (S. aureus, K. pneumoniae, E. coli,
Candida spp., Aspergillus spp.).
➃ Complement deﬁciency: Patients with complement deﬁciency
are prone to be infected with bacteria with capsules, such as
S. pneumoniae, H. inﬂuenzae (capsule strains), and Neisseria
meningitidis [214].
In children, it is not easy to investigate causative microorgan-
isms, but, if drug susceptibility is clariﬁed, it contributes to suc-
cessful treatment. Therefore, various cultures should be conducted
to investigate the etiology, if possible. In addition, testing of various
antigens, such as urinary S. pneumoniae/Legionella antigens, b-D-
glucan, Aspergillus antigen, Cryptococcus antigen, Candida antigen,
and Cytomegalovirus antigen, and tests using nucleic acid ampli-
ﬁcation methods, such as the PCR method, should be utilized, if
possible.First phase, 
before engraŌment 
(within 30 days)
S
aŌe
(3
Neutropenia/mucosal disorder, 
Acute GVHD
Cellular im
Acute and
Non-
infecƟous
InfecƟous
GVHD: graŌ versus host disease, BO: bronchioliƟs obliterans
AŌer
transplantaƟon
Day 0 Day 30
Drug-/radiaƟon-related pulmonary disor
Herpes simplex
Bacterial pneumonia
Candida
Fig. 9. Pulmonary complications after homologous[Rules of antimicrobial drug therapy]
Initial antimicrobial drug therapy should be performed,
considering the severity of pneumonia and an underlying disease.
For the treatment of immunodeﬁciency-/blood disease-related
pneumonia in children, antimicrobial drug therapy should also be
basically selected, considering causative microorganisms. As
described for nosocomial infection, the involvement of drug-
resistant microorganisms, such as MRSA, extended-spectrum b-
lactamase (ESBL)-producing bacteria, and multi-drug-resistant
P. aeruginosa (MDRP), must always be considered for treatment.
Initial antimicrobial drug therapy should be started by combining
two drugs, if necessary, considering various resistant microorgan-
isms, differing from that for community-acquired pneumonia
[213,214]. As the state of resistant bacteria differs among in-
stitutions, antimicrobial drug options should be customized based
on records on antimicrobial drug susceptibility (antibiograms) at
each institution.
A consensus regarding the administration period of antimicro-
bial drugs has not been reached. With respect to the administration
period of antimicrobial drugs, factors such as the type of causative
microorganisms and patient background differ among individual
patients with nosocomial infection; therefore, it is difﬁcult to
establish standardized criteria. In children, disease progression is
often prompt, and the ﬁrst evaluation should be performed after 2
days in younger and severe-status children, and not after 3 days. If
an improvement in clinical symptoms or laboratory data is ach-
ieved, the same antimicrobial drug should be continued until an
appropriate antimicrobial drug and drug susceptibility are clariﬁed.
When the type of microorganisms that caused pneumonia is
identiﬁed, a target-focused antimicrobial drug should be selected
through de-escalation, considering drug susceptibility and phar-
macokinetics [189].
Monitoring culture of the airway is useful for treating immu-
nodeﬁciency-/blood disease-related pneumonia in children [214].
General preventive methods are presented in Table 18 [213]. In
addition, long-term low-dose macrolide therapy or theecond phase, 
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Table 18
Prevention of immunodeﬁciency-/blood disease-related pneumonia in children [213].
Pathogen Prevention
Bacteria Sterilization of the intestinal tract with polymyxin B
In children, there is no evidence regarding the usefulness of prevention with new quinolones.
Fungus In the presence of severe neutropenia (100/mL or less), the preventive administration of ﬂuconazole should be performed.
Use of HEPA ﬁlters
ST combination drugs for Pneumocystis pneumonia
Virus Compliance with standard preventive strategies
The administration of gamma-globulin preparations should be considered using a serum IgG level of 400 mg/dL or less as an index.
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ﬁxation is effective in some patients with chronic bronchitis
[217,218]. In those with chronic granulomatosis, the oral admin-
istration of ITCZ (4e6 mg/kg/day, maximum: 100 mg/day) or
subcutaneous injection of IFN-g (250,000 domestic standard
units/m2, 1e3 times a week) is useful for preventing infection
[219].
In this article, the classiﬁcation of severity (Table 12, p. 30) in the
Guidelines for the Management of Respiratory Infectious Diseases
in Children in Japan 2011 was used (Refer to the section “3. Pneu-
monia (Children), 3.1 Community-acquired pneumonia”.).
- - - Drugs to be recommended- - -
1. Empiric therapy
(1) Pneumonia related to mild immunodeﬁciency in the initial
phase after admission
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3e4
times a day
- CTX, intravenous injection or drip, 40 mg/kg/3e4 times a
day
- CTRX, intravenous injection or drip, 50 mg/kg/twice a day
(2) Pneumonia related to moderate/severe immunodeﬁciency- CAZ, intravenous injection or drip, 50 mg/kg/3e4 times a
day
- CZOP, intravenous injection or drip, 50 mg/kg/3e4 times a
day
- CPR, intravenous injection or drip, 50 mg/kg/3e4 times a
day
In severe cases,
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- VCM, intravenous drip, 15 mg/kg/3 times a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
When there is no response,
- AMK, intravenous drip, 5e7.5 mg/kg/twice a day
- TOB, intravenous drip, 3.3 mg/kg/3 times a dayIf necessary, an antifungal drug (MCFG) and ST combination
drug should be additionally administered.
When Aspergillus infection is suspected, treatment should be
started with VRCZ or L-AMB instead of MCFG.
In patients with cellular immunodeﬁciency, one of the above
drugs should be combined with MCFG and an ST combination drug
in the early stage.
In those with neutrophil abnormalities, one of the above drugs
should be combined with MCFG in the early stage.When legionellosis cannot be ruled out in the severest cases,
one of the above regimens should be combined with a macrolide
(With respect to the administration method/dose, refer to the
section “3.1 Community-acquired pneumonia- - - ➁ Six years or
older- - - (2) Admission (Moderate, general ward)” (p. 32).).
2. Deﬁnitive therapy
➀ Enteric bacteria (E. coli, K. pneumoniae, Proteus spp.)▪ Non-ESBL-producing bacteria
- CTX, intravenous injection or drip, 40mg/kg/3e4 times a
day
- CTRX, intravenous injection or drip, 50 mg/kg/twice a
day
▪ ESBL-producing bacteria
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
➁ Enterobacter spp., Serratia spp., Citrobacter spp.
- CPR, intravenous injection or drip, 40 mg/kg/3e4 times a
day
- CFPM, intravenous injection or drip, 40 mg/kg/3e4 times a
day
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
➂ S. aureus
▪ MSSA
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3e4
times a day
- CEZ, intravenous injection or drip, 50 mg/kg/3 times a
day
▪ MRSA
- VCM, intravenous drip, 15 mg/kg/3 times a day
- TEIC, intravenous drip, 10 mg/kg/every 12 h, 3 times,
subsequently: 6e10 mg/kg/once a day
- ABK, intravenous drip, 4e6 mg/kg/once a day
- LZD, intravenous drip or oral, 10 mg/kg/every 8 h, 3
times a day
➃ P. aeruginosa
- CAZ, intravenous injection or drip, 50 mg/kg/4 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- AMK, intravenous drip, 5e7.5 mg/kg/twice a day
- TOB, intravenous drip, 2e3 mg/kg/twice a day
➄ S. maltophilia
- ST combination drug, intravenous drip or oral, SMX 25 mg/
TMP 5 mg/kg/3e4 times a day
- MINO, intravenous drip, 1e2 mg/kg/twice a day (In chil-
dren aged 7 years or younger, the use of this drug is limited
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responders to other drugs.)
➅ A. baumannii
- IPM/CS, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3e4
times a day
[Note] If there is no susceptibility, combination therapy with
aminoglycosides should be reviewed using the checker-
board method. CL administration should also be considered.
➆ Anaerobes
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3 times
a day
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- CLDM, intravenous drip, 10 mg/kg/3 times a day
➇ Pneumocystis jirovecii
- ST combination drug, intravenous drip or oral, SMX 25 mg/
TMP 5 mg/kg/3e4 times a day
- Pentamidine, intravenous drip, 4 mg/kg/once a day
➈ C. neoformans, FLCZ-susceptible Candida (primarily
C. albicans)
- FLCZ, intravenous drip, 10e12 mg/kg/once a day
➉ Aspergillus, FLCZ-resistant Candida
- MCFG, intravenous drip, 3e6 mg/kg/once a day
- VRCZ, intravenous drip, 9 mg/kg/twice a day on Day 1,
8 mg/kg/twice a day on Day 2 or later. During the admin-
istration period, the blood concentration of this drug
should be monitored.
- L-AMB, intravenous drip, 2.5e5 mg/kg/once a day
⑪ Cytomegalovirus
- GCV, intravenous drip, 10 mg/kg/twice a day
[Note] In the presence of GCV resistance, the intravenous drip of
PFA (foscarnet), 60 mg/kg/3 times a day should be performed.
3.4. Neonatal pneumonia- - - Executive summary- - -
In the treatment of neonatal pneumonia, antimicrobial drugs
should be selected after differentiating congenital from acquired
pneumonia.
Initial antimicrobial drug therapy should be started by
combining two drugs, regarding the condition as severe systemic
infection and considering various causative microorganisms. The
administration method and dose should be selected based on the
age (days) and birth weight (BIII).
[Characteristics and classiﬁcation of the disease]
The incidence of neonatal pneumonia is not high. According to
Sakata, pneumonia occurred in only 40 (0.25%) of approximately
16,000 neonates who were admitted during a 10-year period [220].
Neonatal pneumonia is frequently observed as a portion of sys-
temic infection represented by sepsis, and not as a single condition.
It is classiﬁed into two types: congenital and acquired pneumonia
[221].
In most cases, neonatal pneumonia does not cause any typical
symptoms such as fever or cough in comparison with infantile/
childhood pneumonia. The neonatal protective capacity against
infection is physiologically immature, often leading to a severecondition. In the neonatal phase, artiﬁcial respiration management
is performed in many cases, and ventilator-associated pneumonia
(VAP) is frequently observed [222e224]. In addition, many neo-
nates are admitted to the neonatal intensive care unit (NICU) for a
long period; therefore, the incidence of nosocomial infection is
high.
[Type and frequency of causative microorganisms]
Several types of congenital pneumonia include transplacental
infection, intrauterine infection related to aspiration of infected
amniotic ﬂuid on premature rupture, and birth canal infection
with vaginal discharge on delivery. These types of congenital
pneumonia are primarily caused by various viruses (Cytomeg-
alovirus, herpes simplex virus), bacteria (Streptococcus aga-
lactiae (GBS), E. coli, Listeria monocytogenes), Chlamydia, and
fungus.
The clinical onset of perinatal pneumonia is frequently observed
immediately to 7 days after birth [221].
Postnatal pneumonia usually develops 2 weeks or more after
birth. It is caused by viruses and bacteria. Viral infection may occur
when RS virus, parainﬂuenza virus, or adenovirus prevails in the
ward. However, it rarely leads to the onset of pneumonia. Frequent
causative bacteria include S. aureus, E. coli, P. aeruginosa, Acineto-
bacter spp., Enterobacter spp., and Legionella spp., which exist in the
environment. These often cause nosocomial infection [221]. In
premature babies, Gram staining of tracheal aspirate samples is
useful for selecting antimicrobial drugs to be administered in the
initial phase [225].
In children, it is not easy to investigate causative microor-
ganisms, but, if drug susceptibility is clariﬁed, it contributes to
successful treatment. Therefore, blood or bronchial lavage ﬂuid
culture should be conducted to investigate the etiology, if
possible.
[Rules of antimicrobial drug therapy]
As many neonates have systemic infection in an immunodeﬁ-
ciency state, the same administration method and dose as selected
for the treatment of sepsis should be used [221]. Therefore, the
severity of pneumonia is not considered. When bacterial pneu-
monia is suspected, combination therapy with ABPC and CTX is
commonly selected as initial treatment. Considering
L. monocytogenes infection, combination therapy with ABPC is
recommended. After causative microorganisms are identiﬁed,
antimicrobial drugs should be selected with reference to their drug
susceptibility. In cases of VAP, antimicrobial drug options should be
customized based on records on the drug susceptibility (antibio-
grams) of microorganisms that cause nosocomial infection at each
institution.
In neonates, there are marked age-related differences in the
pharmacokinetics of antimicrobial drugs; therefore, these drugs
must be carefully administered in the neonatal phase. Concretely,
the same dose as established in the ﬁeld of pediatrics should be
used, and the administration interval should be prolonged in
accordance with age [221]. In cases of severe asphyxia or acute
renal failure, the administration interval must be further prolonged.
It should be shortened with an improvement in the kidney function
[226e229].
A consensus regarding the administration period of antimicro-
bial drugs has not been reached. However, the standard adminis-
tration period is 14 days. With respect to the administration
method/dose, refer to the section “XI. Doses for neonates”.
In neonates, disease progression is often prompt, and the
treatment response should be evaluated after 2 days, and not after
3 days. If an improvement in clinical symptoms or laboratory data is
achieved, the same antimicrobial drug should be continued until an
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When the type of microorganisms that caused pneumonia is
identiﬁed, a target-focused antimicrobial drug should be selected
through de-escalation, considering drug susceptibility and phar-
macokinetics [189].
- - - Drugs to be recommended- - -
1. Empiric therapy
[0 dayse4 weeks after birth]
(1) Non-hospital-acquired pneumonia
A First choice
- ABPC, intravenous injection or drip
þ
- CTX, intravenous injection or drip
<> Second choices
- ABPC, intravenous injection or drip
þ one of the followings:
- GM, intravenous drip
- AMK, intravenous drip(2) Hospital-acquired pneumonia (including VAP)
A First choices
- CAZ, intravenous injection or drip
- CZOP, intravenous injection or drip
þ one of the followings:
- GM, intravenous drip
- AMK, intravenous drip
- TOB, intravenous drip
- ABK, intravenous drip (cases in which the involvement
of MRSA is suspected)
<> Second choices
- MEPM, intravenous drip
þ one of the followings:
- VCM, intravenous drip
- TEIC, intravenous drip
- ABK, intravenous drip (cases in which the involvement
of MRSA is suspected)2. Deﬁnitive therapy
➀ S. agalactiae▪ ABPC-susceptible bacteria
- ABPC, intravenous injection or drip
▪ Moderately ABPC-resistant bacteria
- ABPC, intravenous injection or drip þ GM or AMK,
intravenous drip
- MEPM, intravenous drip
➁ Enteric bacteria (E. coli, K. pneumoniae)
- CTX, intravenous injection or drip
- MEPM, intravenous drip (ESBL-producing bacteria)
➂ MSSA
- CEZ, intravenous injection or drip
➃ MRSA
- VCM, intravenous drip
- TEIC, intravenous drip
- ABK, intravenous drip
➄ Listeria spp.
- ABPC, intravenous injection or drip
- MEPM, intravenous drip
➅ Enterococcus
- ABPC, intravenous injection or drip ± GM or AMK, intra-
venous drip
- VCM, intravenous drip
➆ P. aeruginosa
- CAZ, intravenous injection or drip
- GM, intravenous drip- AMK, intravenous drip
- TOB, intravenous drip
- MEPM, intravenous drip
➇ C. trachomatis
- EM, oral4. Pyothorax
4.1. Adults- - - Executive summary- - -
- Pyothorax refers to a condition in which pus accumulates in the
thoracic cavity. Usually, pleural effusion puncture is performed,
and a diagnosis of pyothorax is made based on the results of
various examinations, such as (macroscopic) purulent pleural
effusion, microorganisms detected on Gram staining or culture
of pleural effusion, or pleural effusion pH: <7.2 (BIII).
- In patients with acute pyothorax related to community-acquired
pneumonia, treatment should be performed in accordance with
that for community-acquired pneumonia, considering micro-
organisms that cause community-acquired pneumonia, such as
Streptococcus pneumoniae (BIII).
- In patients with slowly progressing pyothorax, mixed infection
with oral aerobes/anaerobes is frequently observed. Combina-
tion therapy with PCG or ABPC and CLDM or MNZ, which show
anti-anaerobe activities, or therapy with a single antimicrobial
drug with an anti-anaerobe activity, such as SBT/ABPC, should
be selected (BIII).
- When there is a risk of multi-drug-resistant bacteria, mono-
therapy with a carbapenem, combination therapy with a fourth-
generation cephalosporin and CLDM or MNZ, and combination
therapy with a quinolone and CLDM or MNZ should be consid-
ered, assuming ESBL-producing enteric bacteria, resistant P.
aeruginosa, anaerobes, and Acinetobacter (BIII).
- If the results of culture/susceptibility tests are clariﬁed, anti-
microbial drugs should be changed in accordance with them
(AIII).
- The penetration of aminoglycosides to the thoracic cavity is
poor, and their activities reduce when the pH is low. Therefore,
the use of aminoglycosides should be avoided as a rule (BIII).
- If a diagnosis of pyothorax is made, the administration of an
appropriate antimicrobial drug should be started, and drainage
must be performed (AII). If possible, the attending physician
should consult a surgeon in the early stage (AIII).
- In some patients withmarked pleural thickening ormultilocular
pleural effusion, thoracoscopic debridement is necessary (BIII).
In addition, a ﬁbrinolytic drug, such as streptokinase, is
administered through a thoracic drain, or surgical interventions
such as thoracotomy or decortication is performed in some
cases (BIII).- - - Explanation- - -
[Diagnosis]
- Pyothorax is deﬁned as a condition in which pus accumulates in
the thoracic cavity, but this deﬁnition has no diagnostic objec-
tivity. For this reason, usually, pleural effusion puncture is per-
formed, and a diagnosis of pyothorax is made based on the
results of various examinations, such as (macroscopic) purulent
pleural effusion, microorganisms detected on Gram staining or
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[230,231].[Causative microorganisms]
- Pleural effusion appears in 30e40% of patients with bacterial
pneumonia, but leads to pyothorax in 0.5e2%. Other etiological
factors for pyothorax include surgery, trauma, and esophageal
perforation.
- Microorganisms that cause pyothorax depend on its etiology
and course. In the presence of bacterial pneumonia, pyothorax is
caused by the same microorganisms as caused bacterial pneu-
monia. Furthermore, acute pyothorax is frequently caused by
S. pneumoniae and S. aureus. However, in many patients with
chronic pyothorax, mixed infection primarily with anaerobes is
involved. Among anaerobes, Fusobacterium spp. (especially
Fusobacterium nucleatum), Prevotella spp., Peptostreptococcus
spp., and Bacteroides spp. are frequently detected [232e234].
According to recent studies, the detection rate of the Strepto-
coccus anginosus group is high [235,236].
- In many cases, pyothorax with a relatively slow course is asso-
ciated with M. tuberculosis. It must be considered that pulmo-
nary lesions do not always concurrently exist with tuberculous
pleuritis.[Treatment]
- No randomized comparative study regarding antimicrobial drug
treatment for pyothorax has been conducted. An antimicrobial
drug with an activity against microorganisms expected or ob-
tained on culture should be selected and administered. In acute-
onset patients in whom there is no risk of resistant bacteria, for
example, those with pyothorax accompanying community-
acquired pneumonia, antimicrobial drugs such as PCG and
ABPC should be initially selected, considering S. pneumoniae.
These drugs simultaneously cover Fusobacterium, Peptos-
treptococcus, and the viridans Streptococcus group. However,
Prevotella and Bacteroides produce b-lactamase; therefore, when
the results of culture are not obtained, combination therapy
with antimicrobial drugs with activities against anaerobes, such
as CLDM and MNZ, or therapy with such a single drug, such as
SBT/ABPC, should be selected.
- When there is a risk of multi-drug-resistant bacteria, mono-
therapy with a carbapenem should be selected as a ﬁrst choice,
assuming ESBL-producing enteric bacteria, resistant
P. aeruginosa, and Acinetobacter. A fourth-generation cephalo-
sporin should be combined with CLDM, or a quinolone should
be combined with CLDM or SBT/ABPC.
- If the results of culture/susceptibility tests are clariﬁed, anti-
microbial drugs should be changed in accordance with them.
However, the culture of anaerobes is difﬁcult, or is not con-
ducted in some cases. Therefore, this should be conﬁrmed to the
laboratory. When only one type of bacteria are detected on a
culture test despite several types of bacteria detected on Gram
staining of pleural effusion, anaerobes must also be considered.
- The penetration of aminoglycosides to the thoracic cavity is
poor, and their activities reduce when the pH is low. Therefore,
for pyothorax treatment, the use of aminoglycosides should be
generally avoided [237e240].[Treatment period]
- The pyothorax treatment period has not been established.
However, when pneumonia promptly responds to treatmentand thoracic drainage is successfully achieved in patients with
pneumonia-related pyothorax, a treatment period of 10e14
days is required. In patients in whom drainage is unsuccessful,
those with marked pleural thickening, or those with
encapsulated/septum-like pyothorax, a treatment period of
about 4 weeks is often required.[Treatments other than antimicrobial drug therapy]
- After a diagnosis of pyothorax is made, the administration of an
appropriate antimicrobial drug should be promptly started, and
drainage is necessary. When the pleural ﬂuid is purulent and
viscous in the absence of a multilocular pattern, chest-tube
insertion is routinely performed. The position of insertion
should be conﬁrmed using thoracic CT within 24 h after inser-
tion. Wozniak et al. performed multivariate analysis involving
104 patients with pyothorax and indicated that failure in the
ﬁrst drainagewas strongly correlated with mortality, suggesting
the necessity of early consultation with surgeons [241].
- In some patients with marked pleural thickening or multilocular
pleural effusion, thoracoscopic debridement is necessary. In
addition, a ﬁbrinolytic drug, such as streptokinase, is adminis-
tered through a thoracic drain, or surgerical interventions such as
thoracotomy or decortication is performed in some cases [242].- - - Drugs to be recommended- - -
1. Empiric therapy
➀ Cases in which there is no risk of multi-drug-resistant
bacteria
A First choice
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
<> Second choices
- PCG, intravenous drip, 2,000,000 to 3,000,000 units/4
times a day
- ABPC, intravenous drip, 2 g/3e4 times a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
➁ Cases in which there is a risk of multi-drug-resistant bacteria
A First choices- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- MEPM, intravenous drip, 1 g/2e3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
<> Second choices (I)
- CFPM, intravenous drip, 1e2 g/2e4 times a day
- CZOP, intravenous drip, 1e2 g/2e4 times a day
- CPR, intravenous drip, 1e2 g/2e4 times a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
<> Second choices (II)
- LVFX, intravenous drip, 500 mg/once a day
- CPFX, intravenous drip, 300 mg/twice a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day
þ one of the followings:
- CLDM, intravenous drip, 600 mg/2e4 times a day
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
- MNZ, intravenous drip, 500 mg/4 times a day
* With respect to the risk of multi-drug-resistant bacteria,
refer to the section “2.2 Hospital-acquired pneumonia”
Table 3 (p. 10).
Table 19
Indications for continuous drainage [243].
➀ Cases in which pleural effusion obtained on thoracentesis is purulent
➁ Cases in which clinical effects are not achieved by antimicrobial
drug therapy alone (within 72 h)
➂ Cases in which retention ﬂuid affects the respiratory function
K. Mikasa et al. / J Infect Chemother 22 (2016) S1eS65 S41* In particular, MRSA infection must be considered in pa-
tients with nosocomial onset or the previous adminis-
tration of antimicrobial drugs. When Staphylococcus
infection is suspected on Gram staining of pleural effu-
sion, an anti-MRSA drug should be used as an empiric
therapy. If MSSA is identiﬁed as causative bacteria, de-
escalation should be performed.2. Deﬁnitive therapy
- Antimicrobial drugs against causative microorganisms iden-
tiﬁed should be selected in accordance with the section “2.1
Community-acquired pneumonia- - - 2.1.2 Deﬁnitive therapy”
(p. 4) or “2.2 Hospital-acquired pneumonia- - - 2.2.3 Deﬁnitive
therapy” (p. 13).
- If MRSA infection is suspected, antimicrobial drugs should be
selected in accordance with the section “2.2 Hospital-acquired
pneumonia- - - 2.2.3 Deﬁnitive therapy- - - (1) MRSA” (p. 13).
- Tuberculous pleuritis should be treated in accordancewith the
treatment of pulmonary tuberculosis (p. 42).4.2. Children- - - Executive summary- - -
For the treatment of pyothorax in children, antimicrobial
drugs should be administered after investigating the etiology
using thoracentesis or blood culture, if possible. In addition to
antimicrobial drug therapy, treatment for retention ﬂuid (pleural
effusion drainage, continuous drainage) must also be considered
(BIII).
[Characteristics and classiﬁcation of the disease]
Pleuritis refers to inﬂammation of the pleura. Fluid (pleural
effusion) is retained in the pleural cavity. Pleuritis is classiﬁed into
3 types: ﬁbrinous (dry) pleuritis, exudative (wet) pleuritis, and
purulent pleuritis (pyothorax) based on conditions [243]. On
auscultation, the attenuation of respiratory sounds, as well as
pleural friction rubs, are heard. Percussion dullness is noted. In the
chronic stage, localized pleural thickening in various shapes is
observed. When pus is obtained on thoracentesis, a deﬁnitive
diagnosis of pyothorax is made. When the protein level in non-
purulent pleural effusion is high, tuberculous pleuritis should be
differentiated [244].
[Type and frequency of causative microorganisms]
Previously, pyothorax was associated with S. aureus in many
cases. However, recently, such cases have been rare. According to
data form a national survey in the former half of the 1990's, there
were only a few patients with S. pneumoniae- or anaerobe-
related pyothorax [243]. In many cases, pleuritis follows M.
pneumoniae- or virus-related pneumonia. Decubitus-view imag-
ing shows the retention of pleural effusion in approximately 20%
of patients with Mycoplasma pneumonia [245]. If the drug sus-
ceptibility of causative microorganisms is clariﬁed, it contributes
to successful treatment. Therefore, pleural effusion obtained by
thoracentesis should be cultured to investigate the etiology, if
possible.
[Rules of antimicrobial drug therapy]
When bacterial infection-related pyothorax is suspected, the
intravenous injection or drip of SBT/ABPC, CTX, or CTRX should be
selected in community-onset patients without an underlying
disease. On the other hand, combination therapy with SBT/ABPC
(intravenous injection or drip) and CLDM (intravenous drip) orcarbapenem therapy (intravenous drip) should be started in those
with an underlying disease or nosocomial onset, considering
S. pneumoniae, anaerobes, H. inﬂuenzae, and S. aureus [243]. Based
on the Gram staining reactions of pleural effusion, causative
microorganisms should be estimated, and antimicrobial drugs
must be reviewed. If necessary, tuberculosis should also be
investigated.
The administration period of antimicrobial drugsmust be longer
than that for pneumonia. As the type of causative microorganisms,
patient background, and state of retention-ﬂuid drainage differ
among individual patients, it is difﬁcult to establish standardized
criteria. However, target administration periods for S. pyogenes
(GAS)-, S. pneumoniae-, and S. aureus-related pyothorax are 10, 14,
and 21 days or more, respectively.
The treatment response should be evaluated 3e4 days after
the start of administration. If an improvement in clinical
symptoms or laboratory data is achieved, the same antimicro-
bial drug should be continued until causative microorganisms
and their drug susceptibility are clariﬁed. When the type of
microorganisms that caused pneumonia is identiﬁed, a target-
focused antimicrobial drug should be selected through de-
escalation, considering drug susceptibility and pharmacoki-
netics [189].
For the treatment of pyothorax, treatment for retention ﬂuid
(pleural effusion drainage) is also a basic procedure in addition to
antimicrobial drug therapy. If necessary, continuous drainage
should be performed (Table 19) [243]. If pleural thickening leads to
underexpanded lung, decortication should be indicated. The
widespread application of thoracoscopic surgery has facilitated
minimally invasive surgery [246].
- - - Drugs to be recommended- - -1. Empiric therapy
(1) Community onset (without an underlying disease)- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3 times
a day
- CTX, intravenous injection or drip, 40 mg/kg/3e4 times a
day
- CTRX, intravenous injection or drip, 50 mg/kg/twice a day
(2) Community-acquired infection (with an underlying dis-
ease), nosocomial onset
- CLDM, intravenous drip, 10 mg/kg/3 times a day
þ
- SBT/ABPC, intravenous injection or drip, 75 mg/kg/3 times
a day
or one of the following drugs alone should be
administered:
- TAZ/PIPC, intravenous drip, 112.5 mg/kg/3 times a day
- PAPM/BP, intravenous drip, 20 mg/kg/3 times a day
- MEPM, intravenous drip, 20 mg/kg/3 times a day
- DRPM, intravenous drip, 20 mg/kg/3 times a day2. Deﬁnitive therapy
Refer to the section “3.1 Community-acquired pneumonia- - -
3.1.2 Deﬁnitive therapy” (p. 33) or “3.2 Hospital-acquired
pneumonia- - -3.2.2 Deﬁnitive therapy” (p. 34).
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5.1. Adults
1. Pulmonary tuberculosis
- - - Executive summary- - -
- As initial treatment, four drugs (INH, RFP, and PZA þ EB or
SM) should be administered for 2 months. Subsequently, as a
rule, standard treatment (A), in which two drugs, INH and
RFP, are administered for 4 months, should be performed as
maintenance treatment (AI).
- When PZA cannot be used for initial treatment for some
reason, INH, RFP, and EB or SM, should be administered for 2
months as initial treatment. Subsequently, standard treat-
ment (B), in which two drugs, INH and RFP, are administered
for 7 months, should be performed as maintenance treat-
ment (AII).
- In patients in whom chest X-ray shows a cavity on initial
consultation to during initial treatment and the septum
culture is still positive at the completion of initial treatment,
maintenance treatment should be prolonged over 3 months.
In addition, the prolongation of maintenance treatment
should also be considered in patients with severe tubercu-
losis, such as military tuberculosis and tuberculosis of the
central nervous system, those with immune depression, and
those with relapse of tuberculosis (AII).
- For the treatment of latent tuberculosis infection, INH should
be administered for 6 or 9months (AI). WhenM. tuberculosis,
as the source of infection, is resistant to INH, or when the oral
administration of INH is difﬁcult due to side effects, RFP
should be used as a second-choice drug for 4 or 6 months
(AI).
- - - Explanation- - -
- Standard treatment for tuberculosis in the 1950's was com-
bination therapy with INH, SM, and PAS for 18 months. In
1968, RFP became commercially available. In the 1970's,
controlled studies in England indicated the usefulness of
short-term combination chemotherapy with RFP for 6
months [248,249]. Thereafter, the efﬁcacy of short-term
combination chemotherapy with PZA for 2 months after
the start of treatment was demonstrated [250e252]. In 1998,
the British Thoracic Society recommended that conventional
drugs, INH, RFP, and PZA, should be combined with SM or EB
for the ﬁrst 2months, assuming that the rate of INH-resistant
M. tuberculosis will increase. It was also recommended that,
if a smear test becomes negative within 2 months and there
is no drug resistance, INH and RFP, should be used for the
subsequent 4 months (total: 6-month treatment) [253].
- Both the Guidelines for the Management of Tuberculosis in
Japan, Revision No. 2, which was published in 2012, and
Document regarding Tuberculosis Treatment, which was
agreed by the ATS/CDC/IDSA in the United States and
announced in2003, recommendedthat INH,RFP,PZA,andEBor
SM, should be administered for theﬁrst 2months, and that INH
and RFP, should be administered for the subsequent 4 months,
as the most standard, evidence-based treatment method
[254,255]. In particular, this method is named “standard treat-
ment (A)” in theGuidelines for theManagementofTuberculosis
in 2012 in Japan. In this article, this name is also used.
- The secondary assessment of a study examining the efﬁcacy
of rifapentine and INH showed that factors for unsuccessfultreatment/recurrence included a cavity on chest X-ray at the
start of treatment and positive ﬁndings on culture at the
completion of initial treatment for 2 months [256]. Similarly,
when the treatment period was extended from 6 to 8
months in patients with silicotuberculosis, in whom the
unsuccessful treatment/recurrence rates are high, the
recurrence rate decreased from 22 to 7%. Therefore, various
guidelines recommend that maintenance treatment should
be prolonged over 3 months in patients with a cavity and
those showing positive ﬁndings on septum culture at the
completion of initial treatment [254,255].
- In 1990, Combs et al. compared the results of treatment
between a group treated with INH, RFP, and PZA for 2
months and, then, with INH and RFP for 4 months and that
treatedwith INH and RFP for 9months, and reported that the
efﬁcacy and incidence of side effects were similar [257].
Based on such a study, the following regimen is recom-
mended as standard treatment (B) in the Guidelines for the
Management of Tuberculosis in 2012 in Japan: when PZA
cannot be used for some reason, INH, RFP, and EB or SM, are
administered for the ﬁrst 2 months, and, subsequently, two
drugs, INH and RFP, are administered for 7 months.
- Patients who are infected with M. tuberculosis, but do not
develop tuberculosis are regarded as having latent tuber-
culosis infection (LTBI). INH administration for LTBI de-
creases the incidence of tuberculosis by 25e92% [258].
Previously, this was called preventive therapy, but is
currently termed LTBI treatment. The decrease in the inci-
dence of tuberculosis is correlated with compliance with
INH, and more marked preventive effects may be achieved
when compliance is higher [258e260]. In a study involving
INH administration to LTBI patients with an old shadow on
chest X-ray, this therapy inhibited the onset of tuberculosis
in 65 and 75% of patients treated for 6 and 12 months,
respectively (there was no signiﬁcant difference between
the two groups) [261]. Based on the data, some studies
recommended that the period of standard INH adminis-
tration for LTBI should be 9 months [262e264]. However, a
consensus regarding an effective administration period (6
or 9 months) has not been reached from various aspects
including the efﬁcacy, compliance, expenses, and incidence
of side effects. Actually, the administration period should be
determined based on compliance and the incidence of side
effects.
- In LTBI treatment, RFP should be used for 4 or 6months as an
alternative drug when the oral administration of INH is
impossible for some reason. The preventive effects of RFP on
the onset of tuberculosis in LTBI patients may be similar to
those of INH. Furthermore, the incidence of liver dysfunction
is lower than that related to INH [265e267]. However, for the
use of RFP, drug interactions must be considered.
- - - Drugs to be recommended- - -
A First choice
- INH, oral, 5 mg/kg/once a day (maximum: 300 mg/
day) þ RFP, oral, 10 mg/kg/once a day (maximum: 600 mg/
day, orally administered beforemeals as a rule)þ PZA, oral,
25 mg/kg/once a day (maximum: 1500 mg/day) þ EB, oral,
15 mg/kg/once a day (maximum: 750 mg/day) or SM,
intramuscular injection, 15 mg/kg/once a day (maximum:
750 mg/day)/2e3 times a week.
* The above 4 drugs should be administered for 2 months,
and, subsequently, two drugs, INH and RFP, should be
administered for 4 months.
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- INH, oral, 5 mg/kg/once a day (maximum: 300 mg/
day)þ RFP, oral, 10 mg/kg/once a day (maximum: 600 mg/
day, orally administered before meals as a rule) þ EB, oral,
15 mg/kg/once a day (maximum: 750 mg/day) or SM,
intramuscular injection, 15 mg/kg/once a day (maximum:
750 mg/day)/2e3 times a week.
* The above 3 drugs should be administered for 2 months,
and, subsequently, two drugs, INH and RFP, should be
administered for 7 months.2. Non-tuberculous Mycobacterium infection
a. Mycobacterium avium complex (MAC)
- - - Executive summary- - -- To treat pulmonary infection with M. avium complex in
HIV-negative patients, CAM, RFP, and EB should be
administered to those with nodular/bronchodilatation type
infection (AI). In severe-status patients and those with
cavity-type lesions, the intramuscular injection of SM or
KM should be added (BIV).
- The treatment period should be at least 12 months after
culture becomes negative, but there are no criteria
regarding an optimal treatment period (BIV).
- - - Explanation- - -
- In the 1990's, CAM was introduced for the treatment of
pulmonary infection with M. avium complex. Before then,
combination therapy with antituberculous drugs, such as
INH, RFP, and EB, had been used. According to a report from
the Research Committee of the British Respiratory Society
in 2002, 27 of 75 HIV-negative patients with pulmonary
MAC infection died within 5 years, treatment was unsuc-
cessful in 11, and recurrence was noted in 10. CAM was not
used in any patient, and there was no correlation between
the susceptibility to various antituberculous drugs, such as
INH, RFP, and EB, and prognosis [268].
- The introduction of CAM for the treatment of pulmonary
MAC infection in the 1990's has markedly improved the
treatment response and prognosis. Wallace et al. per-
formed combination therapy with CAM (1000 mg/day),
EB, RFP (or RBT), and SM in 39 patients with pulmonary
MAC infection, and reported that 91% of the patients
became negative for MAC [269]. In Japan, Tanaka et al.
conducted combination therapy with CAM (10 mg/kg)
and EB/RFP/KM in 39 patients, and indicated that 89.5%
of those who underwent initial treatment became nega-
tive for MAC [270]. Concerning CAM, many studies have
reported a correlation between the in vitro drug sus-
ceptibility and treatment response [271e273]. Further-
more, a study indicated that AZM was as effective as CAM
[274].
- RBT, which was published in the drug price in NHI scheme
in Japan in 2008, was also approved for tuberculosis and
non-tuberculous Mycobacterium infection, including pul-
monary MAC infection. The drug interactions of RBT are less
marked than those of RFP, and RBT is used as a ﬁrst-choice
drug for disseminated MAC infection in HIV-infected pa-
tients [275]. On the other hand, RBT induces side effects
such as uveitis. In elderly patients, in whom pulmonary
MAC infection frequently develops, various side effects,
such as gastrointestinal disorder, make long-term therapydifﬁcult [276]. In addition, no study has indicated that RBT
is more effective than RFP for pulmonary MAC infection in
non-HIV-infected patients. Therefore, RFP should be
selected as a ﬁrst-choice drug for pulmonary MAC infection
in non-HIV-infected patients.
- Kobashi et al. divided 146 patients with pulmonary MAC
infection into two groups: a group treated with CAM, RFP,
EB, and SM (intramuscularly injected at 15 mg/kg 3 times a
week for 3 months) and a group treated with saline, and
conducted a randomized, double-blind, comparative study
[277]. In the SM-treated group, the rate at which the culture
of sputum became negative was higher than in the saline-
treated group (71.2 vs. 50.7%, respectively). There has
been no high-quality study demonstrating the usefulness of
combination therapy with aminoglycosides other than
their study. However, various guidelines recommend that
combination therapy with SM, AMK, or KM should be
performed for 2e3 months in the initial phase of treatment
in patients with a cavity or severe nodular/bronchodilata-
tion type infection based on experience [276,278,279].
Guidelines in the United States recommend SM or AMK,
and comment that no study has showed which of two
drugs, SM and AMK, is more effective, although SM has
been more frequently used [276]. In Japan, SM or KM is
recommended [279].
- Based on the results of these studies, the Non-tuberculous
Mycobacterium Infection Control Committee, Japanese So-
ciety for Tuberculosis recommends the following doses and
administration methods for chemotherapy for pulmonary
MAC infection in the “Opinions regarding Chemotherapy
for Pulmonary Non-tuberculous Mycobacterium Infection-
- - Revision in 2012”: RFP: 10 mg/kg (up to 600 mg)/day,
once a day, EB: 15 mg/kg (up to 750 mg)/day, once a day,
CAM: 600e800 mg/day (15e20 mg/kg), once a day or two
divided doses (800 mg: two divided doses), and SM or KM:
15 mg/kg or less (up to 1000 mg), intramuscularly injected
2 or 3 times a week [279].
- A cooperative statement on non-tuberculous Mycobacte-
rium infection by the American Thoracic Society/Infectious
Diseases Society of America recommends therapy with
CAM at 500 to 1000 mg/day or AZM at 250 mg/day, EB at
15 mg/kg/day, and RFP at 10 mg/kg/day (up to 600 mg) for
patients with a cavity or severe nodular/bronchodilatation
type infection. In addition, it is recommended that combi-
nation therapy with SM or AMK (8e10 mg/kg, 2e3 times a
week, patients aged over 50 years: 500 mg or less) for 2e3
months in the initial phase should be considered [276,280].
- The treatment period is established as about 1 year after the
culture becomes negative in the above guidelines, but this
is not based on evidence. In the Guidelines for the Man-
agement of Non-tuberculous Mycobacterium Infection,
which were published by the British Thoracic Society, the
treatment period of pulmonary MAC infection is estab-
lished as 2 years. In the future, an optimal treatment period
should be investigated.
- - - Drugs to be recommended- - -
- CAM, oral, 200 mg/3 times a day or 400 mg/twice a
day þ RFP, oral, 10 mg/kg/once a day (maximum: 600 mg/
day, orally administered before meals as a rule) þ EB, oral,
15 mg/kg/once a day (maximum: 750 mg/day)
* Severe-status patients and those with cavity-type lesions
In addition to the above regimen, the intramuscular
injection of SM or KM should be added.
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culture becomes negative.b. Mycobacterium kansasii
- - - Executive summary- - -
- To treat pulmonary infection with M. kansasii in HIV-
negative patients, INH, RFP, and EB should be adminis-
tered (AII).
- The treatment period should be at least 12 months after
culture becomes negative (AI).- - - Explanation- - -
- Pulmonary infectionwithM. kansasii is a type of pulmonary
non-tuberculous Mycobacterium infection on which drug
effects are the most potent. The efﬁcacy of INH, RFP, EB,
CAM, and MFLX in vitro has been conﬁrmed. In particular,
RFP is an important drug in the treatment of pulmonary
infectionwithM. kansasii. In a retrospective study involving
244 patients with pulmonary infection with M. kansasii, all
32 patients who underwent treatment with RFP became
negative for M. kansasii in sputum within 6 months,
whereas 80% of 130 patients who underwent RFP-free
treatment became negative for M. kansasii in sputum
within 6 months [281]. According to a study in Japan, 3
(approximately 1%) of 314M. kansasii strains were resistant
to RFP [282].
- Concerning the treatment period, in a prospective study
involving 28 non-HIV-infected patients with pulmonary
infection with M. kansasii, 14 were treated with 3 drugs,
INH, RFP, and EB, for 12 months (EB: for the ﬁrst 6 months
only), and the other 14 were treated with a similar
regimen for 18 months. Recurrence was noted in 1 in the
former [283]. In both a cooperative statement on non-
tuberculous Mycobacterium infection by the American
Thoracic Society/Infectious Diseases Society of America
and the “Opinions regarding Chemotherapy for Pulmo-
nary Non-tuberculous Mycobacterium Infection- - -
Revision in 2012” published by the Non-tuberculous
Mycobacterium Infection Control Committee, Japanese
Society for Tuberculosis, the treatment period is estab-
lished as at least 12 months after culture results become
negative [276,279].
- - - Drugs to be recommended- - -
- INH, oral, 5 mg/kg/once a day (maximum: 300 mg/
day) þ RFP, oral, 10 mg/kg/once a day (maximum: 600 mg/
day) þ EB, oral, 15 mg/kg/once a day (maximum: 750 mg/
day)
* The treatment period should be at least 12 months after
culture becomes negative.
c. Mycobacterium abscessus
- - - Executive summary- - -
- There is no drug (combination) that can be recommended
to treat pulmonary infectionwithMycobacterium abscessus.
- The drug susceptibility of M. abscessus varies, and a drug
susceptibility test should be generally performed. Usually,M. abscessus is susceptible to CAM, AMK, CFX, and IPM/CS.
However, it is unclear whether there is a correlation be-
tween the drug susceptibility and clinical effects.
- Combination therapy with CAM and several intravenous
antimicrobial drugs (AMK, CFX, and IPM/CS) may control
the symptoms and progression of pulmonary infectionwith
M. abscessus (BIII).
- In patients with pulmonary infection with M. abscessus in
whom the lesion is localized, cure can be targeted by
combining the above drugs with surgical resection (BIII).- - - Explanation- - -
- M. abscessus is a type of environmental bacteria that proliferate
in soil and tap water. It belongs to rapidly growing mycobacteria
(RGM). In the United States, Korea, and Taiwan, it is third most
commonly detected as a type of non-tuberculous Mycobacte-
rium, following MAC and M. kansasii. Previously, there were
many case reports on skin/soft tissue or bone infection. How-
ever, recently, respiratory infection has been increasingly re-
ported, accounting for 80% of patients with respiratory infection
with RGM [284].
- M. abscessus is one of the most resistant types of Mycobac-
terium. In particular, pulmonary infection with M. abscessus
is refractory [285]. M. abscessus is resistant to representative
oral drugs for Mycobacterium infection, such as INH, RFP, and
EB. It may be susceptible to CAM among oral antimicrobial
drugs. Its susceptibility to other antimicrobial drugs varies.
As a rule, a drug susceptibility test should be performed.
Although M. abscessus is sometimes susceptible to AMK, CFX,
and IPM/CS, it is unclear whether there is a correlation be-
tween the drug susceptibility and clinical effects. In vitro, M.
abscessus is sometimes susceptible to LZD, TGC (tigecycline),
and ketolides, but it is unclear whether there is a correlation
between the drug susceptibility and clinical effects
[286,287].
- Combination therapy with CAM and several intravenous anti-
microbial drugs (AMK, CFX, and IPM/CS) may control the
symptoms and progression of pulmonary infection with M.
abscessus [288,289]. However, actually, hospitalization is
required to administer these intravenous antimicrobials, and
the administration period is limited to 2e3 months. Subse-
quently, treatment with oral drugs is performed, but CAM is the
only reliable oral drug, as described above. On the other hand,
monotherapy with CAM should be avoided from the perspective
of resistance induction. Although some studies reported com-
bination therapy with LZD or quinolones, its efﬁcacy has not
been established.
- Based on such a background, a combination of surgical resection
of the lesion and combination chemotherapy is the only treat-
ment that is expected to achieve the complete cure of pulmo-
nary infection with M. abscessus in which the lesion is localized
[284,288,289].- - - Drugs to be recommended- - -
A First choice
Based on the results of a drug susceptibility test, the following
antimicrobial drugs should be combined:
- CAM, oral, 200 mg/3 times a day or 400 mg/twice a dayþ AMK, intravenous drip, 15 mg/kg/once a day
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times a day
* Surgery must be considered. The treatment period
should be at least 12 months after culture becomes
negative.5.2. Children
- - - Executive summary- - -
- For the treatment of childhood tuberculosis, several drugs
should be combined, and administered for a speciﬁc period (AII).
- For the treatment of non-tuberculous Mycobacterium infection,
several drugs should be combined, and administered for a spe-
ciﬁc period. However, Mycobacterium often resists treatment. If
there is no treatment response, surgerymust be considered (CIII).
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
In Japan, tuberculosis is still an important infectious disease.
When encountering patients with chronic infection who do not
respond to general antimicrobial drugs, tuberculosis should be
considered for differential diagnosis. Mycobacteria that can be
cultured are classiﬁed into two types: M. tuberculosis complex and
non-tuberculous Mycobacteria (NTM) [247]. M. tuberculosis is a
major type of M. tuberculosis complex, and has a strong infectivity
from humans to humans. Childhood tuberculosis is classiﬁed into
two types based on age [247]. Brieﬂy, primary tuberculosis repre-
sented by hilar lymph node tuberculosis and meningitis, which
develop following primary infection, is characteristic of infants and
children. The interval from infection until onset is short, and the
morbidity rate is high. In addition, this disease may lead to a severe
condition. Pulmonary/hilar lymph node tuberculosis in infants and
children is asymptomatic, or the general condition is favorable even
in the presence of fever or cough in many cases. When primary
tuberculosis is detected based on dyspnea or an unfavorable general
condition in addition to fever or cough, many infants/children have
military tuberculosis or meningitis. On the other hand, secondary
tuberculosis with a cavity lesion or nodular shadow in the lung ﬁeld
is frequent in juniorhigh school students orolder. Symptoms such as
cough, sputum, fever, and thoracic pain are often observed. In most
children, the source of infection can be clariﬁed through detailed
peripheral contact screening at the time of onset. Usually, the source
of infection is clariﬁed in 2/3 to 3/4 of children. It is often their fa-
thers/mothers or grandfathers/grandmothers [290e292].
As childhood tuberculosis does not form a cavity in the lung
ﬁeld, theM. tuberculosis level in the focus is lower than in adults. In
many cases, it is difﬁcult to bacteriologically or histologically make
a deﬁnitive diagnosis in comparison with adult tuberculosis. Usu-
ally, it is possible tomake a deﬁnitive diagnosis by comprehensively
evaluating epidemiological/clinical information such as opportu-
nities for the source of infection to contact with tuberculosis pa-
tients, tuberculin reaction- or QuantiFERON TB (QFT)-based
veriﬁcation of infection, imaging ﬁndings suggestive of tubercu-
losis, such as chest X-ray ﬁndings, veriﬁcation of M. tuberculosis
from sputum or gastric juice, and individuals' resistance including
the grade of BCG vaccination-acquired immunity and age, as well as
by considering treatment responses in some cases. QFT is a very
useful testing method to quantitatively measure IFN-g and di-
agnose tuberculosis infection without being inﬂuenced by BCG.
However, assessment in infants/children should be further exam-
ined in the future [293]. When a deﬁnitive diagnosis of pulmonarytuberculosis cannot be made based on chest X-ray ﬁndings alone,
thoracic CT, which facilitates the detailed evaluation of the pres-
ence or absence and extent of tuberculous lesions, is useful for
diagnosis. Furthermore, imaging ﬁndings of tuberculosis do not
change in a short period in many cases.
Non-tuberculous Mycobacterium belongs to Mycobacterium, the
same category as reported for M. tuberculosis. Therefore, it is often
detected as a Mycobacterium-positive smear of sputum, that is,
Gaffky's positive reaction. Initially, some patients are regarded as
having infectious tuberculosis, and admitted to a tuberculosis ward.
Symptoms and imaging ﬁndings are also similar between non-
tuberculous Mycobacterium- and M. tuberculosis-infected patients.
Unless detected bacteria are identiﬁed, or unless either gene is
detected using the nucleic acid ampliﬁcation method, it is difﬁcult
to differentiate the two types of bacteria. However, it is important
to recognize that tuberculosis and non-tuberculousMycobacterium
infection are different diseases [276,294]. Themost important point
is that non-tuberculousMycobacterium infection does not transmit
from humans to humans, differing from tuberculosis, an infectious
disease in humans. Therefore, it is not necessary to isolate the pa-
tient, and, as a rule, patients requiring admission should be
managed in a general ward. As there are no public hygiene-
associated problems, it is not necessary to submit a report to a
health center.
[Type and frequency of causative microorganisms]
In Japan, the number of patients with childhood tuberculosis
has markedly decreased. The number of newly registered patients
with tuberculosis decreased from 53,229 (1963) to 95 (2008) in
children aged 0e14 years [290e292]. However, a decrease in the
incidence of smear-positive pulmonary tuberculosis, which is
important as the source of infection, is not marked in great urban
areas. We cannot conclude that the opportunity of infection in
children is favorably decreasing; caution is needed.
The number of patients who newly develop non-tuberculous
Mycobacterium infection in Japan is estimated to be approximately
8000. In the adult ﬁeld, it accounts for about 1/3 of that of patients
who newly develop tuberculosis. However, it is relatively low in
children. Approximately 80% of patients with non-tuberculous
Mycobacterium infection are infected with M. avium complex
(M. avium and Mycoboterium intracellulare, pulmonary MAC infec-
tion), and approximately 15% are infected with M. cansasii.
[Rules of antimicrobial drug therapy]
- The characteristics of antitubercular chemotherapy in children
are that children are tolerable to a relatively high dose per body
weight in comparison with adults with respect to pharmacoki-
netics, and that the incidence of side effects is low [247].
In the pediatric ﬁeld, 6-month treatment with INH, RFP, and PZA
for childhood pulmonary tuberculosis is internationally selected as
standard chemotherapy: three drugs, INH, RFP, and PZA, are
administered every day for the ﬁrst 2 months, and INH and RFP
every day for the subsequent 4 months. When drug resistance is
suspected, these drugs should be combined with SM or EB in the
initial phase until the results of a resistance test are clariﬁed. In
patients with secondary tuberculosis, 4-drug combination therapy
with INH, RFP, PZA, and SM (or EB) should be initially performed. In
addition, as a rule, follow-upmust be continued for 2 years after the
completion of treatment [290e292].
On the other hand, drug resistance, referral to another hospital,
and discontinued treatment are present among patients who drop
out of treatment, although the number of such patients is small. It is
necessary to support the resistance and continuation of treatment.
In particular, recently, the number of patients inwhom it is difﬁcult
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must be considered in connection with direct observed therapy
(DOT) by health centers and welfare activities [247]. Side effects
during treatment include liver dysfunction. However, if the
maximum AST or ALT levels are approximately 100, administration
should be carefully continued without discontinuing treatment. If
these levels exceed 100, treatment should be transiently dis-
continued, and additional administration at a low dose should be
conducted after conﬁrming the normalization of the liver function.
The dose should be gradually increased. Liver dysfunction requiring
a change of treatment is not frequent. Furthermore, there is an
increase in the serum uric acid level, but continuous treatment
leads to normalization. There have been few patients with
arthralgia.
- Prevention of tuberculosis: To prevent the onset of tuberculosis
in uninfected persons, BCG vaccination should be performed.
Concerning its efﬁcacy, a consensus regarding its potent pre-
ventive effects on severe disseminated tuberculosis, such as
tuberculous meningitis and military tuberculosis, has been
reached. Considering the importance of tuberculous meningitis
prevention, BCG vaccination in the early phase of infancy (5e8
months after birth, or earlier in accordance with the state of
peripheral tuberculosis prevalence) is still necessary in Japan
[290].
- Treatment for latent tuberculosis: To prevent the onset of
tuberculosis in persons with a history of tuberculosis, treatment
for latent tuberculosis (conventional chemoprevention) should
be conducted. A large-scale controlled study reported that INH
therapy decreased the incidence of tuberculosis by approxi-
mately 50e60%. For drug administration, the risk of tuberculosis
onset should be concretely and ﬂexibly evaluated based on the
tuberculin reaction, opportunity of infection, age, and state of
BCG vaccination in individual patients [247].
- Treatment for non-tuberculous Mycobacterium infection: Non-
tuberculous Mycobacterium infection is refractory despite
combination therapy with antitubercular drugs. In particular,
there is no evidence regarding treatment in children [276]. The
effects of monotherapy are weak, and monotherapy with CAM
may lead to the appearance of CAM-resistant bacteria within a
few months [279]; therefore, this therapy should be avoided.
The responses of M. kansasii to antitubercular drugs are rela-
tively favorable, and curemay be achieved. However, pulmonary
MAC infection is often resistant to treatment. If there is no
response, surgery must be considered. Recurrence after the
completion of treatment is also often observed.- - - Drugs to be recommended- - -
➀ M. tuberculosis
A First choice- RFP þ INH þ PZA/2 months
subsequently: RFP þ INH/4 months
<> Second choices (secondary tuberculosis)
- RFP þ INH þ PZA þ SM or EB/2 monthssubsequently: RFP þ INH or RFP þ INH þ EB/4 months
* Cases in which PZA administration is impossible
- RFP þ INH þ SM or EB/6 months
subsequently: RFP þ INH or RFP þ INH þ EB/3 months
* Administration method/doses of antitubercular drugs
INH: oral, 10e15 mg/kg/once a day (maximum: 400 mg/day)
RFP: oral, 10e20 mg/kg/once a day (maximum: 450 mg/day)
PZA: oral, 20e30 mg/kg/once a day (maximum: 1.2 g/day)SM: intramuscular injection, 20e40 mg/kg/once a day
(maximum: 750 mg/day)
EB: oral, 15e25 mg/kg/once a day (maximum: 750 mg/day)
➁ M. avium complex
- RFP, oral, 10 mg/kg (maximum: 600 mg)/once a dayþ EB, oral,
15 mg/kg (maximum: 750 mg)/once a day þ CAM, oral,
7.5e10 mg/kg (maximum: 400 mg, 800 mg/day)/twice a day
* In severe cases, the above drugs should be combined with
the intramuscular injection of SM or KM at 15 mg/kg
(maximum: 1000 mg)/once a day, 2 or 3 times a week.
* If there is no response, surgery must be considered.
➂ M. kansasii
- Combination therapy with INH, oral, 5 mg/kg (maximum:
300 mg)/once a day þ RFP, oral, 10 mg/kg (maximum:
600mg)/once a dayþ EB, oral, 15 mg/kg (maximum: 750 mg)/
once a day should be performed for 1 year after culture test
reactions become negative.
* As the administration period is longer than that for tuber-
culosis patients, the development of vision disorder should
be considered even at these doses.
* If there is no response, surgery must be considered.6. Lower respiratory infectious disease (Adults)
6.1. Acute bronchitis- - - Executive summary- - -
- Viruses comprise the greater portion of causative
microorganisms.
- When there are no complications such as chronic respiratory
diseases, the administration of antimicrobial drugs for acute
bronchitis is not recommended as a rule (AI).
- Treatment with macrolides is indicated for patients with
pertussis (AI). Treatment after the catarrhal period does not
reduce the degree or duration of cough, but antimicrobial drugs
are necessary to prevent infection to peripheral persons.
- As ﬁrst-choice antimicrobial drugs for acute bronchitis caused
by M. pneumoniae or C. pneumoniae, macrolides should be
selected (CIII).- - - Explanation- - -
Acute bronchitis is characterized by cough that persists for 5
days or more. In most cases, cough persists for 1e3 weeks, but
spontaneously subsides [295,296]. Sputum is present in some
cases, but is absent in others. Sputum may be purulent even when
viral infection is etiologically involved. Neither chest X-ray nor CT
shows the appearance of a new abnormal shadow, differing from
pneumonia.
Viruses such as inﬂuenza virus A/B, rhinovirus, coronavirus,
adenovirus, RS virus, human metapneumovirus, and parainﬂuenza
virus account for approximately 90% of causative microorganisms
[295e298]. In addition, B. pertussis, M. pneumoniae, and
C. pneumoniae account for approximately 10% [295e298]. There is
no evidence that infectionwith other bacteria directly causes acute
bronchitis in adults without an underlying disease [296]. However,
in a study using the transtracheal aspiration method in Japan, H.
inﬂuenzae, S. pneumoniae, andM. catarrhaliswere primarily isolated
in patients diagnosed with bacterial acute bronchitis in the absence
of a chronic lower respiratory infectious disease as an underlying
disease [299].
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period, and paroxysmal coughing, inspiratory whooping, and
vomiting after coughing may occur [300]. Acute bronchitis caused
byM. pneumoniae also induces severe, persistent cough. In cases of
inﬂuenza, fever, headache, general malaise, and arthralgia are
observed. Furthermore, acute viral bronchitis may lead to acute
bacterial exacerbation in patients with chronic respiratory lesions
as underlying diseases; fever and an increase in the amount of
purulent sputum are observed.
As a rule, when an underlying disease or complication is absent,
the routine administration of antimicrobial drugs for acute bron-
chitis is not recommended [297,298]. To control symptoms such as
cough, symptomatic therapy should be performed if necessary. On
the other hand, antimicrobial drug treatment with macrolides is
indicated for patients with pertussis. Treatment after the catarrhal
period does not reduce the degree or duration of cough, but anti-
microbial drugs are necessary to prevent infection to peripheral
persons [301,302]. When performing antimicrobial drug treatment
for acute bronchitis caused by M. pneumoniae or C. pneumoniae,
macrolides should be selected as ﬁrst-choice drugs. However, an
increase in macrolide-resistant M. pneumoniaemust be considered
[303]. In cases of inﬂuenza, anti-inﬂuenza therapy should be con-
ducted within 48 h after onset [304].
In patients with underlying diseases or elderly persons with
complications, bacterial (e.g., S. pneumoniae) infection may occur
following viral infection, although this is not frequent in healthy
adults. When acute bronchitis related to bacterial infection,
including secondary infection, is strongly suspected based on
cough/sputum, fever, leukocytosis, or ﬁndings suggestive of the
presence of causative microorganisms on Gram staining of sputum
despite the absence of a new inﬁltrative shadow on chest X-ray,
antimicrobial drug treatment is considered in accordance with
treatment for community-acquired bacterial pneumonia [305,306].
- - - Drugs to be recommended- - -
➀ Acute bronchitis caused by viruses
When there are no complications such as chronic respiratory
diseases, the administration of antimicrobial drugs for acute
bronchitis are not recommended as a rule (With respect to the
selection of antimicrobial drugs for acute bronchitis complicated
by chronic respiratory diseases with secondary bacterial infec-
tion, refer to the section “6.2 Respiratory tract infection in the
presence of chronic respiratory disease(COPD, bronchiectasis,
old pulmonary tuberculosis.)” (p. 47)
➁ Pertussis
- EM, oral, 400 mg/3 times a day, 14 days
- CAM, oral, 200 mg/twice a day, 7 days
- AZM sustained-release preparation, oral, 2 g/single dose
➂ Acute bronchitis caused by M. pneumoniae or C. pneumoniaeTable 20
Primary causative microorganisms.
Bacteria Virus Atypical pathogen
Haemophilus inﬂuenzae Rhinovirus Chlamidophila pneumonie
Streptcoccus pneumoniae Parainﬂuenza Mycoplasma pneumoniae
Moraxella catarrhalis Inﬂuenza
Pseudomonas aeruginosa Respiratory
syncytial virus
Enterobacteriaceae Coronavirus
Haemophilus haemolyticus Adenovirus
Haemophilus parainﬂuenzae Human
metapneumovirus
Staphylococcus aureus
References [310] and [311] were modiﬁed./ Refer to the section “2. Pneumonia (Adults) 2.1 Community-
acquired pneumonia 2.1.1 Empiric therapy b. Atypical
pneumonia” (p. 3).
➃ Inﬂuenza
/ Refer to the section “8. Inﬂuenza” (p. 52).
➄ Cases in which bacterial infection is strongly suspected as an
etiological factor
a. Empiric therapyTab
Mil
M
M
P
P
P/ Refer to the section “2. Pneumonia (Adults) 2.1
Community-acquired pneumonia 2.1.1 Empiric therapy a.
Bacterial pneumonia” (p. 3).
b. Deﬁnitive therapy
/ Refer to the section “2.1 Community-acquired pneumonia
2.1.2 Deﬁnitive therapy” (p. 4).6.2. Respiratory tract infection in the presence of chronic
respiratory disease (COPD, bronchiectasis, old pulmonary
tuberculosis)- - - Executive summary- - -
- Infectious exacerbation refers to the bacterial infection-related
exacerbation of symptoms, such as cough, purulent sputum,
fever, and shortness of breath, from a chronic, stable state
[305,307,308].
- Inﬂammatory responses involving the leukocyte count and CRP
level are enhanced, andPaO2 is often reducedonbloodgas analysis.
- Chest X-ray and CT are useful for evaluating an underlying dis-
ease and differentiating chronic respiratory diseases from other
diseases with a shadow.
- At the time of persistent infection, cough and sputum are
continuously eliminated, and a slight inﬂammatory response is
sometimes observed on a blood test. In such cases, antimicrobial
drugs should not be administered as a rule. Gram staining of
sputum is useful for evaluating infection [309] (AIII).
- Frequent causative microorganisms include H. inﬂuenzae, P.
aeruginosa, M. catarrhalis, and S. pneumoniae. Although persis-
tent infection with P. aeruginosa is noted in many cases, it must
be differentiated from acute exacerbation based on clinical
symptoms and laboratory data. In addition, S. aureus and K.
pneumoniae should be considered (Table 20) [310,311].
- Selection of antimicrobial drugs: Respiratory quinolones have
potent antimicrobial activities against all types of causative
microorganisms, and their clinical effects are marked; therefore,
they are ﬁrst-choice drugs [15,312e314] (AI). The use of b-lac-
tams and macrolides must be considered in individual patients.
- The administration period of antimicrobial drugs should be 5e7
days [315e318] (BII).- - - Explanation- - -
[Clinical symptoms]
Respiratory tract infection in the presence of chronic respiratory
disease refers to the new appearance of infectious symptoms, such asle 21
ler & Jones classiﬁcation of purulent sputum.
1: Saliva, complete mucous sputum
2: Mucous sputum containing a small volume of purulent sputum
1: Sputum in which the purulent area comprises 1/3 or smaller
2: Sputum in which the purulent area comprises 1/3 to 2/3
3: Sputum in which the purulent area comprises 2/3 or greater
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respiratory symptoms, such as increases in the frequency of cough,
volumeof purulent sputum, anddegree of purulence, fromthe chronic,
stable conditions of underlying diseases, such as COPD, bronchiectasis,
and old pulmonary tuberculosis. Concerning laboratory data, inﬂam-
matory responses involving the leukocyte count and CRP level are
enhanced, and PaO2 is often reduced on blood gas analysis.
[Imaging ﬁndings]
Imaging ﬁndings are necessary to differentiate chronic respira-
tory disease-related airway infection from pneumonia. The absence
of a shadow must be conﬁrmed. CT should also be performed to
evaluate underlying diseases such as pulmonary emphysema and
bronchiectasis.
[Estimation of causative microorganisms and Gram staining]
It is possible to collect sputum in many patients. Gram stain-
ing is useful for predicting causative microorganisms or differ-
entiating respiratory tract infection in the presence of chronic
respiratory disease from persistent infection. According to a
study, the tone of sputum suggests the presence of pathogenic
microorganisms rather than the degree of purulence; macro-
scopic examination is also necessary [319]. Sputum involves
much information, and is the most important sample. Samples
should be collected before the administration of antimicrobial
drugs. Those collected on waking-up early in the morning are
ideal. To evaluate the degree of sputum purulence, the Miller &
Jones classiﬁcation [305] (Table 21) is used, but, if samples are
evaluated as P2 or higher, causative microorganisms may be
predicted using Gram staining. On Gram staining, an area where
the number of inﬂammatory cells is large should be initially
searched at a low magniﬁcation, and detailed observation should
be conducted at a high magniﬁcation. Before the administration
of antimicrobial drugs, sputum should always be submitted for a
susceptibility test.
[Causative microorganisms]
As causative microorganisms, H. inﬂuenzae, P. aeruginosa,
M. catarrhalis, and S. pneumoniae are frequently detected. Persistent
infection with P. aeruginosa is often observed, but it must be
differentiated from acute exacerbation based on clinical symptoms
and laboratory data. In addition, S. aureus and K. pneumoniae should
be considered [310]. The involvement of atypical pathogens such as
C. pneumoniae or mixed infection with viruses and bacteria must
also be considered.
[Treatment]
The purpose of treatment is to reduce clinical symptoms, pre-
vent recurrence, prolong the interval until subsequent exacerba-
tion, and inhibit lung tissue damage. The administration of
appropriate antimicrobial drugs relieves clinical symptoms, and
maintains the respiratory function [320]. On the other hand,
inappropriate antimicrobial drugs may deteriorate the prognosis,
inducing recurrence.
In Japan, the resistance of S. pneumoniae and H. inﬂuenzae to
macrolides and b-lactams is advanced [13,29]. Several studies have
reported that new quinolones are more useful than b-lactams
[15,312e315]. Respiratory quinolones have potent antimicrobial
activities against all types of causative microorganisms, and against
resistant bacteria [321e323]. Concerning the administration
period, a study indicated that the efﬁcacy of administration for 5
days was similar to that for 7 days, and that the former was safer
than the latter. The administration period should be shortened
[324].- - - Drugs to be recommended- - -
a. Empiric therapy
Internationally, some studies have supported the usefulness
of b-lactams [325,326]. However, in Japan, the resistance of
S. pneumoniae and H. inﬂuenzae to macrolides and b-lactams is
advanced, and P. aeruginosa is also sometimes isolated. There-
fore, the use of b-lactams and macrolides is limited to patients
without risk factors. An international comparative study re-
ported that the efﬁcacy of AZM sustained-release preparations
was similar to that of new quinolones [327]. However, in Japan,
the long-term administration of macrolides is performed in
many patients; therefore, circumstances differ.
(1) Outpatient treatment
A First choices
- LVFX, oral, 500 mg/once a day
- GRNX, oral, 400 mg/once a day
- MFLX, oral, 400 mg/once a day
- STFX, oral, 100 mg/1e2 times a day
These 4 drugs have potent antimicrobial activities
against all types of causative microorganisms predicted,
and are recommended as ﬁrst-choice drugs (AII).
<> Second choices
- CVA/AMPC, oral (125/250 mg), 2 tablets/3e4 times a
day
- SBTPC, oral (375 mg), 1 tablet/3 times a day
- AZM sustained-release preparation, oral, 2 g/single
dose(2) Hospital treatment
<>Mild cases
- CTRX, intravenous drip, 2 g/once a day or 1 g/twice a
day
- LVFX, intravenous drip, 500 mg/once a day
- SBT/ABPC, intravenous drip, 3 g/3e4 times a day
<>Severe cases (P. aeruginosa must be considered.)
- MEPM, intravenous drip, 1 g/2e3 times a day
- DRPM, intravenous drip, 0.5e1 g/3 times a day
- BIPM, intravenous drip, 0.3e0.6 g/3e4 times a day
- IPM/CS, intravenous drip, 0.5e1 g/2e4 times a day
- TAZ/PIPC, intravenous drip, 4.5 g/3e4 times a day
- PZFX, intravenous drip, 500 to 1000 mg/twice a day
- CPFX, intravenous drip, 300 mg/twice a day
- CAZ, intravenous drip, 1e2 g/2e4 times a day
- CFPM, intravenous drip, 1e2 g/2e4 times a day
- CZOP, intravenous drip, 1e2 g/2e4 times a day
- CPR, intravenous drip, 1e2 g/2e4 times a day
* Combination therapy with aminoglycosides should be
considered in accordance with individual patients.
- AMK, intravenous drip, 200 mg/twice a day
- GM, intravenous drip, 60 mg/twice a day
- TOB, intravenous drip, 90 mg/twice a dayb. Deﬁnitive therapy
Refer to the section “2.1 Community-acquired pneumonia
2.1.2 Deﬁnitive therapy” (p. 4).
➀ H. inﬂuenzae
Beta-lactamase-producing strains are detected in approxi-
mately 10e20% of H. inﬂuenzae strains. Beta-lactamase-
negative, ampicillin-resistant (BLNAR) strains account for
approximately 20%. Therefore, when drug susceptibility is
unclear, new quinolones should be selected as ﬁrst-choice
oral antimicrobial drugs. If drug susceptibility is clariﬁed,
they should be switched to effective and narrow-spectrum
drugs. As injection, penicillins should be initially selected,
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carbapenems, and new quinolones.
➁ M. catarrhalis
Beta-lactamase-producing strains account for 100% of
M. catarrhalis strains. As oral antimicrobial drugs, macrolides
should be initially selected, followed by b-lactamase
inhibitor-containing penicillins, second-/third-generation
cephems, and new quinolones. As injection, b-lactamase
inhibitor-containing penicillins, second-/third-generation
cephems, new quinolones, or carbapenems should be
selected.
➂ P. aeruginosa
As oral drugs, new quinolones should be selected. As in-
jection, anti-P. aeruginosa penicillins, cephems, mono-
bactums, carbapenems, or new quinolones should be
selected. As the drug susceptibility of this type of bacteria
markedly differs among strains, drugs should be selected
based on the results of culture tests.
➃ S. pneumoniae
As oral drugs, penicillins should be initially selected, fol-
lowed by new quinolones. In patients with a risk of resistant
bacteria, respiratory quinolones such as LVFX and GRNX
should be selected. As injection, penicillins or CTRX should be
selected, but carbapenems must be considered in severe-
status patients.
➄ S. aureus
Considering Methicillin-sensitive S. aureus (MSSA),
drugs such as b-lactamase inhibitor-containing penicil-
lins, ﬁrst-/second-generation cephems, and carbapenems
should be selected. When Methicillin-resistant S. aureus
(MRSA) is identiﬁed, anti-MRSA drugs should be
selected.
➅ K. pneumoniae
Second-generation cephems should be selected as ﬁrst-
choice drugs. Second-choice drugs include b-lactamase
inhibitor-containing penicillins, second-/third-generation
cephems, carbapenems, and new quinolones.6.3. Diffuse panbronchiolitis- - - Executive summary- - -
- First-choice treatment for diffuse panbronchiolitis (DPB)
consists of EM to be administered at 200 mg 2e3 times a day
(AII).
- As a second-choice drug for patients who do not respond to EM
or those in whom continuous administration is difﬁcult, EM
should be switched to CAM to be administered at 200 mg once
to twice a day or RXM to be administered at 150 mg once to
twice a day (AIII).
- In patients in whom treatment with 14-membered ring mac-
rolides is difﬁcult, a 15-membered ring macrolide, AZM, to be
administered at 250 mg 2e3 times a week, must be considered
as an alternative treatment (BIII).
- Initially, the oral administration of EM should be continued for 6
months to be evaluated its clinical effects. If symptoms or lab-
oratory ﬁndings become stable through improvements, treat-
ment should be continued for a total of 2 years (BIII).
- At the time of acute exacerbation, an antimicrobial drug that
covers H. inﬂuenzae, S. pneumoniae, M. catarrhalis, and
P. aeruginosa should be additionally administered (BIII).- - - Explanation- - -
[Characteristics/classiﬁcation of the disease]
DPB is a chronic inﬂammatory disease of the respiratory tract,
which is frequently observed in East Asians including Japanese.
There is no gender difference, and this disease frequently develops
in persons aged 40e50 years. It is often detected in patients with a
history of chronic sinusitis or in those with the concomitant
development of chronic sinusitis. This disease is classiﬁed as the
category of sinobronchial syndrome.
[Symptoms]
The most typical symptoms of DPB are persistent cough and
purulent sputum. Symptoms such as exertional shortness of breath
and dyspnea appear in accordance with disease progression. In
patients with a complication of chronic sinusitis, purulent nasal
discharge and nasal obstruction are observed.
[Laboratory ﬁndings]
Chest X-ray shows pulmonary overexpansion or a diffuse scat-
tered nodular shadow. Thoracic HRCT reveals a diffuse centrilobular
nodular shadow. Furthermore, obstructive respiratory dysfunction,
hypoxemia, and an increase in the cold agglutinin value (64-fold or
more on the hemagglutination method) are observed.
[Type and frequency of causative microorganisms]
In patients with DPB, persistent respiratory tract infection with
H. inﬂuenzae, S. pneumoniae, or M. catarrhalis is often observed.
However, the incidence of persistent infection with P. aeruginosa
increases with progression.
[Long-term macrolide therapy]
Previously, the prognosis of DPB was unfavorable; respiratory
failure gradually progressed through repeated acute exacerbation
related to respiratory tract infection, leading to a fatal outcome;
however, the prognosis of DPB has been markedly improved since
long-term macrolide therapy with low-dose administration of EM
or other 14-membered ring macrolides was established [328e340].
Early diagnosis/treatment have facilitated the complete cure of
DPB. Therefore, if once a diagnosis of DPB is made, long-term
macrolide therapy should be started promptly.
- - - Drugs to be recommended- - -
➀ Persistent infection
- The oral administration of EM at 400e600 mg/day should be
continued for 6 months to be evaluated its clinical effects
[328].
- In many cases, an improvement in symptoms (such as a
decrease in the volume of sputum) will be achieved within
1e3 months after the start of administration.
- In addition, an improvement in imaging ﬁndings or the res-
piratory function will be achieved after 3e6 months of
treatment.
- If symptoms and laboratory ﬁndings become stable through
improvements, treatment should be continued for a total of 2
years [328,341].
- When symptoms persist even after 2-year treatment, treat-
ment can be further continued.
- When there is no response to EM at 600 mg/day, or when the
oral administration of EM is not able to be continued due to
gastrointestinal complaints, consider to switch from EM to
other 14-membered ring macrolides, such as CAM at
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choice drugs [328,342e344].
- When there is no response to any 14-membered ring macro-
lides, AZM at 250 mg (to be administered 2e3 times a week)
should be considered as an alternative treatment [345].
- Sixteen-membered ring macrolides are not to be effective.
- It does not matter to the clinical effects of long-term macro-
lide therapy whether the drug susceptibility of bacteria that
persistently infect the host (such as P. aeruginosa) is present or
not. For example, even when there is no disappearance of
P. aeruginosa on sputum culture, clinical symptoms of DPB
will be improved by long-term macrolide therapy. Therefore,
the effects of long-term macrolide therapy should be
comprehensively evaluated based on changes of symptoms or
other laboratory ﬁndings as well as the results of sputum
culture.
- In patients with bronchiectasis or chronic bronchitis, persis-
tent bacterial infection of the lower respiratory tract is also
often observed. Several studies have reported the usefulness
of long-term macrolide therapy for the management of such a
condition, as indicated for DPB treatment [346e348].
- Concerning chronic obstructive pulmonary disease (COPD),
long-term macrolide therapy with EM or AZM decreases the
risk of acutely exacerbating COPD [349,350].
A First choice- EM, oral, 200 mg/2e3 times a day
<> Second choices
- CAM, oral, 200 mg/once to twice a day
- RXM, oral, 150 mg/once to twice a day➁ Acute exacerbation
- During the clinical course of DPB, acute exacerbations may
develop in some cases, as reported for other chronic respi-
ratory diseases. Symptoms such as increases in the frequency
of cough/volume of purulent sputum, fever, or respiratory
failure will rapidly progress.
- As causative microorganisms at the time of acute exacerba-
tion, H. inﬂuenzae, S. pneumoniae, M. catarrhalis, and
P. aeruginosa are frequently detected, as indicated for
persistent infection.
- During acute exacerbations, an antimicrobial drug should be
additionally administered to cover these causative microor-
ganisms [351].
a. Empiric therapy
Antimicrobial drugs should be selected in accordance with
the section “6.2 Respiratory tract infection in the presence of
chronic respiratory disease (COPD, bronchiectasis, old pul-
monary tuberculosis, etc.)- - - a. Empiric therapy- - -” (p. 48).
b. Deﬁnitive therapy
Antimicrobial drugs should be selected in accordance with
the section “6.2 Respiratory tract infection in the presence of
chronic respiratory disease (COPD, bronchiectasis, old pul-
monary tuberculosis, etc.)- - - b. Deﬁnitive therapy- - -”
(p. 48).7. Lower respiratory infectious disease (Children)
7.1. Croup syndrome- - - Executive summary- - -
Croup syndrome is caused by viruses, and antimicrobial drugs
are not necessary (AI).- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Croup syndrome is characterized by acute laryngeal stenosis-
associated respiratory disturbance such as barking cough, hoarse-
ness, and inspiratory stridor. Most lesions involve not only the
larynx but also the trachea/bronchus. This disease is sometimes
called laryngotracheobronchitis [352]. Etiological factors are clas-
siﬁed into two types: infectious and non-infectious (allergy-/
foreign body-related) factors [352,353]. The incidence of infectious
croup syndrome is high in infants/children aged 7 monthse3 years
[354,355].
[Type and frequency of causative microorganisms]
Croup syndrome is primarily caused by viruses. Parainﬂuenza
virus type 1 is the most common virus [356]. In addition, para-
inﬂuenza virus type 2/3, inﬂuenza A/B virus, RS virus, human
metapneumovirus, coronavirus, adenovirus, and measles virus are
relatively frequently isolated [353,357].
[Rules of antimicrobial drug therapy]
In most cases, croup syndrome is caused by viruses, and anti-
microbial drugs are not necessary. Therefore, no study has evalu-
ated the efﬁcacy of antimicrobial drugs in patients with croup
syndrome. There are no treatment guidelines regarding croup
syndrome in which antimicrobial drugs are recommended
[358,359].
7.2. Bronchiolitis- - - Executive summary- - -
Bronchiolitis is caused by viruses, and the administration of
antimicrobial drugs is not necessary (AI).
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Bronchiolitis is an acute, inﬂammatory, obstructive disease
involving the bronchiole. Narrowing of the bronchiolar lumen
related to mucosal epithelial injury, inﬂammatory-cell inﬁltration,
interstitial edema, or an increase in mucus secretion causes air
trapping in the peripheral respiratory tract, leading to obstructive
respiratory disorder. This disease frequently develops in children
aged 2 years or younger. However, infants aged 11 months or
younger account for 80% or more [360].
[Type and frequency of causative microorganisms]
Bronchiolitis is primarily caused by viruses. RS virus accounts
for 60e80%. In addition, parainﬂuenza virus, human meta-
pneumovirus, adenovirus, and inﬂuenza virus are relatively
frequently isolated [361e363].
[Rules of antimicrobial drug therapy]
In most cases, bronchiolitis is caused by viruses, and antimi-
crobial drugs are not necessary. Basic treatment is symptomatic
therapy. In double-blind comparative studies involving ABPC and
non-treated groups [364], AZM and non-treated groups [365], and
ABPC intravenous injection/oral EM and non-treated groups [366],
respectively, there were no signiﬁcant differences in the admission
period or symptom improvement. However, a small-scale double-
blind comparative study reported that the interval until recovery in
the CAM-treated group was shorter than in the non-treated group
[367]. According to another study, the incidence of secondary
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litis was 1.2%, and there was no difference between antimicrobial
drug-treated and non-treated groups [368]. Therefore, it is not
necessary to administer antimicrobial drugs to children with
bronchiolitis for routine treatment or the prevention of secondary
bacterial infection. However, follow-upmust be carefully continued
during the course of bronchiolitis. When a diagnosis of secondary
bacterial infection-related pneumonia or otitis media is made,
antimicrobial drug therapy should be started.7.3. Bacterial tracheitis- - - Executive summary- - -
Bacterial tracheitis is a bacterial disease with the rapid pro-
gression of dyspnea. If symptoms are progressive, antimicrobial
drugs should be used even when a deﬁnitive diagnosis is not made
(AIII).
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Fever and croup syndrome-like cough/stridor initially appear,
and respiratory disorder rapidly progresses, but there is no speciﬁc
posture, salivation, or dysphagia, which are characteristic of acute
epiglottitis. A deﬁnitive diagnosis can be made based on charac-
teristic clinical features and purulent secretion in the respiratory
tract. In some cases, a lateral view of the larynx on X-ray shows
stenosis below the larynx [352]. This disease frequently develops in
children aged 3e8 years [369].
[Type and frequency of causative microorganisms]
S. aureus-related tracheitis accounts for approximately 60%,
followed by that related to M. catarrhalis, H. inﬂuenzae, Strepto-
coccus pneumoniae, and Streptococcus pyogenes [370e373]. Mixed
infection with viruses and bacteria is frequent, and parainﬂuenza
virus type I [373] and inﬂuenza A virus [374] are often detected.
[Rules of antimicrobial drug therapy]
Antimicrobial drugs should be intravenously administered for
the following reasons: this disease rapidly progresses, and oral
administration is difﬁcult in many cases. As empiric therapy, com-
bination therapy with VCM, which may be effective for infection
with S. aureus (including MRSA), and third-generation cephems
(CTRX, CTX), which have potent antimicrobial activities against
M. catarrhalis, H. inﬂuenzae, S. pneumoniae, and S. pyogenes, should
be performed. The administration period is 10e14 days [369].
- - - Drugs to be recommended- - -
Refer to the section “3. Pneumonia (Children)- - - Drugs to be
recommended 2. Deﬁnitive therapy- - -” (p. 33).7.4. Acute bronchitis- - - Executive summary- - -
Acute bronchitis is primarily caused by viruses, and the neces-
sity of antimicrobial drug administration is low (AI).
When acute bronchitis is caused by M. pneumoniae, C. pneu-
moniae, or B. pertussis, antimicrobial drugs should be administered
if necessary (AIII).Secondary infection with S. pneumoniae or H. inﬂuenzae may
occur, although its incidence is unclear. Therefore, when there is no
improvement, the administration of antimicrobial drugs should be
considered (AIII).
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Bronchitis causes symptoms such as cough, fever, and general
malaise. Various causative microorganisms induce inﬂammation of
the epithelial tracheobronchial tissue, leading to the onset of
bronchitis. Clinically, there are no special ﬁndings on auscultation,
or only rough respiratory sounds (intermittent accessory murmurs)
are heard. Chest X-ray does not also show any marked inﬁltrative
shadow. Usually, patients in whom the interval after onset is less
than 3 weeks are regarded as having acute bronchitis [360].
However, bronchitis diagnosed in Japan slightly differs from that
in Europe and the United States. The latter primarily causes
persistent cough. In Japan, patients in whom there are no ﬁndings
on chest X-ray despite clinical signs of pneumonia or those in
whom chest X-ray is not performed are often diagnosed with
bronchitis; the disease entity must be arranged.
[Type and frequency of causative microorganisms]
Viruses, such as rhinovirus, inﬂuenza virus, RS virus, adenovirus,
parainﬂuenza virus, human metapneumovirus, and human boca-
virus, account for 90% of causative microorganisms.M. pneumoniae,
C. pneumoniae, and B. pertussis also cause bronchitis, although such
cases are relatively rare [360,375].
[Rules of antimicrobial drug therapy]
Acute bronchitis is primarily caused by viruses, and the
administration of antimicrobial drugs is not necessary. A meta-
analysis compared adults to whom antimicrobial drugs were
administered for bronchitis treatment with non-treated adults, and
indicated that there was no difference in the efﬁcacy [376]. Few
reports on clinical studies involving children have been published,
and the scale is small; objective data are insufﬁcient, but no study
has reported that antimicrobial drugs are effective [377e379].
However, if secondary bacterial infection following viral infection
causes fever, purulent sputum, leukocytosis, or an increase in the
CRP level, antimicrobial drugs should be administered, considering
S. pneumoniae and H. inﬂuenzae.
Other indications for antimicrobial drug administration include
M. pneumoniae-, C. pneumoniae-, or B. pertussis-related bronchitis
with protracted cough. AsM. pneumoniae- or C. pneumoniae-related
bronchitis tends to show spontaneous cure, the administration of
antimicrobial drugs is not always necessary, but the necessity of
administration should be evaluated, considering the severity of
symptoms and course (With respect to indications and adminis-
tration methods, refer to the section “3. Pneumonia (Children)”.).
First-choice drugs for M. pneumoniae-, C. pneumoniae-, or
B. pertussis-related bronchitis are macrolides. In patients with
B. pertussis-related bronchitis, antimicrobial drugs relieve symp-
toms only during the catarrhal period, but, if B. pertussis-related
bronchitis is suspected based on clinical symptoms, previous
vaccination, lymphocyte-predominant leukocytosis, an anti-PT
antibody titer, and LAMP ﬁndings, antimicrobial drugs should be
used. However, 16-membered ring macrolides are ineffective for
B. pertussis-related bronchitis.
Symptoms are similar to those of pneumonia, but, when chest
X-ray does not show any abnormalities, or, when it is impossible to
strictly differentiate bronchitis from pneumonia due to difﬁculty in
chest X-ray, treatment should be performed in accordance with
pneumonia.
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1. Empiric therapy
Secondary bacterial infection after viral infection (Cases in
which fever, purulent sputum, leukocytosis, or an increase in the
CRP level is observed)
A First choices- AMPC, oral, 10e15 mg/kg/3 times a day
- SBTPC, oral, 10 mg/kg/3 times a day
- CDTR-PI, oral, 3 mg/kg/3 times a day
- CFPN-PI, oral, 3 mg/kg/3 times a day
- CFTM-PI, oral, 3 mg/kg/3 times a day
<> Second choices
- AZM, oral, 10 mg/kg/once a day, 3 days
- CAM, oral, 7.5 mg/kg/twice a day
2. Deﬁnitive therapy
➀ B. pertussis- EM, oral, 10e15 mg/kg/3 times a day
- CAM, oral, 7.5 mg/kg/twice a day
- AZM, oral, 10 mg/kg/once a day, 3 days
➁ M. pneumoniae
▪ Macrolide-sensitive strains
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day, 3 days
- CAM, oral, 7.5 mg/kg/twice a day
▪ Macrolide-resistant strains
- MINO, oral or intravenous drip, 1e2 mg/kg/twice a day
(In children aged 7 years or younger, the use of this drug
is limited to those in whom other drugs cannot be used
or non-responders.)
- TFLX, oral, 6 mg/kg/twice a day (Administration is
limited to children aged 7 years or younger in whom
MINO cannot be used.)
➂ Chlamydia (C. pneumoniae, C. psittaci, C. trachomatis)
- EM, oral, 10e15 mg/kg/3 times a day
- AZM, oral, 10 mg/kg/once a day, 3 days
- CAM, oral, 7.5 mg/kg/twice a day
8. Inﬂuenza
8.1. Adults- - - Executive summary- - -
- Both M2 protein inhibitors and neuraminidase inhibitors (NAIs)
are commercially available as anti-inﬂuenza drugs as of July
2013.
- Inﬂuenza viruses A (H3N2) and A (H1N1) pdm09 (seasonal inﬂu-
enza) have been reported to be resistant to amantadine, an M2
protein inhibitorwhichcanbeused in Japan. Theuseof thisdrugas
an anti-inﬂuenza drug should be avoided for a while [380,381].
- During the inﬂuenza outbreak period, anti-inﬂuenza therapy
should be promptly started based on a clinical diagnosis even
when patients with inﬂuenza-like symptoms show negative
results on a rapid diagnosis kits (because inﬂuenza cannot be
completely ruled out) [382] (AI).
- NAIs signiﬁcantly improve inﬂuenza survival, and NAI admin-
istration within 2 days after onset signiﬁcantly reduces the rate
at which the condition becomes severe [383,384] (AI).
- Currently, the following NAIs can be selected in Japan. During
the outbreak period, an appropriate drug should be selected
based on the patient background and latest information on a
prevalent inﬂuenza strain:- Oseltamivir (oral), Efﬁcacy: A (H1N1) pdm09, A (H3N2), B,
Resistance: H275Y mutant
- Zanamivir (inhalation), Efﬁcacy: type A/B
- Laninamivir (inhalation), Efﬁcacy: type A/B
- Peramivir (intravenous drip), Efﬁcacy: type A/B- - - Drugs to be recommended- - -
There is no meta-analysis of anti-inﬂuenza drugs other than
oseltamivir and zanamivir as of July 2013. However, it has been
shown that the early introduction of anti-inﬂuenza therapy for
inﬂuenza signiﬁcantly inhibits not only the mortality and admis-
sion rates but also the incidences of inﬂuenza-associated pneu-
monia, otitis media, and ischemic heart disease in comparisonwith
symptomatic therapy. NAIs such as laninamivir and peramivir have
also been conﬁrmed to be as effective as oseltamivir at the time of
development [385] (AI).
<>Outpatient treatment
- Oseltamivir, oral, 75 mg/twice a day, 5 days (As a rule,
administration to children/adolescents aged 10e19 years
should be avoided.)
- Zanamivir, inhalation, 10 mg/twice a day, 5 days
- Laninamivir, inhalation, 40 mg/single dose
- Peramivir, intravenous drip, 300 mg/single dose
<>Hospital treatment
➀ Patients with severe, life-threatening inﬂuenza
In patients with severe, life-threatening inﬂuenza requiring
admission, respiratory failure or encephalopathy is present.
In either case, the complicationmust be treated, but, as a rule,
NAIs should be introduced within 48 h after the onset of
inﬂuenza to obtain their effects.
- Oseltamivir, oral, 75 mg/twice a day, 5 days (As a rule,
administration to children/adolescents aged 10e19 years
should be avoided.)
- Peramivir, intravenous drip, 600 mg/single dose (This drug
can be repeatedly administered every day in accordance
with symptoms.)
➁ Non-life-threatening inﬂuenza patients with pneumonia
- Oseltamivir, oral, 75 mg/twice a day, 5 days (As a rule,
administration to children/adolescents aged 10e19 years
should be avoided.)
- Peramivir, intravenous drip, 300 mg (600 mg for patients in
whom the condition may become severe)/single dose (This
drug can be repeatedly administered every day in accor-
dance with symptoms.)
➂ Non-life-threatening inﬂuenza patients without pneumonia
- Oseltamivir, oral, 75 mg/twice a day, 5 days (As a rule,
administration to children/adolescents aged 10e19 years
should be avoided.)
- Zanamivir, inhalation, 10 mg/twice a day, 5 days
- Laninamivir, inhalation, 40 mg/single dose
- Peramivir, intravenous drip, 300 mg/single dose (This drug
can be repeatedly administered every day in accordance
with symptoms.)
* Patients with A (H7N9)
- Basic treatment is the early administration of anti-inﬂuenza
drugs [386].
- According to an article, there were no signiﬁcant differ-
ences in the viral level or mortality rate 5 days after the
start of administration between double- and standard-dose
Table 22
Standard doses of neuraminidase inhibitors in children.
Drug name Administration method Dose
Oseltamivira Oral 2 mg/kg, twice a day, 5 days (The use of this drug should be avoided in children/adolescents aged 10e19 years.)
Zanamivirb Inhalation 10 mg, twice a day, 5 days
Laninamivir Inhalation 10 years or older: 40 mg
9 years or younger: 20 mg, single dose
Peramivir Intravenous drip 10 mg/kg, once a day
a The preventive administration of this drug at 2 mg/kg (once a day) for 10 days was approved, but is not covered by health insurance.
b The preventive administration of this drug at 10 mg (once a day) for 10 days was approved, but is not covered by health insurance.
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started within 48 h after onset in all patients in the article.8.2. Children- - - Executive summary- - -
Inﬂuenza is caused by inﬂuenza virus. Antimicrobial drugs are
not necessary. It is recommended that neuraminidase inhibitors
should be administered within 48 h after onset (AI).
If pneumonia or otitis media occurs through secondary bacterial
infection, the administration of antimicrobial drugs must be
considered (BIII).
- - - Explanation- - -
[Characteristics and classiﬁcation of the disease]
Inﬂuenza often appears with sudden fever and shivering/
headache/general malaise/muscular pain/dry cough, followed by
marked respiratory or digestive symptoms. In underlying disease-
free children, recovery is achieved after 3e7 days [388,389].
However, during the outbreak period, even underlying disease-free
children are often admitted with serious symptoms such as en-
cephalopathy, myocarditis, and pneumonia requiring artiﬁcial
respiration. Although the outbreak period is from December until
March every year, outbreaks are observed in the summer in some
areas [388,389].
[Type and frequency of causative microorganisms]
Since inﬂuenza A (H1N1) pdm09 prevailed in 2009, the out-
breaks of 3 types of inﬂuenza, A (H1N1) pdm09, A (H3N2), and B,
have been repeated. Their incidences differ among years.
[Rules of antimicrobial drug therapy]
No antimicrobial drug is indicated for inﬂuenza. It is recom-
mended that neuraminidase inhibitors should be administered
within 48 h after onset [390]. The doses of neuraminidase in-
hibitors approved in Japan are presented in Table 22. During the
course of inﬂuenza, bacterial infection such as pneumonia and
otitis media may occur. Previously, the incidence of secondary
bacterial infection in children exceeded 10% [391], but it has been
3% or less since neuraminidase inhibitors were developed
[392,393]. However, bacterial infection is observed in 25e33% of
severe-status patients requiring intensive care [394,395]. Strepto-
coccus pneumoniae, S. aureus, and H. inﬂuenzae are frequently
detected as causative microorganisms [388,389,394,395].
No study has demonstrated that the prophylactic administration
of antimicrobial drugs at the onset of inﬂuenza prevents secondary
bacterial infection. Among children with inﬂuenza, antimicrobialdrug therapy should be considered in those in whom signs of
pneumonia or otitis media do not subside despite the administra-
tion of a neuraminidase inhibitor.
9. Parasitic diseases of the respiratory system- - - Executive summary- - -
- Parasitic diseases are widely distributed throughout the world.
In addition to domestic infection, Japanese travelers may be
infected in overseas endemic areas. Furthermore, parasitic dis-
eases always considered in foreign patients from endemic areas
[396] (BIV).
- When peripheral blood eosinophilia is observed in addition to
respiratory symptoms and abnormal ﬁndings of the chest im-
aging, examinations should be performed to differentiate
parasitic diseases [396] (BIV).
- Parasitic diseases of the respiratory system are caused by Para-
gonimus spp., Ascaris lumbricoides, Ancylostoma duodenale,
Necator americanus, Strongyloides stercoralis, Toxocara canis,
Toxocara cati, Wuchereria bancrofti, Brugia malayi, or Diroﬁlaria
immitis.
- There are two major diagnostic tests for parasitic diseases: (1)
detection of parasite eggs or larvae in sputum or stools, and (2)
detection of parasite-speciﬁc antibodies using serum or pleural
effusion samples (immunodiagnosis).
- An anti-parasite antibody screening test against 12 species of
parasite is commercially available; Paragonimus spp., Strong-
yloides sp., T. canis, D. immitis, Ascaris suum, Anisakis simplex,
Gnathostoma spp., Fasciola hepatica, Clonorchis sinensis, Spi-
rometra erinaceieuropaei, and Cysticercus cellulosae.
- Diagnosis/treatment consultations regarding parasitic diseases
by the Japanese Society of Parasitology are available (as of 2013).
Refer to the homepage (http://jsp.tm.nagasaki-u.ac.jp).
- - - Explanation- - -
- Paragonimus spp.
Several Paragonimus species are known to cause human
infection. Paragonimus westermani and P. miyazakii are
distributed in Japan. Infection occurs through the con-
sumption of freshwater crabs (intermediate host: Eriocheir
japonica, E. sinensis, Geothelphusa dehaani) or wild boars
(paratenic host:Sus scrofa) contaminated with metacercaria
(infective larvae) as a raw or insufﬁciently cooked food [397].
Typical symptoms are cough, sputum, thoracic pain, and
exertional dyspnea. In patients with such symptoms, the
presence of peripheral blood eosinophilia suggests this dis-
ease. In many cases, a diagnosis is made based on the pe-
ripheral blood eosinophilia, a history taking of food and
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asymptomatic, and the presence of lung lesions is detected
on a health checkup. Extrapulmonary paragonimiasis such as
cutaneous and cerebral paragonimiasis are classically known
form of the ectopic infection with Paragonimus spp. In cases
of cutaneous paragonimiasis, a slowly moving nodular lesion
in the subcutaneous tissue is a characteristic symptom. The
worms may migrate through mediastinal soft tissues to the
brain, causing eosinophilic meningitis or cerebral para-
gonimiasis in some cases [397]. Since Paragonimus spp. is
widely distributed around the world, Japanese travel to
endemic area such as China, Korea, Thailand, and Philippines
possible to infect with Paragonimus spp. As well as foreign
patients from endemic areas, this disease always is consid-
ered when a patient has respiratory symptoms and/or lung
lesions with eosinophilia [398].
Chest X-ray ﬁndings vary: not only pulmonary paren-
chymal lesions, such as nodular (±cavity formation) and
inﬁltrative shadows, but also pleural lesions, such as the
retention of pleural effusion and pneumothorax, are some-
times observed [399]. Many patients show peripheral blood
eosinophilia and/or elevated serum total IgE. Immunodiag-
nosis to detect parasite-speciﬁc antibody has been proven as
the most useful and reliable tool. Not only patient's serum
but also pleural effusion could examine by immunological
test. Commercially available anti-parasite antibody screening
test is including Paragomimus spp. In Japan, egg-detection
rate among paragonimiasis patients nowadays is low; for
example 51.2% in sputum and 53.8% in BALF [66], 66.7% in
bronchoscopic aspirate [397,399].
After a deﬁnitive diagnosis is made, oral treatment should
be started. The type of treatment to be selected, outpatient or
hospital treatment, depends on the patient's general condi-
tion. However, usually, outpatient treatment is possible. In
patients having pleural effusion, pleural ﬂuid must be
extensively drained off before starting chemotherapy [400]
(BIII). In patients with chronically encapsulated pleural
effusion, surgery is required [401] (CIII).
- - - Drugs to be recommended- - -A First choice (same dose for adults and children)
- Praziquantel, oral, 25 mg/kg/3 times a day, 2e3 days
[402] (AIII)- A. lumbricoides, A. duodenale, N. americanus
The larvae of these parasites pass through the lung in the
human body, causing asthma- or pneumonia-like symptoms
such as transient fever, cough, and dyspnea. On chest X-ray,
transient nodular/inﬁltrative shadows are observed. Many
patients show peripheral blood eosinophilia and/or elevated
serum total IgE. Previously, the condition was called Lofﬂer
syndrome. Currently, it is classiﬁed as simple pulmonary
eosinophilia in the category of PIE syndrome [402].
Symptoms appear 1e2 weeks after the oral ingestion of
A. lumbricoides embryonated eggs. The latency period of
percutaneous infection with N. americanus larvae or
percutaneous/oral infection with A. duodenale larvae is
approximately 10 days. Larvae appeared in the small in-
testine penetrate the intestinal wall, enter the portal vein,
migrate through liver to heart/lung. Larvae penetrate the
human skin transfer to the lung with blood ﬂow. Then these
larvae migrate up the bronchi and trachea, over the
epiglottis, down the esophagus/stomach, and reach the
small intestine. In the intestine the larvae develop into
mature adults [403].Simple pulmonary eosinophilia related to parasites
spontaneously resolved in a few weeks. In many cases, a
deﬁnitive diagnosis is made based on parasite eggs detected
on a stool examination, although larvae are sometimes
detected in sputum [403].
- - - Drugs to be recommended- - -A First choice (same dose for adults and children)
- Pyrantel pamoate, oral, 10 mg/kg/single-dose
administration
* Dry syrup for children is available.
* This drug is effective for adult worms in the intestinal
tract, but not for larvae migrating in the human body.
Therefore, a stool examination should be performed 2
weeks after oral administration. If parasite eggs are
detected, additional administration should be
conducted.<> Second choices (same dose for adults and children)
- Albendazol, oral, 400 mg/single-dose administration
- Mebendazole, oral, 100 mg/twice a day, 3 days, or
500 mg/single-dose administration
- Ivermectin, oral, 150e200 mg/kg/single-dose adminis-
tration (after fasting)- S. stercoralis
In Japan, S. stercoralis is distributed in Nansei Islands,
chain of islands extending from southwestern Kyushu to
northern Taiwan. There are few young persons newly
infected with S. stercoralis, but the incidence of infection is
high in elderly persons [404]. Internationally, S. stercoralis is
widely distributed in tropical/subtropical areas. Not only
domestic infection but also Japanese travel to endemic area
possible to infect with this parasite. Foreign patients from
endemic areas, strongyloidiasis always considered when a
patient has respiratory symptoms and/or lung lesions with
eosinophilia.
S. stercoralis percutaneously infects humans. Larvae
penetrate the human skin transfer to the lung with blood
ﬂow. Then these larvae migrate up the bronchi and trachea,
over the epiglottis, down the esophagus/stomach, and
reach the small intestine. In the intestine the larvae develop
into mature adults. Parasite eggs delivered by adults are
hatched while descending the intestinal tract, and larvae
excreted in stools. Some larvae developed to infective form
again invade/transfer through the mucosa around the anus,
maintaining a life cycle in the human body. Such a mode of
infection is termed autoinfection.
With the transfer of larvae to the lung, asthma- or
pneumonia-like symptoms, such as transient fever, cough,
and dyspnea, appear, as indicated for simple pulmonary
eosinophilia related to A. lumbricoides, A. duodenale, or
N. americanus. On chest X-ray, transient nodular/inﬁltrative
shadows are observed. Many patients show peripheral
blood eosinophilia and/or an increase in the total IgE level.
In immunocompromised patients, suppressing the cell-
mediated immunity such as ATL patients, HIV/AIDS pa-
tients, those receiving immunosuppressive drugs, the
number of S. stercoralis increases through acceleration of
autoinfection, and larvae are disseminated in various or-
gans, leading to a severe condition (disseminated strongy-
loidiasis). In such cases, stridor, bloody sputum, tachypnea,
protein-losing gastroenteritis, ileus, and mobile exanthema
are observed. Furthermore, severe pneumonia related to
enteric bacteria disseminated with larvae, lung abscess, or
bacterial meningitis concomitantly occurs [403]. A
K. Mikasa et al. / J Infect Chemother 22 (2016) S1eS65 S55diagnosis is made based on S. stercoralis larvae detected in
stools/sputum. Immunological diagnosis is also useful
[403].
- - - Drugs to be recommended- - -A First choice (same dose for adults and children)
- Ivermectin, oral, 200 mg/kg/single-dose administration
(after fasting), additional administration at the same
dose after 2 weeks (AI)
* Repeated administration must be considered in cases
of disseminated strongyloidiasis [405].
* A study reported that transrectal or percutaneous
administration was useful in patients in whom oral
administration was difﬁcult due to digestive symp-
toms [406].<> Second choice (same dose for adults and children)
- Albendazol, oral, 400 mg/twice a day, 7 days (BI)- T. canis, T. cati
Infection to humans occurs through the oral ingestion of
the embryonated eggs of T. canis or T. cati [407]. It also
occurs through the consumption of beef/chicken liver or
meat contaminated with larvae as a raw or insufﬁciently
heated food. This is considered to be a dominant route of
infection in Japan [407]. As humans are not deﬁnitive host
for T. canis and T. cati, they do not become adults in the
human body [408]. Larvae invading the human body
transfer to various organs with blood ﬂow through the in-
testinal mucosa. Target organs are the lung, liver, eyes, and
central nervous system including spinal cord. Toxocariasis is
a typical larva migrans.
Lesions are often observed in the lung/liver (visceral larva
migrans). There are few symptoms, or nonspeciﬁc symptoms
are present. In many cases, a diagnosis is made based on
peripheral blood eosinophilia and multiple nodular shadows
of the lung or liver on CT. Ocular or central nervous symp-
toms appear in some patients. It is impossible to make a
diagnosis on a stool examination due to larva migrans.
Immunological diagnosis is useful. After a deﬁnitive diag-
nosis is made, treatment should be started. When visceral
larva migrans is asymptomatic, follow-up may be continued.
- - - Drugs to be recommended- - -A First choice (same dose for adults and children)
- Albendazol, oral, 5 mg/kg/2 or 3 times a day, 4e8 weeks
[409] (BIII)
* This drug should be taken with meals for 28 days. A
14-day period of discontinuation should be estab-
lished and then restarted drug if required.<> Second choices (same dose for adults and children)
- Albendazol, oral, 400 mg/twice a day, 5 days [410] (BIII)
- Mebendazole, oral, 100e200 mg/twice a day, 5 days
[411] (CIII)- W. bancrofti, B. malayi
W. bancrofti and B. malayi are called lymphatic ﬁlaria.
Infection occurs when these parasites are transmitted to
humans through mosquitoes. The pathogenesis of lymphatic
ﬁlariasis is relate to structural and functional abnormality of
lymphatic channels induced by parasitized adult worms.
InfectionwithW. bancrofti is characterized by febrile attacks,
lymphedema/elephantiasis, hydrocele, and chyluria. In pa-
tients infected with B. malayi, neither hydrocele nor chyluria
is observed, and lymphedema of the lower limbs/elephantiasis are localized in the lower thighs. Microﬁlaria
produced by adult worms is not pathogenic, but rarely in-
duces allergic reactions in the lung, contributing to tropical
pulmonary eosinophilia (TPE) [403]. This condition shows a
chronic course, differing from simple pulmonary eosino-
philia. Cough, dyspnea, and stridor with exacerbation at
night are observed. Fever, malaise, and weight loss are noted
in some patients. On chest X-ray, bilateral reticular nodular
lesions are detected. Peripheral blood eosinophilia and an
increase in the anti-ﬁlaria antibody titer are observed. In case
of TPE, no microﬁlaria is detected [403]. If treatment is not
performed, the condition may gradually exacerbate. It is
important to adequately make a diagnosis for the differen-
tiation of this disease. In the world, 130,000,000 persons are
infected with lymphatic ﬁlaria, but TPE occurs in less than
0.5% of these. The risk of this disease in travelers is unclear,
and most patients consist of foreign persons from endemic
areas [412].
- - - Drugs to be recommended- - -A First choice (same dose for adults and children)
- Diethylcarbamazine, 2 mg/kg/3 times a day, 12 days
* In cases of malayan ﬁlariasis, marked side effects,
such as digestive symptoms, fever, lymphangitis/
lymphadenitis, and orchitis/epididymitis, may
appear. Therefore, a half dose (1 mg/kg) should be
administered 3 times a day for 12 days [413].- D. immitis
D. immitis parasitize in the dog right ventricle and pul-
monary artery, where mature female worms produce
microﬁlaria that circulate in peripheral blood. Infection to
humans is mediated by microﬁlaria-ingesting mosquitoes.
D. immitis larvae in human subcutaneous tissue inserted by
mosquito bite, some larvae migrate to the heart and die.
Dead worms produce infarcts then they lodge in pulmonary
vessels. There are few symptoms [402]. In patients with
symptoms, thoracic pain, cough, bloody sputum, stridor, and
fever have been reported. Typical chest X-ray ﬁndings
include solitary coin lesions. In many cases, an abnormal
shadow of the chest X-ray is indicated on a health checkup,
and D. immitis infection is pathologically diagnosed from a
tissue specimen extirpated under a tentative diagnosis of
lung cancer. At this point, peripheral blood eosinophilia is
rarely observed [403].
- - - Drugs to be recommended (same dose for adults and
children)- - -- As a diagnosis is made using pathological specimens in
many patients, oral treatment is not necessary.
- If necessary, diethylcarbamazine at 2 mg/kg should be
orally administered 3 times a day for 12 days.
- - - Precautions for each drug- - -
➀ Praziquantel
In the Japanese package inserts, it is described that this
drug at 40 mg/kg/day should be orally administered twice
a day for 2 days for the treatment of paragominiasis.
However, we recommend administration at 75 mg/kg/day
(3 times a day) for 2e3 days based on Reference No. 400.
The incidence of side effects is low, but fever, abdominal
discomfort, nausea, diarrhea, and headache are some-
times observed.
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RFP
Precautions for combination therapy: Decrease in the
blood concentration: dexamethasone, phenytoin, carba-
mazepine, chloroquine
Increase in the blood concentration: cimetidine
➁ Pyrantel pamoate
Patients can take this drug regardless of meals. There
are few side effects.
➂ Albendazol
This drug should be taken with meals for 28 days. A 14-
day period of discontinuation should be established and
then restarted drug if required.
As liver dysfunction is frequently observed, caution is
needed during the administration period. Bone marrow
suppression and Stevens-Johnson syndrome must also be
considered.
Precautions for combination therapy: Decrease in the
blood concentration: ritonavir, phenytoin, carbamazepine,
phenobarbital
Increase in the blood concentration: praziquantel
➃ Mebendazole
Although this drug has been used in few children, the
same dose as established for adults is used. In children
weighing 20 kg or less, a half dose should be used. This
drug is contraindicated for pregnant women or those who
may be pregnant. Combination therapy with cimetidine
may increase the blood concentration of mebendazole.
Combination therapy with metronidazole may cause toxic
epidermal necrolysis (TEN) and Stevens-Johnson
syndrome.
➄ Ivermectin
After fasting, this drug should be taken with water. The
incidence of side effects is low, but nausea/vomiting and
mild hepatic disorder are sometimes observed. The safety
of this drug in pregnant women or children weighing less
than 15 kg has not been established. To these patients, this
drug should be administered only when its therapeutic
advantage is considered to exceed its risk.
➅ Diethylcarbamazine
As side effects, fever, lymphangitis/lymphadenitis, and
orchitis/epididymitis, which result from anti-parasitic
actions, are observed in addition to abdominal discom-
fort, nausea, and abdominal pain. The safety of this drug in
pregnant women has not been established.Conﬂict of interest
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Doses for neonates
Upper row: Dose (mg/kg), Lower row: Frequency of administration per day
Body weight < 1.2 kg 1.2~2 kg S2 kg
After birth (days) ~28 ~7 7~28 ~7 7~28
ABPC
Meningitis (Cases in which
meningitis cannot be ruled out)
50
2
50
2
50
3
50
3
50
4
Other infectious diseases 25
2
25
2
25
3
25
3
25
4
SBT/ABPC -
-
50
2
50
2
50
2
50
2
TAZ/PIPC -
-
100
2
100
3
100
2
100
2
CEZ 20
2
20
2
20
2
20
3
CTX 50
2
50
2
50
3
50
2
50
4
CTRX 50
1
50
1
50
1
75
1
CAZ 50
2
50
2
50
3
50
3
50
3
CZOP
Severe/refractory infectious disease 40
3~4
40
3~4
40
3~4
40
3~4
Other infectious diseases 20
2~3
20
3~4
20
2~3
20
3~4
MEPM
Meningitis 40
3
40
3
40
3
40
3
40
3
Other infectious diseases 20
2
20
3
20
3
30
3
30
3
IPM/CS -
-
20
2
20
2
20
2
20
3
GM 2.5
Every 18 h
2.5
2
2.5
3
2.5
2
2.5
3
(Peak 5~15 mg/mL, Trough value< 2 mg/mL)
ABK 2~6
1
2~6
1
2~6
1
2~6
1
(Peak 9~12 mg/mL, Trough value< 2 mg/mL)
AMK 7.5
2
7.5
2
7.5
3
10
2
10
3
(Peak 20~30 mg/mL, Trough value< 10 mg/mL)
TOB 2.5
Every 1 h or 18 h
2
Every 2 h or 18 h
2
2~3
2
2
2
3
(Peak 5~12 mg/mL, Trough value< 2 mg/mL)
VCM 15
1
10
2
10
2
10
3
10
3
(Trough value< 10~20 mg/mL)
TEIC First dose: 16 mg/kg, Subsequently, the drug at 8 mg/kg should be administered over 30 minutes or more at 24-h intervals.
CLDM 5
2
5
3
5
3
5
4
AZT 30
2
30
3
30
2
40
3
ACV 20
2
20
3
20
3
20
3
AMPH-B (Daily dose) 1 1 1 1
L-AMB (Daily dose) 5 5 5 5
FLCZ 12
Every 48 h
12
1
12
Every 48 h
12
1
EM (Oral) -
-
10
2
10
3
10
2
10
3
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